Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)

ABSTRACT

A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against LIR polypeptides. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.

BACKGROUND OF THE INVENTION

[0001] Immune system cellular activity is controlled by a complex network of cell surface interactions and associated signaling processes. When a cell surface receptor is activated by its ligand a signal is sent to the cell, depending upon the signal transduction pathway that is engaged, the signal can be inhibitory or activatory. For many receptor systems cellular activity is regulated by a balance between activatory signals and inhibitory signals. In some of these it is known that positive signals associated with the engagement of a cell surface receptor by its ligand are downmodulated or inhibited by negative signals sent by the engagement of a different cell surface receptor by its ligand.

[0002] The biochemical mechanisms of these positive and negative signaling pathways have been studied for a number of known immune system receptor and ligand interactions. Many receptors that mediate positive signaling have cytoplasmic tails containing sites of tyrosine phosphatase phosphorylation known as immunoreceptor tyrosine-based activation motifs (ITAM). A common mechanistic pathway for positive signaling involves the activation of tyrosine kinases which phosphorylate sites on the cytoplasmic domains of the receptors and on other signaling molecules. Once the receptors are phosphorylated, binding sites for signal transduction molecules are created which initiate the signaling pathways and activate the cell. The inhibitory pathways involve receptors having immunoreceptor tyrosine based inhibitory motifs (ITIM) which, like the ITAMs, are phosphorylated by tyrosine kinases. Receptors having these motifs are involved in inhibitory signaling because these motifs provide binding sites for tyrosine phosphatases which block signaling by removing tyrosine from activated receptors or signal transduction molecules. While many of the details of the activation and inhibitory mechanisms are unknown, it is clear that functional balance in the immune system depends upon opposing activatory and inhibitory signals.

[0003] One example of immune system activity that is regulated by a balance of positive and negative signaling is B cell proliferation. The B cell antigen receptor is a B cell surface immunoglobulin which, when bound to antigen, mediates a positive signal leading to B cell proliferation. However, B cells also express Fcγ RIIb1, a low affinity IgG receptor. When an antigen is part of an immune complex with soluble immunoglobulin, the immune complex can bind B cells by engaging both the B cell antigen receptor via the antigen and Fcγ RIIbI via the soluble immunoglobulin. Co-engagement of the Fcγ RIIb1 with the B cell receptor complex downmodulates the activation signal and prevents B cell proliferation. Fcγ RIIb1 receptors contain ITIM motifs which are thought to deliver inhibitory signals to B cells via interaction of the ITIMs with tyrosine phosphatases upon co-engagement with B cell receptors.

[0004] The cytolytic activity of Natural Killer (NK) cells is another example of immune system activity which is regulated by a balance between positive signals that initiate cell function and inhibitory signals which prevent the activity. The receptors that activate NK cytotoxic activity are not fully understood. However, if the target cells express cell-surface MHC class I antigens for which the NK cell has a specific receptor, the target cell is protected from NK killing. These specific receptors, known as Killer Inhibitory Receptors (KIRs) send a negative signal when engaged by their MHC ligand, downregulating NK cell cytotoxic activity.

[0005] KIRs belong to the immunoglobulin superfamily or the C-type lectin family (see Lanier et al., Immunology Today 17:86-91,1996). Known human NK KIRs are members of the immunoglobulin superfamily and display differences and similarities in their extracellular, transmembrane and cytoplasmic regions. A cytoplasmic domain amino acid sequence common to many of the KIRs is an ITIM motif having the sequence YxxL/V. In some cases, it has been shown that phosphorylated ITIMs recruit tyrosine phosphatases which dephosphorylate molecules in the signal transduction pathway and prevent cell activation (see Burshtyn et al., Immunity 4:77-85, 1996). The KIRs commonly have two of these motifs spaced apart by 26 amino acids [YxxL/V(x)₂₆YxxL/V]. At least two NK cell receptors, each specific for a human leukocyte antigen (HLA) C allele (an MHC class I molecule), exist as an inhibitory and an activatory receptor. These receptors are highly homologous in the extracellular portions, but have major differences in their transmembrane and cytoplasmic portions. One of the differences is the appearance of the ITIM motif in the inhibitory receptor and the lack of the ITIM motif in the activating receptor (see Biassoni et al., Journal. Exp. Med, 183:645-650, 1996).

[0006] An immunoreceptor expressed by mouse mast cells, gp49B 1, also a member of the immunoglobulin superfamily, is known to downregulate cell activation signals and contains a pair of ITIM motifs. gp49B1 shares a high degree of homology with human KIRs (Katz et al., Cell Biology, 93: 10809-10814, 1996). Mouse NK cells also express a family of immunoreceptors, the Ly49 family, which contain the ITIM motif and function in a manner similar to human KIRs. However, the Ly49 immunoreceptors have no structural homology with human KIRs and contain an extracellular C-type lectin domain, making them a member of the lectin superfamily of molecules (see Lanier et al., Immunology Today 17:86-91, 1996).

[0007] Clearly, the immune system activatory and inhibitory signals mediated by opposing kinases and phosphatases are very important for maintaining balance in the immune system. Systems with a predominance of activatory signals will lead to autoimmunity and inflammation. Immune systems with a predominance of inhibitory signals are less able to challenge infected cells or cancer cells. Isolating new activatory or inhibitory receptors is highly desirable for studying the biological signal(s) transduced via the receptor. Additionally, identifying such molecules provides a means of regulating and treating diseased states associated with autoimmunity, inflammation and infection.

[0008] For example engaging a newly discovered cell surface receptor having ITIM motifs with an agonistic antibody or ligand can be used to downregulate a cell function in disease states in which the immune system is overactive and excessive inflammation or immunopathology is present. On the other hand, using an antagonistic antibody specific to the receptor or a soluble form of the receptor can be used to block the interaction of the cell surface receptor with the receptor's ligand to activate the specific immune function in disease states associated with suppressed immune function. Conversely, since receptors lacking the ITIM motif send activatory signals once engaged as described above, the effect of antibodies and soluble receptors is the opposite of that just described.

SUMMARY OF THE INVENTION

[0009] The present invention provides a new family of immunoreceptor molecules of the immunoglobulin superfamily, designated herein as the Leukocyte Immunoglobulin-Like Receptor (LIR) polypeptides. Within the scope of the present invention are DNA sequences encoding LIR family members and their deduced amino acid sequences disclosed herein. Further included in the present invention are polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences or to DNA or RNA complementary to the probes. The present invention also includes recombinant expression vectors comprising DNA encoding LIR family members. Also within the scope of the present invention are nucleotide sequences which, due to the degeneracy of the genetic code, encode polypeptides that are identical to polypeptides encoded by the nucleic acid sequences described above, and sequences complementary to those nucleotide sequences.

[0010] Further, the present invention includes processes for producing polypeptides of the LIR family by culturing host cells transformed with a recombinant expression vector that contains an LIR family member encoding DNA sequence under conditions appropriate for expressing an LIR polypeptide family member, then recovering the expressed LIR polypeptide from the culture.

[0011] The invention also provides agonistic and antagonistic antibodies to LIR family proteins.

[0012] Further still within the present invention are fusion proteins that include a soluble portion of an LIR family member and the Fc portion of Ig.

[0013] Certain autoimmune disorders are associated with the failure of a negative signaling LIR to downregulate cell function. Such disorders may be treated by administering a therapeutically effective amount of an agonistic antibody or ligand of one or more a LIR family member to a patient afflicted with such a disorder. Disorders mediated by disease states associated with suppressed immune function can be treated by administering a soluble form of the negative signaling LIR. Conversely, disorders mediated by diseases associated with failure of a activatory signaling LIR can be treated by administering an agonistic antibody of the activatory receptor. Disorders mediated by states associated with autoimmune function can be treated by administering a soluble form of the activatory receptor.

DETAILED DESCRIPTION OF THE INVENTION

[0014] A viral glycoprotein having a sequence similarity to MHC class I antigens has been used to isolate and identify a new polypeptide, designated LIR-P3G2, and several members of a new family of cell surface polypeptides that has been designated the LIR polypeptide family. The present invention encompasses isolated nucleic acid molecules encoding LIR polypeptides, and further encompasses isolated LIR polypeptides. Exemplary nucleic acids encoding LIR polypeptides according to the present invention include those nucleotide sequences shown in SEQ ID NOS:1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35 and 37, and exemplary LIR polypeptide sequences are shown in SEQ ID NOS:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38.

[0015] The LIR polypeptide family members possess extracellular regions having immunoglobulin-like domains, placing the members in a new subfamily of the immunoglobulin superfamily. While the LIR family members are characterized as having very similar extracellular portions, the family includes three groups of polypeptides that are distinguishable by their transmembrane regions and their cytoplasmic regions. One group of the LIR polypeptides has a transmembrane region that includes a positively charged residue and a short cytoplasmic tail and a second group has a nonpolar transmembrane region and a long cytoplasmic tail. A third group includes polypeptides expressed as soluble proteins having no transmembrane region or cytoplasmic tail. One of the LIR proteins has characteristics of both groups one and two, and may represent a fourth group. A number of recent reports have described nucleic acid molecules having sequences related to the LIR family of proteins (Hillier et al., GenBank Accession Number N95687, April 9, 1996; Colonna, M., GenBank Accession Nos. AF041261 and AFo41262, Jan. 7, 1999; Lamerdin et al., GenBank Accession No. AC006293, Jan. 6, 1999; Steffans et al., GenBank Accession Nos. AH007466 and AH007465, Mar. 4, 1999; Cosman et al., Immunity 7:273-282 (1997); Borges et al., J. Imunol. 159:5192-96 (1997); Samaridis and Colonna, Eur. J. Immunol 27:660-665 (1997); Colonna et al., J. Exp. Med. 186:1809-1818 (1997); Wagtmann et al., Curr. Biol. 7:615-618 (1997); Rojo et al., J. Immunol. 158:9-12 (1997); Ann et al., J. Immunol. 159:2342-2349 (1997); Cella et al., J. Exp. Med. 185:1743-51 (1997); Torkar et al., Eur. J. Immunol. 28:3959-67 (1998); Yamashita et al., J. Biochem. 123:358-68 (1998); WO 98/31806; WO 98/24906; WO 98/09638).

[0016] The LIR polypeptides encompassed by the subject invention contain at least one Ig-like domain in the extracellular region of the protein, preferably contain either two or four Ig-like domains in the extracellular region. Some LIR polypeptides may contain more than four Ig-like domains. An Ig-like domain is a structural unit that has been identified in a wide variety of cellular proteins. Ig-like domains contain a common fold that forms a sandwich of two P sheets that is stabilized by a characteristic intrachain disulfide bond. Ig-like domains are readily recognizable by reference to a large body of knowledge concerning this structural entity (see, e.g., Williams and Barclay, Ann. Rev. Immunol. 6:381405 (1988)). Typically, Ig-like domains contain about 100 amino acids, although the number of amino acids may vary, e.g., from about 85 to 105 amino acids. Molecules that exhibit Ig-like domains generally play a recognition role at the cell surface, often mediating cell-cell interactions in a variety of biological systems.

[0017] LIR-P3G2 (SEQ ID NO:2) is expressed by a variety of cells and recognizes HLA-B44 molecules, HLA-A2 MHC molecules and the alleles described in Example 14. Another LIR family member, designated LIR-pbm8 (SEQ ID NO:9) is expressed by a variety of cells and also recognizes a number of MHC class I molecules. By analogy with known molecules, LIR-P3G2, LIR-pbm8 and LIR members have a role in immune recognition and self/nonself discrimination.

[0018] Examples 1-3 below describe isolating cDNA encoding P3G2 (LIR-P3G2) and a substantially identical polypeptide designated 18A3 (LIR-18A3). Briefly, the LIR-P3G2 family member was isolated by first expressing UL18, a Class I MHC-like molecule and using UL18 to isolate and identify P3G2 and 18A3, which are closely related and probably are variants of the same gene, which is designated “LIR-1.” The nucleotide sequences of the isolated P3G2 cDNA and 18A3 cDNA are presented in SEQ ID NO:1 and SEQ ID NO:3, respectively. The amino acid sequences encoded by the cDNA presented in SEQ ID NO:1 and SEQ ID NO:3 are presented in SEQ ID NO:2 and SEQ ID NO:4, respectively. The P3G2 amino acid sequence (SEQ ID NO:2) has a predicted extracellular domain of 458 amino acids (1-458) including a signal peptide of 16 amino acids (amino acids 1-16); a transmembrane domain of 25 amino acids (amino acids 459-483) and, a cytoplasmic domain of 167 amino acids (amino acids 484-650). The extracellular domain includes four immunoglobulin-like domains. Ig-like domain I includes approximately amino acids 17-118; Ig-like domain II includes approximately amino acids 119-220; Ig-like domain III includes approximately amino acids 221-318; and Ig-like domain IV includes approximately amino acids 319-419. Significantly, the cytoplasmic domain of this polypeptide includes four ITIM motifs, each having the consensus sequence of YxxLIV. The first ITIM motif pair is found at amino acids 533-536 and 562-565 and the second pair is found-at amino acids 614-617 and 644-647. This feature is identical to the ITIM motifs found in KIRs except that KIRs contain only one pair of ITIM motifs.

[0019] The 18A3 amino acid sequence (SEQ ID NO:4) has a predicted extracellular region of 459 amino acids (1459) including a signal peptide of 16 amino acids (amino acids 1-16); a transmembrane domain of 25 amino acids (amino acids 460484) and a cytoplasmic domain of 168 amino acids (485-652). The 18A3 amino acids sequence (SEQ ID NO:4) is substantially identical to that of P3G2 (SEQ ID NO:2) except that 18A3 has two additional amino acids (at amino acid 438 and 552) and 18A3 possesses an isoleucine residue at amino acid 142 in contrast to a threonine residue for P3G2. Additionally, 18A3 has a serine residue at amino acid 155 and P3G2 has an isoleucine at 155. Finally, the 18A3 polypeptide has a glutamic acid at amino acid 627 and P3G2 has a lysine at 625 which is aligned with the 627 residue of the 18A3 polypeptide. The four ITIM motifs in the 18A3 cytoplasmic domain are at amino acids 534-537 and 564-567 and at 616-619 and 646-649. Glycosylation sites occur at the amino acid triplet Asn-X-Y, where X is any amino acid except Pro and Y is Ser or Thr. Thus, potential glycosylation sites on LIR-P3G2 occur at amino acids 140-142; 281-283; 302-304; and 341-343. Sites on LIR-18A3 are at 281-283; 302-304; and 341-343. The features of these encoded polypeptides are consistent with type I transmembrane glycoproteins.

[0020] Examples 8-10 describe isolating and identifying eight additional LIR polypeptide family members by probing cDNA libraries for plasmids that hybridize to a probe obtained from DNA encoding the extracellular region of LIR-P3G2. The nucleotide sequences (cDNA) of the isolated LIR family members are presented in SEQ ID NO:7 (designated pbm25, or LIR4), SEQ ID NO:9 (designated pbm8, or LIR-2), SEQ ID NO:11 (designated pbm36-2, or LIR-6b), SEQ ID NO:13 (designated pbm364, or LIR-6a); SEQ ID NO:15 (designated pbmhh, or LIR-7); SEQ ID NO:17 (designated pbm2, or LIR-5), SEQ ID NO:19 (designated pbm17, or LIR-3) and SEQ ID NO:21 (designated pbmnew, or LIR-8). The amino acid sequences encoded thereby are presented in SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20 and SEQ ID NO:22, respectively.

[0021] Example 15 describes the isolation of LIR-9 ml (SEQ ID NOS:29, 30), LIR-9m2 (SEQ ID NO:31, 32), LIR-9s1 (SEQ ID NO:33, 34), and LIR-9s2 (SEQ ID NO:35, 36), which are four alternatively spliced variants of LIR-9, another new member of the LIR family. The first step in identifying these LIR-9 group of clones was the isolation of a short cDNA clone that was obtained from a human dendritic cell library and whose sequence analysis indicated that it had significant homology with the LIR family, particularly with the sequences shown in SEQ ID NOS:11, 13 and 15. Using PCR primers based on this clone, further cloning efforts yielded four full-length cDNAs corresponding to LIR-9 ml, -9m2,-9s1 and -9s2. LIR-9m1 and LIR-9m2 are transmembrane proteins that differ by 12 amino acids that are found in the extracellular region of LIR-9 ml, but that are absent from LIR9m2. These 12 amino acids correspond to amino acids 29-40 of SEQ ID NO:30. LIRs-9sl and -9s2 do not contain a transmembrane domain, thus encode soluble versions of LIR-9. The LIR-9s1 polypeptide (SEQ ID NO:34) includes the 12 amino acid insert that is present in LIR-9 ml. Amino acids 1-238 of LIR-9s1 (SEQ ID NO:34) and LIR-9 ml (SEQ ID NO:30) are identical, but the remainder of the LIR-9s1 sequence is not identical to the corresponding region of LIR-9 ml. Amino acids 1-226 of LIR-9s2 (SEQ ID NO:36) are identical to the first 226 amino acids of LIR-9m2 (SEQ ID NO:32), but the remaining amino acid sequence of LIR-9s2 diverges from that of LIR-9m2.

[0022] The same PCR primers that were used to isolate the LIR-9 clones yielded an additional cloned LIR cDNA that has been designated LIR-10 (SEQ ID NOS:37 and 38). By comparing the nucleotide sequence of LIR-10 with the most closely related LIRs that were previously identified, i.e, with SEQ ID NOS: 13 and 15, it has been determined that the LIR-10 cDNA is an incomplete clone that lacks sequences located at the 5′ end of the corresponding mRNA, including the 5′ untranslated region, and nucleotides encoding the first 26 amino acids of the LIR-10 protein.

[0023] The identified extracellular, transmembrane and cytoplasmic regions for the polypeptides of LIR family members shown in SEQ ID NOS:10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38 are presented below. The polypeptides presented in SEQ ID NOS:8, 34 and 36 are soluble proteins having no transmembrane or cytoplasmic regions. As will be understood by the skilled artisan, the transmembrane region of P3G2 and 18A3 described above and those of LIR polypeptide family members presented below are identified in accordance with conventional criteria for identifying hydrophobic domains associated with such regions. Accordingly, the precise boundaries of any selected transmembrane region may vary from those presented herein. Typically, the transmembrane domain does not vary by more than five amino acids on either end of the domain as described herein. Computer programs known in the art and useful for identifying such hydrophobic regions in proteins are available.

[0024] The polypeptide presented in SEQ ID NO:8 (LIR-pbm25) has an extracellular domain that includes the entire amino acid sequence of amino acids 1439 and a signal peptide of amino acids 1-16. The amino acid sequence presented in SEQ ID NO:10 (LIR-pbm8) has a predicted extracellular region of 458 amino acids (1458) including a 16 amino acid signal peptide (amino acids 1-16); a transmembrane domain that includes amino acids 459483; and a cytoplasmic domain that includes amino acids 484-598. The extracellular domain includes four immunoglobulin-like domains and the cytoplasmic domain includes an ITIM motif at amino acids 533-536 and 562-565.

[0025] The amino acid sequence presented in SEQ ID NO:12 (LIR-pbm36-2) has a predicted extracellular domain of amino acids including a 16 amino acid signal peptide of from amino acids 1-16; a transmembrane domain which includes amino acids 262-280 and a cytoplasmic domain of from amino acids 281-289. The transmembrane domain includes a charged arginine residue at 264 and the cytoplasmic domain is short, having only a length of only 9 amino acids.

[0026] The amino acid sequence presented in SEQ ID NO:14 (IR-pbm364) has a predicted extracellular domain of amino acids 1-461 including a signal peptide from amino acids 1-16; a transmembrane domain that includes amino acids 462-480 and possesses a charged arginine residue at amino acid 464; and a cytoplasmic domain that includes amino acids 481-489. SEQ ID NO:14 is nearly identical to that of SEQ ID NO:12 except that it possesses four immunoglobulin domains in contrast to the two domains found in the extracellular region of SEQ ID NO:12. The amino acid sequences presented in SEQ ID NO:12 and SEQ ID NO:14 are likely proteins encoded by alternatively spliced transcripts from the same gene.

[0027] The amino acid sequence presented in SEQ ID NO:16 (LIR-pbmhh) has a predicted extracellular domain that includes amino acids 1-449 and a signal peptide from amino acids 1-16; a transmembrane domain that includes amino acids 450-468 with a charged arginine residue at amino acid 452; and a cytoplasmic domain that includes amino acids 469-483. The cytoplasmic domain is short with a length of 15 amino acids. The extracellular domain includes four immunoglobulin-like domains.

[0028] The amino acid sequence presented in SEQ ID NO:18 (LIR-pbm2) has a predicted extracellular region that includes amino acids 1-259 and a signal peptide of amino acids 1-16; a transmembrane domain that includes amino acids 260-280; and a cytoplasmic domain that includes amino acids 281-448. This LIR family member has cytoplasmic domain which includes an ITIM motif at amino acids 412-415 and 442-445. The extracellular domain includes two immunoglobulin-like domains.

[0029] The amino acid sequence presented in SEQ ID NO:20 (LIR-pbm17) has a predicted extracellular domain of amino acids 1443 that includes a signal peptide of amino acids 1-16; a transmembrane domain which includes amino acids 444-464; and a cytoplasmic domain of amino acids 465-631. The extracellular domain has four immunoglobulin-like domains. SEQ ID NO:20 has two pairs of ITIM YxxL/V motifs in the cytoplasmic domain. A first pair is at amino acids 514-517 and 543-546, and a second pair is at amino acids 595-598 and 625-628.

[0030] The amino acid sequence presented in SEQ ID NO:22 (LIR-pbmnew) has a predicted extracellular domain of amino acids 1-456 including a signal peptide of amino acids 1-16; a transmembrane domain which includes amino acids 457-579; and a cytoplasmic domain of amino acids 580-590. The extracellular includes four immunoglobulin-like domains. SEQ ID NO:22 has an ITIM motif at amino acids 554-557 and 584-587.

[0031] The LIR-9 m1 protein has an extracellular domain located at amino acids 1-262 of SEQ ID NO:30, including a signal peptide at amino acids 1-34 of SEQ ID NO:30. Amino acids 263-284 of SEQ ID NO:30 define the transmembrane region of LIR-9 ml, and amino acids 285-299 of SEQ ID NO:30 form the cytoplasmic region. For LIR-9m2, the extracellular region corresponds to amino acids 1-250 of SEQ ID NO:32, including a signal sequence at amino acids 1-35 of SEQ ID NO:32, a transmembrane region at residues 251-272 of SEQ ID NO:32, and a cytoplasmic region at amino acids 273-287 of SEQ ID NO:32. LIR-9s1 (SEQ ID NO:34) and LIR-9s2 (SEQ ID NO:36) consist, respectively, of 265 and 253 amino acids, with their signal sequences being found at amino acids 1-34 of SEQ ID NO:34, and amino acids 1-35 of SEQ ID NO:36.

[0032] For LIR-10, amino acids 1-393 of SEQ ID NO:38 correspond to most of the extracellular portion of the LIR-10 protein, though the coding sequences for about 26 amino acids at the amino terminus of this protein, including the signal peptide, are believed to be missing from the LIR-10 CDNA clone that is described herein. The transmembrane region of LIR-10 is defined by amino acids 394-417 of SEQ ID NO:38, and the intracellular region by amino acids 418-449. A single ITIM motif is located at amino acids 438-443 of SEQ ID NO:38.

[0033] The amino acid sequences presented in SEQ ID NO:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38 reveal that the LIR family, with the exception of LIR-10, can be categorized into three groups of polypeptides. One group includes the polypeptides of SEQ ID NOS: 12, 14, 16, 30 and 32, which are distinguishable by a charged arginine residue in their transmembrane regions and their short cytoplasmic regions. A second group includes SEQ ID NO:2, 4, 10, 18, 20 and 22 which are distinguishable by their hydrophobic cytoplasmic domains and the presence of one or more ITIM motifs in their cytoplasmic regions. A third group includes the polypeptides of SEQ ID NOS: 8, 34 and 36, which are expressed as soluble polypeptides and have no transmembrane or cytoplasmic regions. These soluble polypeptides may function to block the interactions of cell surface family members with their receptors. Alternatively, the soluble polypeptides may act as an activatory signal when bound to the receptor. Like the members of group one, LIR-10 has a relatively short cytoplasmic domain and a charged residue in its transmembrane domain, though its charged residue is histidine instead of arginine. However, LIR-10 also has an ITIM motif in its cytoplasmic domain, like the members of group two. Thus, LIR-10 has some of the characteristics of both groups one and two, and may represent a fourth group of LIR proteins. The LIR polypeptides are characterized generally by the ability of their encoding DNA to hybridize to DNA encoding the P3G2 extracellular region.

[0034] The invention should be understood to encompass isolated nucleic acid molecules encoding LIR polypeptides having the amino acid sequences shown in SEQ ID NOS:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38. In one embodiment of the invention, these nucleic acid molecules have the nucleic acid sequences shown in SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35 and 37.

[0035] The extracellular regions of the LIR family member proteins presented in SEQ ID NO:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38 have a high degree of homology, which varies from 59%-84. Several of the LIR isolates are closely related, thus must represent allelic variants or splicing variants. For example, the extracellular regions of SEQ ID NO:12 and SEQ ID NO:14 share sequence homology which is close to 100%, thus indicating that these polypeptides derive from the same gene. In addition, SEQ ID NOS:2 and 4 share sequence homology that is in excess of 95%, thus probably represent two alleles of the same gene. Moreover, as discussed above, the extracellular regions of SEQ ID NOS:30, 32, 34 and 36 are nearly identical, thus indicting that these four proteins derive from mRNAs that are splicing variants.

[0036] While sharing some structural similarities with other members of the immunoglobulin superfamily, the LIR family members have limited homology to other members of the immunoglobulin superfamily. Molecules having the closest structural similarity to the LIRs are the human KIRs and mouse gp49. However, LIR extracellular regions share only a 3842% identity with the extracellular regions of NKAT3 and p58 CI-39, respectively. The extracellular regions of the LIR family members are only 35-47% homologous with that of mouse gp49. In contrast, KIRs in general are known to share at least a 80% amino acid identity, with NKAT3 and p58 CL-39 being 81% homologous Additionally, none of the known KIR molecules has four extracellular immunoglobulin domains which is characteristic of all but two of the known LIR family members. In view of the high sequence homology among the LIR related polypeptides disclosed herein and their relatively low homology with KIRs, the LIR polypeptides are members of a new family of immunoregulators.

[0037] An analysis of the amino acid sequences of the LIR polypeptides reveals that specific stretches of amino acids of the LIR polypeptides are highly conserved. One conserved region is a sequence of 46 amino acids found at amino acids 5-50 of SEQ ID NO:2. A data base search determined that the LIR family members differ substantially from the most structurally similar prior art polypeptides in this LIR conserved region. The data base search and structural analysis was performed using BLAST NB 1, a local alignment search tool for searching data bases and aligning amino acid sequences to determine identities and variations in a given sequence. The BLAST NB1 software is accessible on the internet at http://www3.ncbl.nlm.nih.gov/entrez/blast. The BLAST NB 1 search for sequences having homology to the sequence of amino acids 5 to 50 of SEQ ID NO:2 found that the most structurally similar proteins are FcγIIR, gp49B form 2, and gp49B form 1 having identities with amino acids 5 to 50 of SEQ ID NO:2 of 63%, 67%, and 67% respectively. This contrasts with an LIR family identity with amino acids 5 to 50 of SEQ ID NO:2 which ranges from about 71% to 100%. Specifically, LIR family members of the present invention contain conserved regions near their amino termini having the following identities with amino acids 5-50 of SEQ ID NO:2: SEQ ID NO:8 has a 96% identity; SEQ ID NO:10 has a 90% identity; SEQ ID NO:12 has a 96% identity; SEQ ID NO:14 has a 91% identity; SEQ ID NO:16 has a 97% identity; SEQ ID NO:18 has a 77% identity; SEQ ID NO:20 has an 80% identity; SEQ ID NO:22 has an 80% identity; SEQ ID NO:30 has a 78% identity; SEQ ID NO:32 has a 71% identity; SEQ ID NO:34 has a 78% identity; SEQ ID NO:36 has a 71% identity. This conserved region appears to be present also in LIR-1 (SEQ ID NO:38), but is incomplete due to the LIR-10 cDNA clone disclosed herein being truncated at its 5′ end.

[0038] Sequence identity as used herein is the number of aligned amino acids which are identical, divided by the total number of amino acids in the shorter of the two sequences being compared. A number of computer programs are available commercially for aligning sequences and determining sequence identities and variations. These programs provide identity information based upon the above stated definition of identity. One suitable computer program is the GAP program, version 6.0, described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970), as revised by Smith and Waterman (Adv. Appl. Math 2:482, 1981). The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of I for identities and 0 for non-identities) for nucleotides or amino acids, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Another similar program, also available from the University of Wisconsin as part of the GCG computer package for sequence manipulation is the BESTFIT program.

[0039] In another aspect, the polypeptides of the present invention have conserved regions which are uniquely characterized as having the amino acid sequence (SEQ ID NO:28):

[0040] Leu Xaa_(a) Leu Ser Xaa_(b) Xaa_(c) Pro Arg Thr Xaa_(d) Xaa_(e) Gln Xaa_(f) Gly Xaa_(g) Xaa_(h) Pro Xaa_(i) Pro Thr Leu Trp Ala Glu Pro Xaa_(j) Ser Phe Ile Xaa_(j) Xaa₇₀ Ser Asp Pro Lys Leu Xaa_(k) Leu Val Xaa_(m) Thr Gly,

[0041] where Xaa_(a) is Gly or Arg; Xaa_(b) is Leu or Val; Xaa_(c) is Gly or Asp; Xaa_(d) is His Arg or Cys; Xaa_(e) is Val or Met; Xaa_(f) is Ala or Thr; Xaa_(g) is His Pro or Thr; Xaa_(h) Leu Ile or Phe; Xaa_(i) is Gly Asp or Ala; Xaa_(j) is Thr Ile Ser or Ala; Xaa_(k) is Gly or Val; Xaa_(m) is Met or Ala; and Xaa₇₀ is a sequence of 70 amino acids.

[0042] As mentioned above, certain LIR family members have ITIM motifs (YxxL/V₂₅₋₂₆YxxL/V) in their cytoplasmic domains. It is known that many immune regulating receptors such as KIRs, CD22, FcγRIIb1 also have ITIMs in their cytoplasmic domain and function to send inhibitory signals which down regulate or inhibit cell function. It has been shown that these receptors associate with SHP-1 phosphatase via binding to the ITIM motifs. Recruitment of the SHP-1 phosphatase by the receptor appears to be required for intracellular signaling pathways that regulate the inhibitory function of the receptors. The experiment described in Example 11 demonstrates that LIR-P3G2 and LIR-pbm8 polypeptides associate with SHP-1 phosphatase upon phosphorylation and generate inhibitory signals through monocyte activation pathways. It is known that many immune regulating receptors such as KIRs, CD22, FcyRIIb1 have ITIMs in their cytoplasmic domain and function to send inhibitory signals which down regulate or inhibit cell function. Thus, by analogy with KIRs, CD22 and FcyRIIb1, LIR family members presented in SEQ ID NO:2, 4, 10, 18, 20, 22 and 38 that have ITIM motifs deliver an inhibitory signal via the interaction of its ITIM with SHP-1 tyrosine phosphatase, or other tyrosine phosphatases, when the LIR is coligated with an appropriate receptor. Also by analogy with immunoregulatory receptors possessing ITIMs, LIR family members have a regulatory influence on humoral, inflammatory and allergic responses.

[0043] The LIR family members presented in SEQ ID NO:12, 14, 16, 30 and 32 have relatively short cytoplasmic domains, have transmembrane regions possessing at least one charged residue, and do not possess the ITIM motif. By analogy with membrane proteins that lack ITIM motifs and have charged transmembrane regions, these family members mediate stimulatory or activatory signals to cells. For example, membrane bound proteins containing a charged residue in the transmembrane regions are known to associate with other membrane-bound proteins that possess cytoplasmic tails having motifs known as immunoreceptor tyrosine-based activation motifs (ITAM). Upon association, the ITAMs become phosphorylated and propagate an activation signal.

[0044] The LIR polypeptide designated LIR-P3G2 is expressed on the surface of transfected or normal cells. This is evidenced by the results of the experiments described in Example 3 and Example 5 in which flow cytometry and precipitation techniques demonstrate that LIR-P3G2 is found on monocytes, a subpopulation of NK cells, and B cells. P3G2 was detected on small subset of T cells. P3G2 is expressed as a 110-120 kDa glycoprotein. Since P3G2 has four potential glycosylation sites, the molecular size of this protein will vary with the degree of its glycosylation. Glycosylation sites occur at the amino acid triplet Asn-X-Y, where X is any amino acid except Pro and Y is Ser or Thr. Potential glycosylation sites on P3G2 occur at amino acids 139-141; 280-282; 302-304; and 340-342.

[0045] P3G2-LIR isolated as described in Example 3 was tested for its ability to bind to cell surface ligands distinct from UL18. As demonstrated by the experimental results detailed in Example 7, P3G2 binds HLA-B 44 and HLA-A2, class I MHC antigens. Similarly, as demonstrated in Example 14, LIR-P3G2 and LIR-pbm8 bind to a variety of HLA-A, -B, and -C alleles and recognize a broad spectrum of MHC class I specificities. Since Class I MHC molecules play a central role in immune surveillance, self/non-self discrimination, the immune response to infection etc., the LIR-P3G2 and LIR-pbm8 polypeptides have a role in regulation of immune responses. It is known that NK cytolytic activity for killing tumor cells and cells infected with a virus is regulated by a delicate modulation of activatory and inhibitory signals. It has been shown that receptors specific for the same HLA class I molecules to which LIR-P3G2 and LIR-pbm8 bind may be activatory or inhibitory in their triggering mechanism. By analogy, LIR-P3G2 and LIR-pbm8, which bind MHC class I molecules, play a role in balancing immune system cell activity and are useful in treating disease states in which the immune system balance is disrupted.

[0046] Within the scope of the present invention are polypeptides which include amino acid sequences encoded by DNA that hybridizes to LIR-P3G2 extracellular DNA probes under moderate to highly stringent conditions as taught herein. Probes that hybridize to DNA that encode polypeptides of the present invention include probes which encompass nucleotides 310-1684 of SEQ ID NO:1 or fragments thereof. Fragments of SEQ ID NO: I utilized as hybridization probes are preferably greater than 17 nucleotides in length, and more typically are greater than 20 nucleotides in length, and may include nucleotides 358-1684; nucleotides 322459 (encoding LIR conserved sequence); or DNA or RNA sequences complementary to SEQ ID NOS:5, 6, 23, 24, 27 and I or fragments thereof. Fragments of SEQ ID NOS:5, 6, 23, 24 and 27 include these sequences without the restriction sites. The nucleotide sequences described herein also can be used to design PCR primers, for which a convenient length is about 17-30 nucleotides.

[0047] Conditions for hybridization may be moderately stringent conditions described in, for example, in Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989, which is hereby incorporated by reference (see, e.g., Vol. 1, pp 1.101-104). Conditions of moderate stringency, as defined by Sambrook et al., include, for example, the use of a prewashing solution containing 5× SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0) and hybridization conditions of about 55° C. in 5× SSC, incubated overnight. Highly stringent conditions include higher temperatures of hybridization and washing. The skilled artisan will recognize that a given degree of stringency may be maintained while varying the hybridization or wash temperature or composition of the hybridization buffer in accord with formulae known to those in the art (e.g., see Sambrook et al., 9.50-9.51 and 11.45-11.47). Such formulae take into account factors such as the length of the probe, the G+C content of the probe, salt concentration of the hybridization buffer. If desired, formamide may be added to the hybridization buffer, which permits the use of lower hybridization temperatures (e.g., see Sambrook et al., 9.50-9.51).

[0048] Preferred embodiments include amino acid sequences encoded by DNA that hybridizes to probes of the extracellular region of LIR-P3G2 having at least 17 nucleotides. Preferred hybridizing conditions include an incubation temperature of 63° C. for 16 hours in a solution of Denhart's solution, 0.05 M TRIS at pH 7.5, 0.9 M NaCl, 0.1% sodium pyrophosphate, 1% SDS and 200 μg/mL salmon sperm DNA, followed by washing with 2× SSC at 63° C. for one hour and then washing with 1× SSC at 63° C. for one hour. However, as explained above, one skilled in the art can devise other hybridization conditions that produce the same degree of stringency. Generally, stringent hybridization conditions involve a combination of buffer and incubation temperature that supports the formation of specific, i.e., well-matched duplexes while still allowing the formation of stable duplexes at an acceptable rate. Conditions of reduced stringency permit the formation of stable duplexes containing a higher degree of mismatched base pairs than can form under more stringent conditions.

[0049] Stringent hybridization conditions for PCR primers can be achieved, for example, by hybridizing labeled probes to filter-bound target nucleic acid overnight at 50-55° C. in aqueous buffer containing 5× SSC or 6× SSC (1× SSC=0.15 M NaCl, 0.015 M sodium citrate), followed by washes in 6× SSC at 50-55° C. However, the skilled artisan will recognize that stringent hybridization conditions for oligonucleotide probes will vary, depending on the length, base composition and sequence of the probe (e.g., see Sambrook et al., 11.45-11.49).

[0050] The present invention includes polypeptides having amino acid sequences that differ from, but are highly homologous to, those presented in SEQ ID NOS:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38. Examples include, but are not limited to, homologs derived from other mammalian species, variants (both naturally occurring variants and those generated by recombinant DNA technology), and LIR P3G2 and LIR family member fragments that retain a desired biological activity. Preferably, such polypeptides exhibit a biological activity associated with the LIR polypeptides described in SEQ ID NOS:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38, and comprise an amino acid sequence that is at least 80% identical to any of the amino acid sequences of the signal peptide and extracellular domains of the polypeptides presented in SEQ ID NOS:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38. Preferably such polypeptides are at least 90% identical to any of the amino acid sequences of the signal peptide and extracellular domains of the polypeptides presented in SEQ ID NOS: 2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38. Determining the degree of identity between polypeptides can be achieved using any algorithms or computer programs designed for analyzing protein sequences. The commercially available GAP program described below is one such program. Other programs include the BESTFIT and GCG programs which are also commercially available.

[0051] Within the scope of the present invention are LIR polypeptide fragments that retain a desired biological property of an LIR polypeptide family member such as binding to MHC class I or other ligand. In one such embodiment, LIR polypeptide fragments are soluble LIR polypeptides comprising all or part of the extracellular domain, but lacking the transmembrane region that would cause retention of the polypeptide on a cell membrane. Soluble LIR polypeptides are capable of being secreted from the cells in which they are expressed. Advantageously, a heterologous signal peptide is fused to the N-terminus such that the soluble LIR is secreted upon expression. Soluble LIR polypeptides include extracellular domains incorporating the signal peptide and those in which the signal peptide is cleaved signal peptide.

[0052] The use of soluble forms of a LIR family member is advantageous for certain applications. One such advantage is the ease of purifying soluble forms from recombinant host cells. Since the soluble proteins are secreted from the cells, the protein need not be extracted from cells during the recovery process. Additionally, soluble proteins are generally more suitable for intravenous administration and can be used to block the interaction of cell surface LIR family members with their ligands in order to mediate a desirable immune function.

[0053] Further encompassed within the present invention are soluble LIR polypeptides, which may include the entire extracellular domain or any desirable fragment thereof, including extracellular domains that exclude signal peptides. Thus, for example, soluble LIR polypeptides include amino acids x₁-458 of SEQ ID NO:2, where x₁ is amino acids 1 or 17; amino acids x₂-459 of SEQ ID NO:4, where x₂ is amino acid 1 or 17; amino acids x₃-439 of SEQ ID NO:8, where x₃ is amino acid 1 or 17; amino acids x₄-458 of SEQ ID NO:10, where x₄ is amino acid 1 or 17; amino acids x₅-241 of SEQ ID NO:12, where amino acid x5 is amino acid 1 or 17; amino acids x₆461 of SEQ ID NO:14, where x₆ is amino acid 1 or 17; amino acids x₇-449 of SEQ ID NO:16, where x₇ is amino acid I or 17; amino acids x ₈-259 of SEQ ID NO:18, where x₈ is amino acid 1 or 17; amino acids x₉-443 of SEQ ID NO:20, where x₉ is amino acid I or 17; amino acids x₁₀-456 ofSEQ ID NO:22, where x₁₀ is amino acid 1 or 17; amino acids x₁-262 of SEQ ID NO:30, where x₁₂ is amino acid 1 or 35; amino acids x₁₂-250 of SEQ ID NO:32, where x₁₂ is amino acid 1 or 36; amino acids x₃ of SEQ ID NO:34, where x₁₃ is amino acid 1 or 35; amino acids x ₄of SEQ ID NO:36, where x₁₄ is amino acid 1 or 36; and amino acids 1-393 of SEQ ID NO:38. The above identified soluble LIR polypeptides include LIR extracellular regions that include and exclude signal peptides. Also encompassed herein are LIRs that lack a transmembrane and cytoplasmic region, such as SEQ ID NOS:8, 34 and 36. Additional soluble LIR polypeptides include fragments of the extracellular domains of family members that retain a desired biological activity, such as binding to ligands that include MHC class I molecules.

[0054] LIR family member fragments, including soluble polypeptides, may be prepared by any of a number of conventional techniques. A DNA sequence encoding a desired LIR polypeptide encoding fragment may be subcloned into an expression vector for production of the LIR polypeptide fragment. The selected encoding DNA sequence advantageously is fused to a sequence encoding a suitable leader or signal peptide. The desired LIR member encoding DNA fragment may be chemically synthesized using known DNA synthesis techniques. DNA fragments also may be produced by restriction endonuclease digestion of a full length cloned DNA sequence, and isolated by electrophoresis on an appropriate gel. If necessary, oligonucleotides that reconstruct the 5′ or 3′ terminus to a desired point may be ligated to a DNA fragment generated by restriction enzyme digestion. Such oligonucleotides may additionally contain a restriction endonuclease cleavage site upstream of the desired coding sequence, and position an initiation codon (ATG) at the N-terminus of the coding sequence.

[0055] Another technique useful for obtaining a DNA sequence encoding a desired protein fragment is the well-known polymerase chain reaction (PCR) procedure. Oligonucleotides which define the termini of the desired DNA are used as primers to synthesize additional DNA from a desired DNA template. The oligonucleotides may also contain recognition sites for restriction endonucleases, to facilitate inserting the amplified DNA fragment into an expression vector. PCR techniques are described, for example, in Saiki et al., Science 239:487(1988): Recombinant DNA Methodology, Wu et al., eds., Academic Press, Inc., San Diego (1989), pp. 189-196; and PCR Protocols: A Guide to Methods and Applications, Innis et al., eds., Academic Press, Inc. (1990).

[0056] The LIR nucleic acid molecules of the present invention include isolated cDNA, chemically synthesized DNA, DNA isolated by PCR, cloned genomic DNA, and combinations thereof. Genomic LIR family DNA may be isolated by hybridization to the LIR family cDNA disclosed herein using standard techniques. Isolated RNA transcribed from LIR family DNA molecules is also encompassed by the present invention.

[0057] Within the scope of the present invention are DNA fragments such as LIR polypeptide coding regions and DNA fragments that encode soluble polypeptides. Examples of DNA fragments that encode soluble polypeptides include DNA that encodes entire extracellular regions of LIR family members and DNA that encodes extracellular region fragments such as regions lacking the signal peptide. More specifically, the present invention includes nucleotides 310-2262 of SEQ ID NO:1 (P3G2 coding region); nucleotides x,-1683 of SEQ ID NO:1, where x₁ is 310 or 358 (encoding the P3G2 extracellular domain); nucleotides 168-2126 of SEQ ID NO:3 (the 18A3 coding region) and nucleotides x₂-1544 of SEQ ID NO:3, where x₂ is 168 or 216 (the 18A3 extracellular domain coding region); nucleotides X₃-1412 of SEQ ID NO:7, where x₃ is 93 or 141 (the pbm25 coding region and extracellular region); nucleotides 184-1980 of SEQ ID NO:9, (the pbm8 coding region) and nucleotides x₄-1557 of SEQ ID NO:9, where X₃ is 184 or 232 (the pmb8 extracellular domain coding region); nucleotides 171-1040 of SEQ ID NO:11 (pbm36-2 coding region) and nucleotides x₅-878 of SEQ ID NO:11, where x₅ is 171 or 219 (encoding the pbm36-2 extracellular domain); nucleotides 183-1652 of SEQ ID NO:13 (coding region for pbm36-4) and nucleotides x₆-1565 of SEQ ID NO:13, where x₆ is 183 or 231 (encoding the pbm364 extracellular domain); nucleotides 40-1491 of SEQ ID NO:15 (the pbmhh coding region) and nucleotides x₇-1386 of SEQ ID NO:15, where x₇ is 40 or 88 (encoding the pbmhh extracellular domain); nucleotides 30-1376 of SEQ ID NO:17 (the pbm2 coding region) and nucleotides x₈-806 of SEQ ID NO:17, where x is 30 or 78 (encoding the pbm2 extracellular region); nucleotides 66-1961 of SEQ ID NO:19 (the pbm17 coding region) and nucleotides x₉-1394 of SEQ ID NO:19, where x₉ is 66 or 114 (encoding the pbm17 extracellular domain); nucleotides 67-1839 of SEQ ID NO:21 (the pbmnew coding region) and nucleotides x₁₀-1434 of SEQ ID NO:21, where x₁₀ is 67 or 115 (encoding the pbmnew extracellular domain); nucleotides 69-968 of SEQ ID NO:29 (the coding region of LIR-9 ml) and nucleotides x₁₁-854 of SEQ ID NO:29, where x₁₁ is 69 or 170 (encoding the LIR-9 ml extracellular domain); nucleotides 95-958 of SEQ ID NO:31 (the LIR-9m2 coding region) and nucleotides x₁₂-844 of SEQ ID NO:31, where x₁₂ is 95 or 200 (encoding the LIR-9m2 extracellular domain); nucleotides x₁₃-912 of SEQ ID NO:33, where x₁₃ is 115 or 216 (the LIR-9s1 coding region and extracellular region); nucleotides x₁₄-834 of SEQ ID NO:35, where x₁₄ is 73 or 178 (the LIR-9s2 coding region and extracellular region); nucleotides 1-1350 of SEQ ID NO:37 (the LIR-10 coding region) and nucleotides 1-1179 of SEQ ID NO:37 (encoding all but a few amino-terminal amino acids of the LIR-10 extracellular domain).

[0058] Included in the present invention are DNAs encoding biologically active fragments of the LIR proteins whose amino acid sequences are presented in SEQ ID NOS:2,4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38.

[0059] The present invention encompasses nucleotide sequences which, due to the degeneracy of the genetic code, encode polypeptides that are identical to polypeptides encoded by the nucleic acid sequences described above, and sequences complementary to them. Accordingly, within the present invention are DNA encoding biologically active LIR family members that include the coding region of a native human LIR family member cDNA, or fragments thereof, and DNA that is degenerate as a result of the genetic code to the native LIR polypeptide DNA sequence or the DNA of native LIR family members described herein.

[0060] In another aspect, the present invention includes LIR variants and derivatives as well as variants and derivatives of LIR family polypeptides, both recombinant and non-recombinant, that retain a desired biological activity. An LIR variant, as referred to herein, is a polypeptide substantially homologous to a native LIR polypeptide, as described herein, except the variant amino acid sequence differs from that of the native polypeptide because of one or more deletions, insertions or substitutions.

[0061] LIR family variants may be obtained from mutations of native LIR nucleotide sequences. Within the present invention are such DNA mutations or variants that include nucleotide sequences having one or more nucleotide additions, nucleotide deletions, or nucleotide substitutions compared to native DNA of LIR family members and that encode variant LIR polypeptides or variant LIR family members having a desired biological activity. Preferably the biological activity is substantially the same as that of the native LIR polypeptide.

[0062] Variant amino acid sequences and variant nucleotide sequences of the present invention preferably are at least 80% identical to that of a native LIR family member sequence. One method for determining the degree of homology or identity between a native amino acid or nucleotide sequence and a variant amino acid or nucleotide sequence is to compare the sequences using computer programs available for such purposes. One suitable computer program is the GAP program, version 6.0, described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970), as revised by Smith and Waterman (Adv. Appl. Math 2:482, 1981). Briefly, the GAP program defines identity as the number of aligned symbols (i.e., nucleotides or amino acids) which are identical, divided by the total number of symbols in the shorter of the two sequences being compared. The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

[0063] Alterations of native LIR amino acid sequences may be provided by using any of a number of known techniques. As described above, mutations can be introduced at selected sequence sites by synthesizing oligonucleotides containing a mutant coding sequence, flanked by restriction sites enabling its ligation to fragments of the native sequence. After ligating the synthesized oligonucleotides to the native sequence fragments, the resulting reconstructed nucleotide sequence will encode an analog or variant polypeptide having the desired amino acid insertion, substitution, or deletion. Another procedure suitable for preparing variant polypeptides is oligonucleotide-directed site-specific mutagenesis procedures which provide genes having specific codons altered in accordance with the desired substitution, deletion, or insertion. Techniques for making such alterations include those disclosed in the following references: Walder et al. Gene, 42:133, 1986; Bauer et al., Gene 37:73, 1985; Craik, BioTechniques, 12-19 January, 1985; Smith et al. Genetic Engineering: Principles and Methods, Plenum Press, 1981; and U.S. Pat. Nos. 4,518,584 and 4,737,462, all of which are incorporated herein by reference.

[0064] Variant polypeptides of the present invention may have amino acid sequences which are conservatively substituted, meaning that one or more amino acid residues of a native LIR polypeptide family member is replaced by different residues, such that the variant polypeptide retains a desired biological activity that is essentially equivalent to that of a native LIR family member. In general, a number of approaches to conservative substitutions are well known in the art and can be applied in preparing variant of the present invention. For example, amino acids of the native polypeptide sequence may be substituted for amino acids which do not alter the secondary and/or tertiary structure of the LIR polypeptide. Other suitable substitutions include those which involve amino acids outside of the ligand-binding domain of interest. One approach to conservative amino acid substitutions involves replacing one or amino acids with those having similar physiochemical characteristics, e.g. substituting one aliphatic residue for another such as Ile, Val, Leu, or Ala for one another); substituting one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gln and Asn); or substituting entire regions having similar hydrophobicity or hydrophilic characteristics.

[0065] LIR polypeptide variants can be tested for binding to cells as described in Examples 5 and 6 and for phosphatase binding activity as described in Example 11 to confirm biological activity. Other LIR variants within the present invention include polypeptides which are altered by changing the nucleotide sequence encoding the polypeptide so that selected polypeptide Cys residues are deleted or replaced with one or more alternative amino acids. These LIR variants will not form intramolecular disulfide bridges upon renaturation. Naturally occurring LIR polypeptides selected for alteration by deleting or altering Cys residues preferably do not have biological activities which depend upon disulfide bridges formed by the Cys residue. Other possible variants are prepared by techniques which cause the modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. EP 212,914 discloses site-specific mutagenesis techniques for inactivating KEX2 protease processing sites in a protein. KEX2 protease processing sites are inactivated by deleting, adding or substituting residues to alter Arg-Arg, Arg-Lys, and Lys-Arg pairs to eliminate the occurrence of these adjacent basic residues. Lys-Lys and pairings are considerably less susceptible to KEX2 cleavage, and conversion of Arg-Lys or Lys-Arg to Lys-Lys represents a conservative and preferred approach to inactivating KEX2 sites.

[0066] Naturally occurring LIR variants are also encompassed by the present invention. Examples of such variants are proteins that result from alternative mRNA splicing events or from proteolytic cleavage of an LIR polypeptide. Alternative splicing of mRNA may yield a truncated but biologically active LIR polypeptide such as a naturally occurring soluble form of the protein. Variations attributable to proteolysis include difference in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the LIR polypeptide. In addition, proteolytic cleavage may release a soluble form of LIR from a membrane-bound form of the polypeptide. Other naturally occurring LIR variations are those in which differences from the amino acid sequence of SEQ ID Nos:2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36 and 38 are attributable to genetic polymorphism, the allelic variation among individuals.

[0067] Within the scope of the present invention are derivative LIR family polypeptides which include native or variant LIR polypeptides modified to form conjugates with selected chemical moieties. The conjugates can be formed by covalently linking another moiety to a native or variant LIR or by non-covalently linking another moiety to a native or variant LIR. Suitable chemical moieties include but are not limited to glycosyl groups, lipids, phosphates, acetyl groups, and other proteins or fragments thereof. Techniques for covalently linking chemical moieties to proteins are well known in the art and are generally suitable for preparing derivative LIR polypeptides. For example, active or activated functional groups on amino acid side chains can be used as reaction sites for covalently linking a chemical moiety to a LIR polypeptide. Similarly, the N-terminus or C-terminus can provide a reaction site for a chemical moiety. LIR polypeptides or fragments conjugated with other proteins or protein fragments can be prepared in recombinant culture as N-terminal or C-terminal fusion products. For example, the conjugate or fusion portions may include a signal or leader sequence attached to an LIR molecule at its N-terminus. The signal or leader peptide co-translationally or post-translationally directs transfer of the conjugate from its site of synthesis to a site inside or outside of the cell membrane.

[0068] One useful LIR polypeptide conjugate is one incorporating a poly-His or the antigenic identification peptides described in U.S. Pat. No. 5,011,912 and in Hopp et al., Bio/Technology 6:1124, 1988. For example, the FLAG® peptide, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (SEQ ID NO:39) is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, thus enabling rapid assay and facile purification of expressed recombinant protein. This sequence is specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may be resistant to intracellular degradation in E. coli. Murine hybridoma designated 4E11 produced a monoclonal antibody that binds the peptide of SEQ ID NO:39 in the presence of certain divalent metal cations, and has been deposited with the American Type Culture Collection under accession no HB 9259. Expression systems useful for producing recombinant proteins fused to the FLAG® peptide, and monoclonal antibodies that bind the peptide and are useful in purifying the recombinant proteins, are available from Eastman Kodak Company, Scientific Imaging Systems, New Haven, Conn.

[0069] Particularly suitable LIR fusion proteins are those in which an LIR polypeptide is in the form of an oligomer. Oligomers may be formed by disulfide bonds between cysteine residues on more than one LIR polypeptide, or by noncovalent interactions between LIR polypeptide chains. In another approach, LIR oligomers can be formed by joining LIR polypeptides or fragment thereof via covalent or noncovalent interactions between peptide moieties fused to the LIR polypeptide. Suitable peptide moieties include peptide linkers or spacers, or peptides that have the property of promoting oligomerization. Leucine zippers and certain polypeptides derived from antibodies are among the peptides that can promote oligomerization of LIR polypeptides attached thereto.

[0070] Other LIR fusion proteins which promote oligomer formation are fusion proteins having heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain). Procedures for preparing such fusion proteins are described in Ashkenazi et al. PNAS USA 88:10535, 1991; Byrne et al. Nature 344:667, 1990, and Hollenbaugh and Aruffo Current Protocols in Immunology, Supplement 4, pages 10.19.1-10.19.11, 1992; all of which are incorporated herein by reference. Example 1 and Example 5 below describe methods for preparing UL18:Fc and P3G2:Fc fusion proteins, respectively, by fusing P3G2 and UL18 to an Fc region polypeptide derived from an antibody. This is accomplished by inserting into an expression vector a gene fusion encoding the P3G2:Fc fusion protein and expressing the P3G2:Fc fusion protein. The fusion proteins are allowed to assemble much like antibody molecules, whereupon interchain disulfide bonds form between the Fc polypeptides, yielding divalent P3G2 polypeptide. In a similar approach, P3G2 or any LIR polypeptide may be substituted for the variable portion of an antibody heavy or light chain. If fusion proteins are made with heavy and light chains of an antibody, it is possible to form a LIR oligomer with as many as four LIR regions.

[0071] Thus, the invention encompasses nucleic acids that encode fusion proteins that include the Fc region of Ig and an amino acid sequence including the extracellular region of any of the LIR family member proteins. Such extracellular regions include, e.g., amino acids x₁-458 of SEQ ID NO:2, where x₁ is amino acids 1 or 17; amino acids x₂-459 of SEQ ID NO:4, where x₂ is amino acid 1 or 17; amino acids x₃-439 of SEQ ID NO:8, where x₃ is amino acid 1 or 17; amino acids x₄-458 of SEQ ID NO:10, where x₄ is amino acid 1 or 17; amino acids x₅ to 261 of SEQ ID NO:12, wherein x₅ is amino acid 1 or 17; amino acids x₆ to 461 of SEQ ID NO:14, wherein x₆ is amino acid 1 or 17; amino acids x₇-449 of SEQ ID NO:16, where x7 is amino acid 1 or 17; amino acids x₈-259 of SEQ ID NO:18, where x₈ is amino acid 1 or 17; amino acids x₉-443 of SEQ ID NO:20, where x₉ is amino acid I or 17; amino acids x₁₀ to 456 of SEQ ID NO:22, wherein x₁₀ is amino acid 1 or 17; amino acids x₁₁ to 262 of SEQ ID NO:30, wherein x₁₁ is amino acid 1 or 35; amino acids x₁₂ to 250 of SEQ ID NO:32, wherein x₁₂ is amino acid 1 or 36; amino acids x₁₃ to 265 of SEQ ID NO:34, wherein x₁₃ is amino acid 1 or 35; and amino acids x₁₄ to 253 of SEQ ID NO:36, wherein x₁₄ is amino acid 1 or 36; and amino acids 1-393 of SEQ ID NO:38.

[0072] As used herein, a Fc polypeptide includes native and mutein forms, as well as truncated Fc polypeptides containing the hinge region that promotes dimerization. One suitable Fc polypeptide is the native Fc region polypeptide derived from a human IgGI, which is described in PCT application WO 93/10151, hereby incorporated herein by reference. Another useful Fc polypeptide is the Fc mutein described in U.S. Pat. No. 5,457,035. The amino acid sequence of the mutein is identical to that of the native Fc sequence presented in WO 93/10151, except that amino acid 19 has been changed from Leu to Ala, amino acid 20 has been changed from Leu to Glu, and amino acid 22 has been changed from Gly to Ala. This mutein Fc exhibits reduced affinity for immunoglobulin receptors.

[0073] Alternatively, oligomeric LIR polypeptide variants may include two or more LIR peptides joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627, incorporated herein by reference. Fusion proteins which include multiple LIR polypeptides separated by peptide linkers may be produced conventional recombinant DNA technology.

[0074] Another method for preparing oligomeric LIR polypeptide variants involves use of a leucine zipper. Leucine zipper domains are peptides that promote oligomerization of the proteins in which they are found. Leucine zippers were first identified in several DNA-binding proteins (Landschulz et al. Science 240:1759, 1988). Among the known leucine zippers are naturally occurring peptides and peptide derivatives that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble oligomeric LIR polypeptides or oligomeric polypeptides of the LIR family are those described in PCT application WO 94/10308, incorporated herein by reference. Recombinant fusion proteins having a soluble LIR polypeptide fused to a peptide that dimerizes or trimerizes in solution may be expressed in suitable host cells, and the resulting soluble oligomeric LIR polypeptide recovered from the culture supernatant.

[0075] Numerous reagents useful for cross-linking one protein molecule to another are known. Heterobifunctional and homobifunctional linkers are available for this purpose from Pierce Chemical Company, Rockford, Ill., for example. Such linkers contain two functional groups (e.g., esters and/or maleimides) that will react with certain functional groups on amino acid side chains, thus linking one polypeptide to another.

[0076] One type of peptide linker that may be employed in the present invention separates polypeptide domains by a distance sufficient to ensure that each domain properly folds into the secondary and tertiary structures necessary for the desired biological activity. The linker also should allow the extracellular portion to assume the proper spatial orientation to form the binding sites for ligands.

[0077] Suitable peptide linkers are known in the art, and may be employed according to conventional techniques. Among the suitable peptide linkers are those described in U.S. Pat. Nos. 4,751,180 and 4,935,233, which are hereby incorporated by reference. A peptide linker may be attached to LIR polypeptides by any of the conventional procedures used to attach one polypeptide to another. The cross-linking reagents available from Pierce Chemical Company as described above are among those that may be employed. Amino acids having side chains reactive with such reagents may be included in the peptide linker, e.g., at the termini thereof. Preferably, a fusion proteins formed via a peptide linker are prepared by recombinant DNA technology.

[0078] The fusion proteins of the present invention include constructs in which the C-terminal portion of one protein is fused to the linker which is fused to the N-terminal portion of another protein. Peptides linked in such a manner produce a single protein which retains the desired biological activities. The components of the fusion protein are listed in their order of occurrence (i.e., the N-terminal polypeptide is listed first, followed by the linker and then the C-terminal polypeptide).

[0079] A DNA sequence encoding a fusion protein is constructed using recombinant DNA techniques to insert separate DNA fragments encoding the desired proteins into an appropriate expression vector. The 3′ end of a DNA fragment encoding one protein is ligated (via the linker) to the 5′ end of the DNA fragment encoding another protein with the reading frames of the sequences in phase to permit translation of the mRNA into a single biologically active fusion protein. A DNA sequence encoding an N-terminal signal sequence may be retained on the DNA sequence encoding the N-terminal polypeptide, while stop codons, which would prevent read-through to the second (C-terminal) DNA sequence, are eliminated. Conversely, a stop codon required to end translation is retained on the second DNA sequence. DNA encoding a signal sequence is preferably removed from the DNA sequence encoding the C-terminal polypeptide.

[0080] A DNA sequence encoding a desired polypeptide linker may be inserted between, and in the same reading frame as, the DNA sequences encoding the two proteins using any suitable conventional technique. For example, a chemically synthesized oligonucleotide encoding the linker and containing appropriate restriction endonuclease cleavage sites may be ligated between the sequences encoding Fc and a P3G2 polypeptide.

[0081] Within the scope of the present invention are recombinant expression vectors for expressing polypeptides of the LIR family, and host cells transformed with the expression vectors. Expression vectors of the invention include DNA that encodes a LIR family member operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the LIR DNA sequence. Thus, a promoter nucleotide sequence is operably linked to a LIR DNA sequence if the promoter nucleotide sequence controls the transcription of the LIR DNA sequence. An origin of replication that confers the ability to replicate in the desired host cells, and a selection gene by which transformants are identified, are generally incorporated in the expression vector.

[0082] In addition, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in frame to the LIR sequence so that the LIR is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells promotes extracellular secretion of the LIR polypeptide. The signal peptide is cleaved from the LIR polypeptide upon secretion of the LIR polypeptide from the cell.

[0083] The recombinant expression vectors of the present invention may include any DNA encoding a LIR polypeptide. Exemplary DNAs for inclusion in such expression vectors include the nucleic acid molecules whose sequences are shown in SEQ ID NOS:1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35 and 37.

[0084] Suitable host cells for expression of LIR polypeptides include prokaryotes, yeast or higher eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. Coning Vectors: A Laboratory Manual, Elsevier, New York, (1985). Cell-free translation systems could also be employed to produce P3G2 polypeptides using RNAs derived from DNA constructs disclosed herein.

[0085] Prokaryote host cells suitable in the practice of the present invention include gram negative or gram positive organisms, for example, E. coli or Bacilli. Suitable prokaryotic host cells for transformation include, for example, E. coli, Bacillus subtilis, Salmonella typhimurium, and various other species such as Pseudomonas, Streptomyces, and Staphylococcus. In a prokaryotic host cell, such as E. coli, a P3G2 polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide. The N-terminal Met may be cleaved from the expressed recombinant LIR polypeptide.

[0086] Expression vectors for use in prokaryotic host cells generally include one or more phenotypic selectable marker genes. A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokarytoic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. An appropriate promoter and a LIR family DNA may be inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, Wis., USA).

[0087] Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include β-lactamase (penicillinase), lactose promoter system (Chang et al. Nature 75:615, 1978; and Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980); and EP-A-36776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phase λP_(L) promoter and a cI857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λP_(L) promoter include plastid pHUB2 (resident in E. coli strain JMB9, ATCC 37092) and pPLc28 (resident in E. coli RRI, ATCC 53082).

[0088] Alternatively, LIR polypeptides may be expressed in yeast host cells, preferably from the Saccharomyces genus (e.g., S. cerevisiae). Other genera of yeast, such as Pichia or Kluyveromyces may also be employed. Yeast vectors will often contain an origin of replication sequence from a 2μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Suitable promoter sequences for yeast vectors include, among others, promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem 255:2073, 1980) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149, 1968); and Holland et al., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,675. Another alternative is the glucose-repressible ADH2 promoter described by Russell et al. (J. Biol. Chem. 258:2674, 1982) and Beier et al. (Nature 300:724, 1982). Shuttle vectors replicable in both yeast and E. coli may be constructed by inserting DNA from pBR322 for selection and replication in E. coli (Amp^(r) gene and origin of replication) into the above-described yeast vectors.

[0089] The yeast α-factor leader sequence may be employed to direct secretion of the LIR polypeptide. The α-factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kurjan et al., Cell 30:933,1982 and Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, 1984. Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3′ end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

[0090] Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929, 1978. The Hinnen et al. protocol selects for Trp⁺ transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 μg/mL adenine and 20 μg/mL uracil.

[0091] Yeast host cells transformed by vectors containing an ADH2 promoter sequence may be grown for inducing expression in a “rich” medium. An example of a rich medium is one having 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 μg/mL uracil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

[0092] Mammalian or insect host cell culture systems may be used to express recombinant LIR polypeptides. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47 (1988). Established cell lines of mammalian origin also may be employed. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651)(Gluzman et al., Cell 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CVI/EBNA cell dine derived from the African green monkey cell line CVI (ATCC CCL 70) as described by McMahan et al. (EMBO J. 10:2821, 1991). COS-1 (ATCC CRL-1650).

[0093] Transcriptional and translational control sequences for mammalian host cell expression vectors may be excised from viral genomes. Commonly used promoter sequences and enhancer sequences are derived from Polyoma virus, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment which may also contain a viral origin of replication (Fiers et al., Nature 273:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the HIND III site toward the Bgl/I site located in the SV40 viral origin of replication site is included.

[0094] Suitable expression vectors for use in mammalian host cells can be constructed as disclosed by Okayama and Berg (Mol. Cell. Biol. 3:280, 1983). One useful system for stable high level expression of mammalian receptor cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (Mol. Immunol. 23:935, 1986). A high expression vector, PMLSV N1/N4, described by Cosman et al., Nature 312:768, 1984 has been deposited as ATCC 39890. Additional mammalian expression vectors are described in EP-A-0367566, and in WO 91/18982. Still additional expression vectors for use in mammalian host cells include pDC201 (Sims et al., Science 241:585, 1988), pDC302 (Mosley et al. Cell 59:335, 1989), and pDC406 (McMahan et al., EMBO J. 10:2821, 1991). Vectors derived from retroviruses also may be employed. One preferred expression system employs pDC409 as discussed in Example 5 below.

[0095] For expression of LIR polypeptides the expression vector may comprise DNA encoding a signal or leader peptide. In place of the native signal sequence, a heterologous signal sequence may be added, such as the signal sequence for interleukin-7 (IL-7) described in U.S. Pat. No. 4,965,195; the signal sequence for interleukin-2 receptor described in Cosman et al., Nature 312:768, 1984); the interleukin4 signal peptide described in EP 367,566; the type I interleukin-1 receptor signal peptide described in U.S. Pat. No. 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP 460,846.

[0096] Further contemplated within the present invention are purified LIR family polypeptides, and processes for their purification. The purified polypeptides of the present invention may be purified from the above-described recombinant expression systems or may be purified from naturally occurring cells. The desired degree of purity may depend on the intended use of the protein with a relatively high degree of purity preferred when the protein is intended for in vivo use. Preferably, LIR polypeptide purification processes are such that no protein bands corresponding to proteins other than the desired LIR protein are detectable by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). It will be recognized by one skilled in the art that multiple bands corresponding to any LIR polypeptide my be detected by SDS-PAGE, due to differential glycosylation, variations in post-translational processing, and the like, as discussed above. Most preferably, any specific LIR polypeptide is purified to substantial homogeneity, as indicated by a single protein band upon analysis by SDS-PAGE. The protein band may be visualized by silver staining, Coomassie blue staining, or by autoradiography or fluorescence if the protein is appropriately labeled.

[0097] One process for providing purified LIR polypeptides includes first culturing a host cell transformed with an expression vector comprising a DNA sequence that encodes the desired polypeptide under conditions that promote expressing the desired LIR polypeptide and then recovering the LIR polypeptide. As the skilled artisan will recognize, procedures for recovering the polypeptide will vary according to such factors as the type of host cells employed and whether the polypeptide is secreted in the culture medium is extracted from cells.

[0098] When the expression system secretes the polypeptide into the culture medium, the medium may be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, such as a resin matrix or resin substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Similarly, a purification matrix having cation exchange groups such as sulfopropyl or carboxymethyl functionalities on an insoluble matrix can be used. Sulfopropyl groups are preferred. Still other purification matrices and methods suitable for providing purified LIR are high performance liquid chromatography using hydrophobic reversed phase media (RP-HPLC). One skilled in the art will recognized the any or all of the foregoing purification steps, in various combinations, can be employed to provide a purified LIR polypeptide.

[0099] Alternatively, LIR polypeptides can be purified by immunoaffinity chromatography. An affinity column containing an antibody that binds a LIR polypeptide may be prepared by conventional procedures and employed in purifying LIR. Example 5 describes a procedures for generating monoclonal antibodies directed against P3G2 which may be utilized in immunoaffinity chromatography.

[0100] Recombinant protein produced in bacterial culture may be isolated by first disrupting the host cells by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents and then extracting the polypeptide from cell pellets if the polypeptide is insoluble, or from the supernatant fluid if the polypeptide is soluble. After the initial isolation step, the purification process may include one or more concentrating, salting out, ion exchange, affinity, or size exclusion chromatography purification steps. For many application a final RP-HPLC purification step is beneficial.

[0101] Additional methods for providing LIR polypeptides and purified LIR polypeptides involves fermenting yeast which express proteins as a secreted protein. Secreted recombinant protein resulting from a large-scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (J. Chromatog. 296:171, 1984), involving two sequential, reversed-phase HPLC steps for purification of a recombinant protein on a preparative HPLC column.

[0102] LIR-P3G2 DNA in pDC406 vector was deposited with the American Type Culture Collection on Apr. 22, 1997 and assigned accession No.97995. The deposit was made under the terms of the Budapest Treaty.

[0103] As described above and shown in Examples 6 and 14, LIR-P3G2 and LIR-pbm8 are MHC class I receptor molecules found on the surface of certain monocytes, B cells, and NK cells. With respect to monocytes, the expression of LIRs that are MHC class I binding proteins suggests that there is some requirement for monocytes to recognize MHC class I molecules. LIR-P3G2, LIR-pbm8 LIR and certain additional LIR family members contain cytoplasmic ITIM motifs. By analogy with the structure and function of known MHC class I receptor molecules, these LIRs are inhibitory receptors mediating negative signaling. Indeed, the results demonstrated in Example 11 reveal that LIRS associate with SHP-1 and inhibit FcR-mediated activation events. Thus, monocytes may express class I receptors in order to suppress cell-mediated lytic mechanisms. Monocytes rapidly phagocytes extracellular pathogens via FcR and, monocyte-FcR engagement induces propagation of immune responses by producing more systemic mediators, particularly TNF-α, IL-6 and IL-8. Thus, the LIRs play a role in monocyte and macrophage regulation of cytolytic and inflammatory responses against self tissues. The interplay between the FcR activatory signals and LIR inhibitory signal may allow low levels of self-reactive IgG to exist in circulation and bind to the monocyte membrane with initiating an immune response. For example, the expression of these inhibitory receptors can protect the developing embryo from maternal antibody-mediated allogeneic recognition.

[0104] With respect to LIRs on cells of the DC lineage, as described in Example 13 CD33⁺CD14⁻CD16-HLA⁻DR⁺DC co-express LIR-P3G2 and LIR-pbm8. It is suggested the DC FcR play a role in binding immune complexes and triggering DC activation signal following binding. Thus, LIRs expressed on DC may suppress DC activation through interactions of FcR.

[0105] Many LIR family members lack the ITIM motif and by analogy with the structure and function of known MHC class I receptors lacking ITIMs are activatory receptors. Failure of a receptor that mediates negative signaling could result in autoimmune diseases. Thus, engaging an LIR family member having ITIM motifs with an agonistic antibody or ligand can be used to downregulate a cell function in disease states in which the immune system is overactive and excessive inflammation or immunopathology is present. On the other hand, using an antagonistic antibody specific to the ITIM possessing LIR receptor or a soluble form of the receptor can be used to block the interaction of the cell surface receptor with the receptor's ligand to activate the specific immune function in disease states associated with suppressed immune function. Since receptors lacking the ITIM motif send activatory signals once engaged as described above, failure of a receptor that mediates an activatory signal could result in suppressed immune function. Engaging the receptor with its agonistic antibody or ligand can be used to treat diseases associated with the suppressed immune function. Using an antagonistic antibody specific to the activatory LIR receptor or a soluble form of the receptor can be used to block the interaction of the activatory receptor with the receptor's ligand to downregulate the activatory signaling.

[0106] Since LIR-P3G2 binds to various cells, LIR-P3G2 may be used to purify or isolate these cells from heterogeneous preparations. Additionally, P3G2 probes can be used to isolate and identify related molecules.

[0107] LIR polypeptides of the present invention may be used in developing treatments for any disorder mediated directly or indirectly by defective or insufficient amounts of any of the LIR polypeptides. A therapeutically effective amount of purified LIR protein is administered by a patient afflicted with such a disorder. Alternatively, LIR DNA may be employed in developing a gene therapy approach to treating such disorders. Disclosure herein of native LIR nucleotide sequence permits the detection of defective LIR genes, and the replacement thereof with normal LIR-encoding genes. Defective genes may be detected in vitro diagnostic assays, and by comparison of the native LIR nucleotide sequence disclosed herein with that of an LIR gene derived from a person suspected of harboring a defect in the gene.

[0108] The present invention also provides pharmaceutical compositions which may include an LIR polypeptide, or fragments or variants thereof with a physiologically acceptable carrier or diluent. Such carriers and diluents will be nontoxic to recipients at the dosages and concentrations employed. Such compositions may further include buffers, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients commonly used in pharmaceutical compositions. The pharmaceutical compositions of the present invention may be formulated as a lyophilizate using appropriate excipient solutions as diluents. The pharmaceutical compositions may include an LIR polypeptide in any for described herein, including but not limited to active variants, fragments, and oligomers. LIR polypeptides may be formulated according to known methods that are used to prepare pharmaceutically useful compositions. Components that are commonly employed in pharmaceutical formulations include those described in Remington's Pharmaceutical Sciences, 16th ed. (Mack Publishing Company, Easton, Pa., 1980).

[0109] The pharmaceutical preparations of the present invention may be administered to a patient, preferably a human, in a manner appropriate to the indication. Thus, for example, the compositions can be administered by intravenous injection, local administration, continuous infusion, sustained release from implants, etc. Appropriate dosages and the frequency of administration will depend on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient and so forth.

[0110] In preferred embodiments an LIR polypeptide used in the pharmaceutical compositions of the present invention is purified such that the LIR polypeptide is substantially free of other proteins of natural or endogenous origin, desirably containing less than about 1% by mass of protein contaminants residual of the production processes. Such compositions, however, can contain other proteins added as stabilizers, carriers, excipients or co-therapeutics.

[0111] LIR encoding DNAs and DNA fragments disclosed herein find use in the production of LIR polypeptides, as described above. In one embodiment, such fragments comprise at least about 17 consecutive nucleotides, more preferably at least 30 consecutive nucleotides, of LIR DNA. DNA and RNA complements of the fragments have similar utility. Among the uses of LIR nucleic acid fragments are as probes or primers in polymerase chain reactions. For example, a probe corresponding to a fragment of DNA encoding the extracellular domain of LIR may be employed to detect the presence of LIR nucleic acids in in vitro assays and in other probing assays such as Northern Blot and Southern blot assays. Cell types expressing an LIR polypeptide can be identified using LIR family nucleic acid probes using probing procedures well known in the art. Those skilled in the art have the knowledge to choose a probe of suitable length and apply conventional PCR techniques to isolate and amplify a DNA sequence.

[0112] Nucleic acid fragments may also be used as a probe in cross species hybridization procedures to isolate LIR DNA from other mammalian species. As one example, a probe corresponding to the extracellular domain of an LIR polypeptide may be employed. The probes may be labeled (e.g., with ³²P) by conventional techniques.

[0113] Other useful fragments of LIR nucleic acids are sense or antisense oligonucleotides, which may comprise either RNA or DNA, and which correspond in sequence to an LIR mRNA (sense), to the complement of an LIR mRNA (antisense), or to the non-coding strand of a double-stranded LIR DNA, such as P3G2 DNA (antisense). Thus, an antisense oligonucleotide will form a hybrid duplex with an mRNA sequence. Such oligonucleotides generally are at least 14 nucleotides, and preferably are from about 14 to about 30 nucleotides. The ability to create an antisense or a sense oligonucleotide based upon a cDNA sequence for a given protein is described in, for example, Stein and Cohen, Cancer Res. 48:2659, 1988 and van der Krol et al., BioTechniques 6:958, 1988.

[0114] Binding antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block translation (RNA) or transcription (DNA) by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. These oligonucleotides thus may be used to block LIR expression.

[0115] In one embodiment antisense or sense LIR oligonucleotides used in binding procedures may encompass oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Oligonucleotides having sugar linkages resistant to endogenous nucleases are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences. Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10448, and other moieties that increase affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

[0116] Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO₄-mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. Antisense or sense oligonucleotides are preferably introduced into a cell containing the target nucleic acid sequence by inserting the antisense or sense oligonucleotide into a suitable retroviral vector, then contacting the cell with the retroviral vector containing the inserted sequence, either in vivo or ex vivo. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see PCT Application US 90/02656).

[0117] Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugating the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind its corresponding molecule or receptor, or block entry of the sense of antisense oligonucleotide or its conjugated version into the cell.

[0118] Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

[0119] In still a further aspect, the present invention provides antibodies that specifically bind LIR polypeptides, i.e., antibodies bind to LIR polypeptides via an antigen-binding site of the antibody (as opposed to non-specific binding). Antibodies of the present invention may be generated using LIR polypeptides or immunogenic fragments thereof. Polyclonal and monoclonal antibodies may be prepared by conventional techniques. See, for example, Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York 1980; and Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988. An exemplary procedure for producing monoclonal antibodies immunoreactive with P3G2-LIR is further illustrated in Example 5 below.

[0120] Included within the scope of the present invention are antigen binding fragments of antibodies which specifically bind to an LIR polypeptide. Such fragments include, but are not limited to, Fab, F(ab′), and F(ab′)₂. Antibody variants and derivatives produced by genetic engineering techniques are contemplated as within the presented invention.

[0121] The monoclonal antibodies of the present invention include chimeric antibodies, e.g., humanized versions of murine monoclonal antibodies. Such antibodies may be prepared by known techniques and offer the advantage of reduced immunogenicity when the antibodies are administered to humans. In one embodiment a humanized monoclonal antibody comprises the variable region of a murine antibody (or just the antigen binding site thereof) and a constant region derived from a human antibody. Alternatively, a humanized antibody fragment may comprise the antigen binding site of a murine monoclonal antibody and a variable region fragment (lacking the antigen-binding site) derived from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al., Nature 332:232, 1988; Lie et al. PNAS 84:3439, 1987; Larrick et al. Bio/Technology 7:934, 1989; and Winter and Harris TIPS 14:139, 1993.

[0122] As mentioned above, antibodies of the present invention are useful in in vitro or in vivo assays to detect the presence of LIR polypeptides and in purifying an LIR polypeptide by affinity chromatography.

[0123] Additionally, antibodies capable of blocking an LIR from binding to target cells may be used to inhibit a biological activity of an LIR polypeptide. More specifically, therapeutic compositions of an antibody antagonistic to one or more LIR family members having the ITIM motif may be administered to an individual in order to block the interaction of a cell surface LIR with its ligand. The result is an activation of immune function and is particularly beneficial in disease states in which the immune system is hyporesponsive or suppressed. Conversely, therapeutic compositions of an antibody antagonistic to one or more LIR family members lacking the ITIM motif may be used to obtain the opposite effect and be beneficial in disease states in which the immune system is overactive and excessive inflammation or immunopathology is present.

[0124] Pharmaceutical compositions which include at least one antibody that is immunoreactive with an LIR polypeptide and a suitable-diluent, excipient, or carrier, are considered with the present invention. Suitable diluents, excipients, and carriers are described in the context of pharmaceutical compositions which include polypeptides of the present invention.

[0125] The following examples are provided to illustrate certain embodiments of the invention, and are not to be construed as limiting the scope of the invention.

EXAMPLES Example 1 Isolating and Expressing Viral Protein

[0126] DNA encoding P3G2 polypeptide of the present invention was identified by isolating and expressing a viral glycoprotein, UL18, known to be expressed on cells infected with HCMV, and then expressing and using a UL18/Fc fusion protein to search for UL18 receptors. DNA encoding UL18 and its amino acid sequence are known and described in Beck, S., B. G. Barrell, Nature 331:269-272, 1988. The following describes isolating UL18 and preparing the UL18/Fc fusion protein.

[0127] Using standard techniques, total RNA was isolated from Human Foreskin Fibroblasts infected with HCMV (AD 169) at three different transcription stages-immediate early (IE, 8 p.i.h.), early (24 p.i.h.) and late (48 p.i.h.). Because UL18 is known to be transcribed early in the infection, the IE total RNA was polyA+ selected and used to construct an HCMV-IE cDNA library using a cDNA kit according to the manufacturer's instructions (Pharmacia TIME SAVER cDNA Kit). In order to isolate the full length UL18 gene, two oligonucleotide primers known to include the terminal sequences of the UL18 gene were synthesized and used to isolate and amplify the UL18 gene from the HCMV-IE cDNA library. The primers had the following sequences and included Not I restriction sites which incorporate into the PCR product:          Not I 5′-TAT GCG GCC GCC ATG ATG ACA ATG (SEQ ID NO:23) TGG T-3′ 5′-TAT GCG GCC GCC CCT TGC GAT AGC (SEQ ID NO:24) G-3′          Not I

[0128] The PCR conditions included one 5 minute 95° C. cycle followed by 30 cycles of 45 seconds at 95°, 45 seconds at 58° and 45 seconds at 72°, and then one cycle for 5 minutes at 72° C. The PCR product was electrophoresed on a 1% agarose gel and sized using ethidium bromide to visualize the separated DNA products. The presence of DNA of having the expected size of approximately 1.1 kb was confirmed.

[0129] The pDC409 expression vector, a vector derived from pDC406 (McMahan et al., EMBO J. 10:2821, 1991) but having a single Bgl II site was selected for the cloning process. The PCR product was subcloned into a pDC409 expression vector through the Not I sites, sequenced and the amino acid sequence deduced from the DNA sequence. The determined nucleotide sequence and amino acid sequence were identical to the previously published sequences (ibid.).

[0130] A fusion protein of the extracellular region of UL18 and a mutein human IgG1 Fc region (UL18:Fc) was prepared by first isolating cDNA encoding the extracellular region of UL18 using primers which flank the extracellular region of UL18. The primers were synthesized with Sal I and Bgl II restriction sites inserted at the 5′ and 3′ termini so that the PCR amplified cDNA introduced Sal I and Bgl II restriction sites at the 5′ and 3′ ends, respectively. The primers had the following sequences: 5′-ATA GTC GAC AAC GCC ATG ATG ACA (SEQ ID NO:25) ATG TGG TG-3′         Sal I 5′-TAA AGA TCT GGG CTC GTT AGC TGT (SEQ ID NO:26) CGG GT-3′          Bgl II

[0131] The conditions for the PCR reaction were as described above except that the template was the full length gene isolated as just described.

[0132] To prepare a vector construct for expressing fusion protein, sUL18:Fc, for use in cell binding studies, a DNA fragment encoding the Fc region of a human IgG1 antibody was isolated from a plasmid using Bgl II and Not I restriction enzymes. The encoded Fc portion was the mutein Fe described in U.S. Pat. No. 5,457,035 having reduced affinity for immunoglobulin receptors. The Bgl II site on the sUL18 gene was used to ligate the sUL18 gene DNA to the Bgl II site on the Fc gene to form a sUL18:Fc fusion DNA construction having an N-terminal Sal I restriction site and a C-terminal Not I restriction site. This fusion sUL18:Fc DNA construct was then ligated into pDC409 expression vector at its Sal I and Not I sites to form a 409/sUL18/Fc DNA construct.

[0133] The monkey cell line COS-1 (ATCC CRL-1650) was used to confirm expression of the fusion protein. COS-1 cells in 6-well plates (2×10⁵ cells per well) were transfected with about 2 μg of the DNA construct 409/sUL18/Fc per well. The cells were cultured for 2-3 days in 5% FBSDMEMIF12 (available from GIBCO), then washed twice with PBS, starved for 1 hour in cysteine/methionine depleted RPMI (available from GIBCO as RPMI 1640) and metabolically labeled with 100 μCi/mL of ³⁵S-Met/Cys for 4 hours. The supernatant was spun clear to remove loose cells and 150 μL of the supernatant was incubated with 100 μL of RIPA (0.05% Tween 20, 0.1% SDS, 1% Triton X-100, 0.5% deoxycholate in PBS) buffer and 50 μL of 50% Protein A-Sepharose solid support beads at 4° C. for 1 hour. Protein A-Sepharose is a Sepharose solid support (available from Pharmacia) having immobilized Protein A which binds the Fc portion of the fusion protein. After washing the solid support with RIPA to remove unbound material, fusion protein bound to the Protein A-Sepharose solid support was eluted from the Protein A-Sepharose using 35μL of SDS-PAGE reducing sample buffer and then heated at 100° C. for 5 minutes. The eluant was then electrophoresed on a 4-20% SDS polyacrylamide gradient gel with ¹⁴C labeled protein molecular weight markers. After electrophoresis the gel was fixed with 8% acetic acid and enhanced at room temperature for 20 minutes with Amplifier available from Amersham. After drying the gel under vacuum it was exposed to x-ray film. Film analysis confirmed that the expected protein, a 100-120 kDa protein which includes the mutein Fc region of IgG and UL18 extracellular domains fused to the Fc, was expressed.

[0134] Once cells expressing the fusion protein were identified large scale cultures of transfected cells were grown to accumulate supernatant from cells expressing the fusion protein. This procedure involved transfecting COS-1 cells in T175 flasks with 15 jig of the UL18/Fc/409 fusion DNA per flask. After 7 days of culture in medium containing 0.5% low immunoglobulin bovine serum, a solution of 0.2% azide was added to the supernatant and the supernatant was filtered through a 0.22 μm filter. Then approximately 1 L of culture supernatant was passed through a BioCad Protein A HPLC protein purification system using a 4.6×100 mm Protein A column (POROS 20A from PerSeptive Biosystems) at 10 mL/min. The Protein A column binds the Fc portion of the sUL18/Fc fusion protein in the supernatant, immobilizing the fusion protein and allowing other components of the supernatant to pass through the column. The column was washed with 30 mL of PBS solution and bound sUL18/Fc was eluted from the HPLC column with citric acid adjusted to pH 3.0. Eluted purified sUL18/Fc was neutralized as it eluted using IM Hepes solution at pH 7.4. The pooled eluted protein was analyzed using SDS PAGE with silver staining, confirming expression of the 100-120 kDa UL18/Fc fusion protein.

Example 2 Screening Cell Lines for Binding to UL18

[0135] The sUL18/Fc protein isolated as described in Example 1 was used to screen cells lines to which it binds using quantitative binding studies according to standard flow cytometry methodologies. For each cell line screened, the procedure involved incubating approximately 100,000 of the cells blocked with 2% FCS (fetal calf serum), 5% normal goat serum and 5% rabbit serum in PBS for 1 hour. Then the blocked cells were incubated with 5 μg/mL of sUL18/Fc fusion protein in 2% FCS, 5% goat serum and 5% rabbit serum in PBS. Following the incubation the sample was washed 2 times with FACS buffer (2% FCS in PBS) and then treated with mouse anti human Fc/biotin (purchased from Jackson Research) and SAPE (streptavidin-phycoerythrin purchased from Molecular Probes). This treatment causes the anti human Fclbiotin to bind to any bound sULI8/Fc and the SAPE to bind to the anti human Fc/biotin resulting in a fluorescent identifying label on sUL18/Fc which is bound to cells. The cells were analyzed for any bound protein using fluorescent detection flow cytometry. The results indicated that UL18 binds well to B cell lines CB23, RAJI and MP-1; monocytic cell lines Thp-1 and U937; and primary B cell and primary monocytes. UL18 does not bind detectably to T cell lines nor does it bind to primary T cells.

Example 3 Isolating a P3G2 cDNA and Polypeptide

[0136] The following describes screening cDNA of one of the cell lines found to bind UL18 and the isolation of a novel polypeptide expressed by the cell line. A CB23 cDNA library in the mammalian expression vector pDC406, prepared as described in U.S. Pat. No. 5,350,683 (incorporated herein by reference) was obtained and plasmid DNA was isolated from pools consisting of approximately 2,000 clones per pool. The isolated DNA was transfected into CV1-EBNA cells (ATCC CRL 10478) using DEAE-dextran followed by chloroquine treatment. The CV1-EBNA cells were maintained in complete medium (Dulbecco's modified Eagles' media containing 10% (v/v) fetal calf serum, 50 U/mL penicillin, 50 U/mL streptomycin, and 2 mM L-glutamine) and were plated to a density of approximately 2×10⁵ cells/well in single-well chambered slides. The slides had been pre-treated with 1 mL of a solution of 10 μg/mL human fibronectin in PBS for 30 minutes followed by a single washing with PBS. Media was removed from adherent cells growing in a layer and replaced with 1.5 mL complete medium containing 66.6 μM chloroquine sulfate. About 0.2 mL of a DNA solution (2μg DNA, 0.5 mg/mL DEAE-dextran in complete medium containing chloroquine) was added to the cells and the mixture was incubated at 37 C. for about five hours. Following incubation, the media was removed and the cells were shocked by addition of complete medium containing 10% DMSO (dimethylsulfoxide) for 2.5 minutes. Shocking was followed by replacing the solution with fresh complete medium. The cells were grown in culture for two to three days to permit transient expression of the inserted DNA sequences. These conditions led to a 30% to 80% transfection frequency in surviving CV1-EBNA cells.

[0137] Each slide was incubated with 1 mL of UL18:Fc at a concentration of 1 μg/mL in binding buffer (RPMI 1640 containing 25 mg/mL bovine serum albumin, 2 mg/mL sodium azide, 20 mM Hepes at pH 7.2, and 50 mg/mL nonfat dry milk) at room temperature for 1 hour. The incubated slides were washed with the binding buffer and then incubated with Fc specific ¹²⁵I-mouse anti-human IgG (see Goodwin et al., Cell 73:447-456, 1993). This was followed by a second wash with buffer after which the slides were fixed with a 2.5% glutaraldehyde/PBS solution, washed with PBS solution and allowed to air dry. The dried slides were dipped in Kodak GTNB-2 photographic emulsion (6× dilution in water). After air drying, the slides were placed in a dark box and refrigerated. After three days the slides were developed in Kodak D19 developer, rinsed in water and fixed in Agfa G433C fixer. The fixed slides were individually examined under a microscope at 25-40x magnification. Positive cells demonstrating binding of sUL18:Fc were visualized by the presence of autoradiographic silver grains against the film background. Two positive pools were identified. Bacterial clones from each pool were titered and plated to provide plates containing approximately 200 colonies each. Each plate was scraped to provide pooled plasmid DNA for transfection into CV1-EBNA cells and screening as described above. Following subsequent breakdowns and screenings, two positive individual colonies were obtained. The cDNA inserts of the two positive clones were 2922 and 2777 nucleotides in length as determined by automated DNA sequences. The coding regions of the two inserts, designated P3G2 and 18A3 were 1953 (nucleotides 310-2262) and 1959 (nucleotides 168-2126) nucleotides, respectively. The two cDNA clones encode proteins that are substantially similar and probably represent different alleles of the same gene.

[0138] The cDNA sequence and encoded amino acid of P3G2 are presented in SEQ ID NO:1 and SEQ ID NO:2, respectively. The cDNA sequence and encoded amino acid of 18A3 are presented in SEQ ID NO:3 and SEQ ID NO:4; respectively. The P3G2 amino acid sequence (SEQ ID NO:2) has a predicted signal peptide of 16 amino acids (amino acids 1-16); an extracellular domain of 442 amino acids (amino acids 17-458); a transmembrane domain of 25 amino acids (amino acids 459-483) and, a cytoplasmic domain of 167 amino acids (amino acids 484-650. The extracellular domain includes four immunoglobulin-like domains. Ig-like domain I includes approximately amino acids 17-118; Ig-like domain II includes approximately amino acids 119-220; Ig-like domain III includes approximately amino acids 221-318; and Ig-like domain IV includes approximately amino acids 319419. Significantly, the cytoplasmic domain of this polypeptide includes four ITIM motifs, each having the consensus sequence of YxxL/V. The first ITIM motif pair is found at amino acids 533-536 and 562-565 and the second pair is found at amino acids 614-617 and 644-647. The amino acid sequence of 18A3 is nearly identical having the features describes above.

[0139] The features of these encoded polypeptides are consistent with a type I transmembrane glycoprotein.

Example 4 Preparing P3G2 Fusion Protein

[0140] The following describes procedures used to generate a P3G2 fusion protein which was then used to identify cell lines to which it binds and finally isolate a normal cell-surface P3G2 ligand which is distinct from UL18. A fusion protein of the extracellular region of P3G2 and the mutein human Fc region (sP3G2:Fc) was prepared by first isolating cDNA encoding the extracellular region of P3G2 using primers which flank the extracellular region of P3G2. The primers were synthesized with Sal I and Bgl II restriction sites inserted at the 51 and 3′ termini so that the PCR amplified cDNA introduced Sal I and Bgl II restriction sites at the 5′ and 3′ ends, respectively. The primers had the following sequences:             Sal I 5′ - TAT GTC GAC CAT GAC CCC CAT CCT CAC GGT -3′ (SEQ ID NO:5)                                   Bgl II    Xa 5′ - TAT GGG CTC TGC TCC AGG AGA AGA TCT TCC TTC TAT AAC CCC CAG GTG CCT T (SEQ ID NO:6)

[0141] The conditions for the PCR reaction were as described above and the template was the full length gene P3G2 gene isolated as described in Example 3 above.

[0142] To prepare a vector construct for expressing fusion protein sP3G2:Fc for use in cell binding studies, the mutein human Fc region of IgGi was cut from the plasmid described above in Example 1 using Bgl II and Not I restriction enzymes. The Bgl II site on the sP3G2 gene was used to ligate the sP3G2 gene DNA to the Bgl II site on the human mutein Fc gene to form a sP3G2/Fc fusion DNA construction having an N-terminal Sal I restriction site and a terminal Not I restriction site. This fusion sP3G2:Fc DNA construct was then ligated into pDC409 expression vector at its Sal I and Not I sites to form a 409/sP3G2/Fc DNA construct.

[0143] The monkey cell line COS-1 (ATCC CTL-1650) was used to confirm expression of the fusion protein. COS-1 cells in 6-well plates (2×10⁵ cells per well) were transfected with about 2g of the DNA construct 409/sP3G2/Fc per well. The cells were cultured in 5% FBS/DM/F12 (available from GIBCO) and at day two or three following transfection, the cells were starved for 1 hour in cysteinelmethionine depleted RPMI and the transfected cells were metabolically labeled with 100 μCi/mL of ³⁵S-Met/Cys for 4 hours. The supernatant was spun clear to removed loose cells and debris and 150 μL of the supernatant was incubated with 100 μL of RIPA buffer and 50 μL of 50% Protein A-Sepharose solid support beads at 4° C. for 1 hour. After washing the solid support with RIPA to remove unbound material, fusion protein bound to the Protein A-Sepharose solid support was eluted from the Protein A-Sepharose using 30 μL of SDS-PAGE reducing sample buffer and then heated at 100° C. for 5 minutes. The eluant was then electrophoresed on a 4-20% SDS polyacrylamide gradient gel with ¹⁴C labeled protein molecular weight markers. After electrophoresis the gel was fixed with 8% acetic acid and enhanced at room temperature for 20 minutes with Amplifier available from Amersham. After drying the gel under vacuum it was exposed to x-ray film. Film analysis confirmed that the expected protein, having a molecular weight of 120-130 kDa, was expressed.

[0144] Once fusion protein expression was verified, large scale cultures of transfected cells were grown to accumulate supernatant from COS-1 cells expressing the fusion protein as described in Example I above. The P3G2/Fc fusion protein was purified according to the procedure described in Example 3 above using the BioCad system and the POROS 20A column from PerSeptive Biosystems. The pooled eluted protein was analyzed using SDS PAGE with silver staining, confirming expression.

Example 5 Generating LIR-P3G2 Antibody

[0145] The following example describes generating monoclonal antibody to P3G2 that was used in flow cytometry analysis to identify cells on which P3G2 is expressed. Purified P3G2/Fc fusion protein was prepared by COS-1 cell expression and affinity purification as described in Example 4. The purified protein or cells transfected with an expression vector encoding the full length protein can generate monoclonal antibodies against P3G2 using conventional techniques, for example those techniques described in U.S. Pat. No. 4,411,993. Briefly BALB-C mice were immunized at 0, 2 and 6 weeks with 10 μg P3G2/Fc. The primary immunization was prepared with TITERMAX adjuvant, from Vaxcell, Inc., and subsequent immunization were prepared with incomplete Freund's adjuvant (IFA). At 11 weeks, the mice were IV boosted with 34 μg P3G2 in PBS. Three days after the IV boost, splenocytes were harvested and fused with an Ag8.653 myeloma fusion partner using 50% aqueous PEG 1500 solution. Hybridoma supernatants were screened by ELISA using P3G2 transfected COS-1 cells in PBS at 2×10³ cells per well and dried to polystyrene 96-well microtiter plates as the platecoat antigen. Positive supernatants were subsequently confirmed by FACS analysis and RIP using P3G2 transfected COS-1 cells. Hybridomas were cloned and followed using the same assays. Monoclonal cultures were expanded and supernatants purified by affinity chromatography using BioRad Protein A agarose.

[0146] The monoclonal antibodies to P3G2/Fc were used to screen cells and cell lines using standard flow cytometry procedures to identify cells on which P3G2 is expressed. Cell lines and cells screened in the flow cytometry analyses were CB23, CB39, RAJI, AK778, K299, PS-1, U937, THP-1, JURKAT and HSB2. For each cell line or cell sample screened, the procedure involved incubating approximately 100,000 of the cells blocked with 2% FCS (fetal calf serum), 5% normal Goat serum and 5% rabbit serum in PBS with 5 μg of FITC conjugated mouse anti-P3G2 antibody for 1 hour. Following the incubation the sample was washed 2 times with FACS buffer (2% FCS in PBS). The cells were analyzed for any bound protein using fluorescent detection flow cytometry to detect FITC. The results indicated that LIR-P3G2 antibody binds well to B cell lines CB23 and RAJI1; monocytic cell lines THP-1 and U937; and primary B cell and primary monocytes. The highest expression of LIR-P3G2 was shown on monocytes that stained brightly for CD16 and less brightly for CD14 and CD64. The antibody does not bind detectably to T cell lines nor does it bind detectably to primary T cells.

[0147] In a related experiment, the P3G2 antibody generated as described above was used in immunoprecipitation experiments. The immunoprecipitation analyses involved first surface biotinylating 2.5×10⁶ monocytes by washing the cells with PBS and suspending the cells in a biotinylation buffer of 10 mM sodium borate and 150 mM NaCl at pH 8.8, followed by adding 5 μL of a 10 mg/mL solution of biotin-CNHS-ester (D-biotinoyl-e-aminocaproic acid-N-hydroxysuccinimide ester purchased from Amersham) in DMSO to the cells. After quenching the reaction with 10 μL of 1 M ammonium chloride per 1 mL of cells and washing the cells in PBS, the cells were lysed in 1 mL of 0.5% NP40-PBS and the lysate was recovered following centrifugation. Then 100 μL of 0.5% NP40-PBS was added to 150 μL of the lysate and the resulting mixture was incubated with 2 μg/mL of antibody, at 4° C. for 16 hours. Fifty microliters of 50% Protein A-Sepharose slurry was added to the antibody mixture and the slurry was shaken at 4° C. for 1 hour. The slurry was centrifuged and the resulting pellet was washed with 0.75 mL of 0.5% NP40 in PBS six times. Protein bound to the Protein A-Sepharose was eluted with 30 μL of SDS-PAGE reducing sample buffer and heating at 100° C. for five minutes.

[0148] The eluted proteins were analyzed using 4-20% gradient SDS-PAGE with enhanced chemiluminescence (ECL) protein markers. Then the electrophoreses samples were transferred in a Western Blot onto nitrocellulose membranes. The membranes were treated with blocking reagent (0.1% Tween-20 and 3% nonfat dry milk in PBS) for one hour at room temperature and then they were washed once for 15 minutes followed and twice for 5 minutes with 0.1% Tween-20 in PBS. The washed membranes were incubated with 10 mL of 1:100 HRP-Streptavidin for 30 minutes and then washed I times for 15 minutes followed by 4 times for 5 minutes with 0.1% Tween-20 in PBS.

[0149] Bound streptavidin HRP was detected with ECL Detection Reagents purchased from Amersham and used according to manufacturer's instructions. The developed membranes were exposed to x-ray film and then visualized. The results showed that LIR-P3G2 was immunoprecipitated from CB23 cells and P3G2 transfected COS-1 cells, indicating that P3G2 is expressed by these cells.

Example 6 Screening Cells and Cell Lines for Binding to P3G2

[0150] The following describes flow cytometry analyses used to identify cells and cell lines which bind to P3G2. The cells and cell lines tested were CB23, HSB2, MP-1, Jurkat, primary T cells, primary B cells, and primary NK cells. For each cell line or cell line tested the procedure involved washing the cells three times with FACS buffer (2% FCS in PBS with 0.2% azide) and incubating each sample (10⁵ cells) in 100 μL blocking buffer (2% FCS, 5% NGS, 5% rabbit serum in PBS) for one hour. For each cell line 4 test samples were prepared, one each having 0, 2, 5, or 10 μg of W6/32 (ATCC HB-95) in 100 μL blocking buffer added to the sarnples, respectively. W6/32 is an antibody against MHC Class I heavy chains (an anti HLA-A, B, and C molecule). Following the addition of the W6/32 solution, the samples were incubated on ice for 1 hour and then washed three times with 200 μL of FACS buffer. Then 5 μg of P3G2/Fc in blocking buffer was added to each sample and they were incubated on ice for one hour. The P3G2/Fc competes with W6/32 for binding sites on the cells.

[0151] Following the incubation, the cells were washed three times with 200μL of FACS buffer and treated with mouse anti human Fc/biotin and SAPE for 45 minutes. This treatment causes the anti human Fcfbiotin to bind to any cell bound sP3G2/Fc and the SAPE to bind to the anti human F/Biotin. Since the SAPE is a fluorescing compound its detection using appropriate excitation and emission conditions positively identifies cell bound P3G2/Fc. Finally the treated cells were washed three times with FACS buffer and subjected to flow cytometry to identify cells bound to protein.

[0152] The results demonstrated that W6/32 competed with P3G2 for binding to all cells and cell lines tested. The P3G2 binding was totally blocked at 5 μg W6/32 indicating that W6/32 and P3G2 are binding to the same or overlapping sites on the MHC Class I heavy chains.

Example 7 Screening HSB2 cDNA Library to Isolate a P3G2 Binding Ligand

[0153] The following describes screening a cDNA library from of one of the cell lines, HSB-2, a T lymphoblastic leukemia cell line, found to bind P3G2, and identifying a P3G2 binding ligand. An HSB2 cDNA library in the mammalian expression vector pDC302, was prepared as generally described in U.S. Pat. No. 5,516,658 and specifically in Kozlosky et al. Oncogene 10.299-306, 1995. Briefly, mRNA was isolated from sorted HSB-2 cells and a first cDNA strand was synthesized using 5 μg polyA⁺ and the reverse transcriptase AMV RTase from Life Science. The second cDNA strand was synthesized using DNA polymerase I from BRL at concentration of 1.5 U/μL. Using standard techniques as described in Haymerle et al., Nucl. Acids Res. 14:8615, 1986, the cDNA was ligated into the appropriate site of the pDC302 vector.

[0154]E.coli. strain DH5α cells were transformed with the cDNA library in pDC302. After amplifying the library a titer check indicated that there was a total of 157,200 clones. The transformed cells were plated into 15 different plates. Plasmid DNA was isolated from pools consisting of approximately 2,000 clones per pool. The isolated DNA was transfected into CV1-EBNA cells (ATCC CRL 10478) using DEAE-dextran followed by chloroquine treatment. The CVI-EBNA cells were maintained in complete medium (Dulbecco's modified Eagles' media containing 10% (v/v) fetal calf serum, 50 U/mL penicillin, 50 U/mL streptomycin, and 2 mM L-glutamine) and were plated to a density of approximately 2×10⁵ cells/well in single-well chambered slides. The slides had been pretreated with 1 mL of a solution of 10 μg/mL human fibronectin in PBS for 30 minutes followed by a single washing with PBS. Media was removed from adherent cells growing in a layer and replaced with 1.5 mL complete medium containing 66.6 μM chloroquine sulfate. About 0.2 mL of a DNA solution (2μg DNA, 0.5 mg/mL DEAE-dextran in complete medium containing chloroquine) was added to the cells and mixture was incubated at 37 C. for about five hours. Following incubation media was removed and the cells were shocked by adding complete medium containing 10% DMSO for 2.5 minutes. After shocking the cells the complete medium was replaced with fresh complete medium and the cells were grown in culture for three days to permit transient expression of the inserted DNA sequences. These conditions led to a 30% to 80% transfection frequency in surviving CVI-EBNA cells.

[0155] Each slide was incubated with 1 mL of P3G2:Fc at a concentration of 0.45 μg/mL in binding buffer (RPMI 1640 containing 25 mg/mL bovine serum albumin, 2 mg/mL sodium azide, 20 mM Hepes at pH 7.2, and 50 mg/mL nonfat dry milk) at room temperature for 1 hour. After incubating the slides, they were washed with binding buffer and then incubated with Fc specific ¹²⁵I-mouse anti-human IgG (see Goodwin et al. Cell 73:447-456, 1993). This was followed by a second wash with buffer after which the slides were fixed with a 2.5% glutaraldehyde/PBS solution, washed in PBS and allowed to air dry. The slides were dipped in Kodak GTNB-2 photographic emulsion (6× dilution in water). After air drying the slides were placed in a dark box and refrigerated. After three days the slides were developed in Kodak D19 developer, rinsed in water and fixed in Agfa G433C fixer. The fixed slides were individually examined under a microscope at 25-40× magnification. Positive pools demonstrating binding of sP3G2:Fc were visualized by the presence of autoradiographic silver grains against the film background. Two positive pools were titered and plated to provide plates containing approximately 200 colonies each. Each plate was scraped to provide pooled plasmid DNA for transfection into CV1-EBNA cells and screening as described above. Following subsequent breakdowns and screenings, one positive individual colony was obtained for each pool. The cDNA insert of the positive clones were identified as HLA-B44 and HLA-A2, class I MHC antigens.

Example 8 Northern Blot Analysis

[0156] Since the experiments described in Example 4 resulted in the detection of LIR-P3G2 surface expression on a number of cell lines, conventional Northern Blot analysis procedures were used to study the expression of LIR-P3G2 and any LIR-P3G2 related mRNAs in different tissue types. The cell lines selected for Northern Blot analysis were RAJI, PBT, PBM, YT, HEP3B, HELA, KB, KG-1, IMTLH, HPT, HFF, THP-1, and U937. The following describes the Northern Blot analysis and the analysis results.

[0157] The cDNA encoding the extracellular region of P3G2 was isolated using primers which flank the extracellular region of P3G2 and having the following sequences:           Sal I 5′ - TAT GTC GAC CAT GAC CCC CAT CCT CAC GGT -3′ (SEQ ID NO:5)          Bgl II 5′ - TAT AGA TCT ACC CCC AGG TGC CTT CCC AGA CCA (SEQ ID NO:27)

[0158] The PCR template was the full length P3G2 gene isolated as described in Example 3 above. The conditions for the PCR reaction were as follows: One cycle at 95° C. for 5 minutes; 30 cycles which included 95° C. for 45 seconds, 64° C. for 45 seconds and 72° C. for 45 seconds; and, one cycle at 72° C. for 5 minutes. The PCR product was cloned into PCR II vector, purchased from Invitrogen, in accordance with the supplier's instructions. The isolated DNA encoding the extracellular region of P3G2 was used to make a riboprobe with the Ambion MAXISCRIPT Kit according to the manufacturer's instructions.

[0159] Northern blots containing poly A+ selected RNA or total RNA from a variety of human cell lines were prepared by resolving RNA samples on a 1.1% agarose-formaldehyde gel, blotting onto Hybond-N as recommended by the manufacturer (Amersham Corporation) and staining with methylene blue to monitor RNA concentrations. The blots were prepared using 1 μg of the PolyA+ RNA or 10 μg of total RNA and each blot was probed with 10⁶ cpm/mL RNA extracellular P3G2 riboprobe, prepared as just described, at 63° C. for 16 hours. The probed blots were washed with 2× SSC at 63° C. for 30 minutes 2 times; 1× SSC at 63° C. for 30 minutes 2 times; and, 0.1× SSC at 63° C. for 5 minutes 2 times.

[0160] The probed blots were autoradiographically developed. The developed blots showed that the P3G2 RNA hybridized to a 3.5 kb RNA expressed by RAJI, CB23 and U937; an approximately 1.5kb RNA expressed by THP-1; and multiple RNAs ranging from 1.5 kb to 3.5 kb expressed by PBM. These results suggest that different genes having extracellular domains similar in structure to that of P3G2 may be expressed by peripheral blood monocytes.

Example 9 Probing PBM cDNA Library to Isolate LIR Polypeptides

[0161] The following describes steps taken to screen a peripheral blood monocyte cDNA library to isolate polypeptides relating to the P3G2 polypeptide using conventional Southern Blot methodologies. A peripheral blood monocyte cDNA library was prepared using substantially the same procedures described in Example 7.

[0162] DNA from an initial 15 pools of cDNA having 10,000 clones per pool was digested with Bgl II restriction enzyme and electrophoresed on a 1% agarose gel at 100 V for 2 hours. Southern Blots were prepared by electroblotting the electrophoresed DNA in 0.55% TBE buffer onto Hybond membranes. The blotted DNA was denatured in 0.5 M NaOH in 0.6M NaCl solution for 5 minutes and then neutralized in 0.5 M TRIS in 1.5 M NaCl at pH 7.8 for 5 minutes. The membranes were placed in a STRATALINKER UV crosslinker for 20 seconds to crosslink the blotted DNA to the membrane. The membrane and bound DNA were placed in pre-hybridization solution of 10× Denhart's Solution, 0.05M TRIS at pH 7.5, 0.9M NaCl, 0.1% sodium pyrophosphate, 1% SDS and 200 μg/mL salmon sperm DNA at 63° C. for 2 hours and then the bound DNA was probed with ³²P labeled probe of DNA encoding the extracellular region of LIR-P3G2, including the signal peptide and Sal I and Bgl II restriction sites. The concentration of the DNA probe in hybridization solution was 10⁶ CPM per mL of hybridization solution. The probed blots were incubated for 16 hours at 63° C. and then washed with 2× SSC at 63° C. for 1 hour with one solution change; 1× with SSC at 63° C. for one hour with one solution change; and, with 0.1× SSC at 68° C. for 45 minutes with one solution change. After drying the blots they were autoradiographically developed and visualized for DNA bands which hybridized to the P3G2 extracellular DNA probe.

[0163] The results of the autoradiography visualization indicated that all pools contained DNA which hybridized to the probe. One pool showing 7 positive DNA bands was selected and subsequently subdivided to 10 pools having 3,000 clones per pool. Applying subsequent Southern Blotting methodologies to the 10 pools resulted in one pool showing 9 positively hybridizing DNA sequences. Single hybridizing clones were isolated by standard colony hybridization techniques.

[0164] Duplicate bacterial colonies on filters were probed with the P3G2 extracellular probe described above at a concentration of 500,000 cpm/mL at 63° C. for 16 hours. The hybridized filters were washed with 2× SSC at 63° C. for 30 minutes; with 1× SSC at 63° C. for 30 minutes; and finally with 0.1× SSC at 68° C. for 15 minutes.

[0165] Forty-eight clones were visualized as hybridizing on duplicate filters by autoradiography and DNA obtained from these clones using standard DNA preparation methodologies was digested with Bgl II. Then Southern Blots of the digests were obtained and probed with the P3G2 extracellular probe described above. Seven different sized cloned inserts were identified as positively hybridizing to the P3G2 probe. The nucleotide sequence of each of the inserts was obtained using automated sequencing technology. Of the 8 different cloned inserts, one was identical in sequence to LIR-P3G2. The others were identified as DNA encoding polypeptides of the new LIR family of polypeptides. The nucleotide sequences (cDNA) of the isolated LIR family members are presented in SEQ ID NO:7 (designated pbm25), SEQ ID NO:9 (designated pbm8), SEQ ID NO:11 (designated pbm36-2), SEQ ID NO:13 (designated pbm364); SEQ ID NO:15 (designated pbmhh); SEQ ID NO:17 (designated pbm2) and SEQ ID NO:19 (designated pbm17). The amino acid sequences encoded thereby are presented in SEQ ID NO:8 (designated pbm25), SEQ ID NO:10 (designated pbm8), SEQ ID NO:12 (designated pbm36-2), SEQ ID NO:14 (designated pbm364), SEQ ID NO:16 (designated pbmhh); SEQ ID NO:18 (designated pbm2); and SEQ ID NO:20 (designated pbm17).

Example 10 Screening a Human Dendritic Cell cDNA Library for LIR cDNA Sequences

[0166] The following describes the isolation and identification of an LIR family member by screening a human bone marrow-derived dendritic cell cDNA library in the λ Zap vector with a radiolabeled Hh0779 cDNA fragment. The Hh0779 cDNA fragment is a 0.7kb insert of the Hh0779 clone previously isolated from a human dendritic cell cDNA library and obtained by restriction digestion with the enzymes PstI and Spel. The Hh0779 cDNA fragment was labeled with [a-³²P]dCTP using the DECAprime II DNA labeling kit purchased from Ambion.

[0167] The X Zap cDNA library was plated at a density of 20,000 pfu per plate to provide a total of 480,000 plagues for the initial screening. The λ Zap cDNA was blotted in duplicate onto Hybond membranes, purchased from Amersham, and then denatured in a solution of 0.5N NaOH and 0.5M NaCl for 5 minutes. The membranes were neutralized in a solution of 0.5M Tris (pH 7.8) and 1.5M NaCl for 5 minutes, and then washed in 2× SSC for 3 minutes. The cDNA was crosslinked to the Hybond membranes using a STRATALINKER UV crosslinker in the auto setting.

[0168] The membranes were pre-hybridized at 65° C. for 2.25 hours in hybridization buffer containing 10× Denhardt's, 0.05M Tris (pH 7.5), 0.9M NaCl, 0.1% sodium pyrophosphate, 1% SDS and 4 mg/mL heat denatured salmon sperm DNA. After the pre-hybridization, the radiolabeled Hh0779 cDNA was added to the hybridization buffer to a final concentration of 0.54×10⁶ cpm/mL. After 24 hours of hybridization, the membranes were washed in 0.25× SSC, 0.25% SDS at 65° C. for 1.5 hours. The blots were then exposed to autoradiographic film to visual positive clones.

[0169] A total of 146 positive clones showing hybridization signals in both membranes of a duplicate set were identified, isolated, and saved for future use. Of the 146 clones, 35 were selected for secondary screening. The selected clones were plated at low density and single clones were isolated after hybridization to the Hh0779 probe using the hybridization conditions described above. The plasmids were then isolated from the λ Zap clones using the VCSM13 helper phage purchased from Stratagene. The plasmid DNA was analyzed by restriction digestion and PCR, and the clones containing the 24 largest inserts were selected and sequenced. Of the 24 sequenced clones, 6 encoded LIR-P3G2, 3 encoded LIR-pbm2, 8 encoded LIR-pbm364 and LIR-pbm36-2, 1 encoded LIR-pbm8, 2 encoded LIR-pmbhh, and 1 encoded a novel sequence designated LIR-pbmnew. Three clones were identified as encoding amino acid sequences that are not relevant to the LIR polypeptide family.

Example 11 Association of LIR-P3G2 and LIR-pbm8 with Tyrosine Phosphatase, SHP-1

[0170] The following describes the tests performed to demonstrate that LIR-P3G2 and LIR-pbm8 associate with SHP-1. Human monocytes were cultured in RPMI medium supplemented with 10% FBS, concentrated by centrifugation and finally subdivided into two aliquots. One aliquot was stimulated with a solution of 50 mM/mL sodium pervanadate for 5 minutes. The second aliquot was not stimulated. After stimulation, the cells in each aliquot were immediately lysed in RIPA buffer containing 1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris pH8, 2 mM EDTA, 0.5 mM sodium orthovanadate, 5 mM sodium fluoride, 25 mM β-glycerol phosphate, and protease inhibitors. Samples of 24×10⁶ cell equivalents were incubated for 2 hours at 4° C. with either 5 μg/mL of anti-SHP-1 antibody purchased from Transduction Laboratories, or 5 μg/mL of an isotype-matched antibody control (anti-Flag-M5 IgG1). The resulting immunocomplexes were precipitated by incubation with protein G-agarose (Boehringer Mannheim), washed, and resuspended in 40 mL of 2× SDS-PAGE sample buffer. Twenty microliters of each immunoprecipitate were loaded onto electrophoresis gels, electrophoresed under reducing conditions, and transferred to nitrocellulose membranes purchased from Amersham. Western blots were probed with anti-LIR-P3G2 monoclonal antibody sera and anti-LIR-pbm8 monoclonal antibody antisera and the immunocomplexes were detected by enhanced chemiluminescence (NEN).

[0171] A protein having a molecular weight of approximately 120 kDa, corresponding to LIR-P3G2 was readily detected in SHP-1 immunoprecipitates, but not the immunoprecipitates generated with the anti-Flag-M5 antibody control. Similarly, a protein of 90-100 kDa, corresponding to LIR-pbm8, was detected in SHP-1 immunoprecipitates, but not in the control immunoprecipitates. Neither the LIR-P3G2 band nor the LIR-pbm8 band was seen in the absence of sodium pervanadate treatment. This confirms that tyrosine phosphorylation of LIR-P3G2 is essential for the association of LIR-P3G2 and SHP-1 and phosphorylation of LIR-pbm8 is essential for the association of LIR-pbm8 and SHP-1.

[0172] To study the inhibition of FcγRI-mediated tyrosine phosphorylation events upon LIR coligation, peripheral blood monocytes were incubated with or without 10 μg/mL of F(ab)₂ version of a number of antibodies (α-LIR-1+α-LIR-2, α-CD11c, αCD14, αCD64, α-CD64+α-LIR-1, α-CD64+α-LIR-2, α-CD64+α-LIR-1+α-LIR-2, αCD64+α-CD11c, α-CD64+α-CD14). This was followed with crosslinking with 30 μ/mL of polyclonal F(ab)₂ goat anti-mouse. Cell lysates were immunoprecipitated overnight with anti-phosphotyrosine conjugated agarose, electrophoresed, and transferred onto nitrocellulose Western blotting was performed using a combination of PY-20 and 4G10 HRP-conjugated anti-phosphotyrosine mAbs. This data demonstrates the specific inhibition of FcyRI-mediated tyrosine phosphorylation events upon LIR-P3G2 and LIR-pbm8 coligation.

Example 12 Generating Antibodies Immunoreactive with LIR Polypeptides

[0173] The following describes generating monoclonal antibody immunoreactive with LIR family members. A purified LIR polypeptide is prepared by COS-1 cell expression and affinity purification as described in Example 4. The purified protein or cells transfected with an expression vector encoding the full length protein can generate monoclonal antibodies against the LIR polypeptide using conventional techniques, for example those techniques described in U.S. Pat. No. 4,411,993. Briefly BALB-C mice are immunized at 0, 2 and 6 weeks with 10 μg of the LIR polypeptide. The primary immunization is prepared with TITERMAX adjuvant and subsequent immunizations are prepared with incomplete Freund's adjuvant (IFA). At 11 weeks, the mice are IV boosted with 3-4 μg the LIR polypeptide in PBS. Three days after the IV boost, splenocytes are harvested and fused with an Ag8.653 myeloma fusion partner using 50% aqueous PEG 1500 solution. Hybridoma supernatants are screened by ELISA using the LIR transfected cells in PBS at 7×10³ cells per well and dried to polystyrene 96-well microtiter plates as the platecoat antigen. Positive supernatants are subsequently confirmed by FACS analysis and RIP using LIR transfected cells. Hybridomas are cloned and followed in the same manner of screening. Monoclonal cultures are expanded and supernatants purified by affinity chromatography.

Example 13 Flow Cytometric Analysis For Expression of LIR-P3G2 and LIR-pbm8 on Lymphoid and Myeloid Cells

[0174] In order to compare the differential expression and distribution of LIR-P3G2 and LIR-pbm8 on lymphocyte populations, freshly isolated peripheral blood mononuclear cells (PBMC) were stained with PE-labeled anti-CD3, anti-CD19, or anti-CD56 mAb in the presence of either biotin labeled anti-LIR-P3G2 or anti LIR-pbm8 mAb. Then the stained cells were treated with APC-labeled streptavidin. Density plots representing 5×10⁴ events were collected on a FACScaliber (from Beckton Dickinson). The results demonstrated that LIR-P3G2 is expressed on 80%-95% of CD19⁺ B cells, on 5%-15% CD3⁺ T cells, and on 10%-30% CD56⁺ NK cells. On the cells examiner from the same 12 donors, LIR-pbm8 expression was not detected on CD19⁺ B cells, CD3⁺ T cells, and CD56⁺ NK cells.

[0175] Countercurrent elutriated fractions containing a high percentage of circulating monocytes and dendritic cells (DC) were obtained. The monocytes were characterized according to the phenotypes subsets CD14⁺CD16⁻ and CD14⁺CD16⁺. The peripheral blood DC were characterized with the phenotype CD33⁺CD14⁻CD16⁻HLA-DR⁺ The monocytes subsets and DC's were stained with FITC-labeled antiCD14, PE-labeled anti CD3, percp-labeled antiHLA-DR, and either biotin-labeled anti-CD16, anti-LIR-P3G2, or anti LIR-pbm8. Then the stained cells were treated with APC-labeled streptavidin. Both monocyte subsets co-express similar levels of LIR-P3G2 and LIR-pbm8, with the highest LIR-P3G2 and LIR-pbm8 expression detected on the CD14⁺CD16⁺ subset. Blood DC express lower levels of LIR-P3G2 and LIR-pbm8 compared to monocytes. The results of these experiments demonstrate the LIR-P3G2 is expressed on lymphocytes, monocytes and DC, and LIR-pbm8 is expressed on monocytes and DC.

Example 14 Screening LIR-P3G2 and LIR-pbm8 Binding to HLA Class I Alleles

[0176] The following describes flow cytometry analyses used to screen LIR-P3G2 and LIR-pbm8 for binding to HLA Class I alleles. The B lymphoblastoid class 1-deficient 721.221 cell line, untransfected or transfected with a panel of HLA class I alleles was used for staining. LIR-P3G2/Fc and LIR-pbm8/Fc fusion proteins were used in the binding studies and both bound detectably to seven of the eleven HLA-A, HLA-B and HLA-C alleles that were tested. In general, LIR-P3G2/Fc and LIR-pbm8/Fc bind with higher affinity to HLA-B alleles than to HLA-A or HLA-C alleles. W6/32 (ATCC HB-95), an antibody against MHC Class I heavy chains (an anti HLA-A, B, and C molecule) inhibits LIR-P3G2/Fc and LIR-pbm8/Fc binding to all class I transfectants. Finally, LIR-P3G2 and LIR-pbm8 binding does not correlate with the MHC class I expression levels. Thus, LIR-P3G2 and LIR-pbm8 bind to several HLA-A, -B, and -C alleles, and recognize a similar broad spectrum of MHC class I specificities.

Example 15 Isolation of LIR-9 ml, LIR-9m, LIR-9s1, LIR-9s2 and LIR-10

[0177] In the course of high throughput sequencing of a human dendritic cell cDNA library, it was noted that the sequence of an incomplete cDNA (clone ss4894) was strikingly similar to the nucleotide sequences of LIRs 6a, 6b and 7, thus suggesting that ss4894 was a member of the LIR gene family. To obtain the remainder of this cDNA clone, the Rapid Amplification cDNA Extension system (RACE) was used to amplify a human leukocyte cDNA library (Chenchik et al., A new method for full-length cDNA cloning by PCR, In A Laboratory Guide to RNA: Isolation, Analysis, and Synthesis, Ed. Kreig, P. A. (Wiley-Liss, Inc.), pages 273-321). The first round of amplification employed one primer corresponding to the RACE adapter at the 5′ end of the cDNAs, and a second primer corresponding to sequences near the 3′ end of ss4894. This effort yielded several clones that contained sequence that was highly homologous though not identical to that of ss4894 and that extended upstream beyond an initiating methionine codon. These clones, however, lacked some of the sequence at the 3′ end of the coding region. In an effort to obtain an entire coding region, another round of RACE sequencing was performed, this time using a first primer from near the 5′ end of the first RACE products, and a second primer corresponding to the 3′ adapter. This effort yielded five clones containing LIR inserts, four of which are closely related and appear to encode variants of the same gene. These four closely related cDNA sequences were designated LIR-9m1, LIR-9m2, LIR-9s1 and LIR-9s2 (SEQ ID NOS:29, 31, 33 and 35). The fifth of the clones obtained using this last set of primers represented a different gene, which has been designated LIR-10 (SEQ ID NO:37).

[0178] All four of the LIR-9 clones encode variants of the same protein, and are presumed to be the products of alternative splicing. The proteins encoded by LIR-9 ml (SEQ ID NO:30) and LIR-9s1 (SEQ ID NO:34) contain a 12 amino acid insert that is absent from LIR-9m2 (SEQ ID NO:32) and LIR-9s2 (SEQ ID NO:36). The soluble forms of the LIR-9 protein, i.e., LIR-9s1 and LIR-9s2, diverge near their carboxy termini from the membrane forms, i.e., LIRs-9m1 and -9m2. This divergence presumably is due to different exons being used by the soluble and membrane forms to encode that region of the protein.

1 39 1 2922 DNA human CDS (310)..(2262) 1 agggccacgc gtgcatgcgt cgactggaac gagacgacct gctgtgaccc ccttgtgggc 60 actccattgg ttttatggcg cctctacttt ctggagtttg tgtaaaacaa aaatattatg 120 gtctttgtgc acatttacat caagctcagc ctgggcggca cagccagatg cgagatgcgt 180 ctctgctgat ctgagtctgc ctgcagcatg gacctgggtc ttccctgaag catctccagg 240 gctggaggga cgactgccat gcaccgaggg ctcatccatc cacagagcag ggcagtggga 300 ggagacgcc atg acc ccc atc ctc acg gtc ctg atc tgt ctc ggg ctg 348 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu 1 5 10 agt ctg ggc ccc cgg acc cac gtg cag gca ggg cac ctc ccc aag ccc 396 Ser Leu Gly Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro 15 20 25 acc ctc tgg gct gaa cca ggc tct gtg atc acc cag ggg agt cct gtg 444 Thr Leu Trp Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val 30 35 40 45 acc ctc agg tgt cag ggg ggc cag gag acc cag gag tac cgt cta tat 492 Thr Leu Arg Cys Gln Gly Gly Gln Glu Thr Gln Glu Tyr Arg Leu Tyr 50 55 60 aga gaa aag aaa aca gca ccc tgg att aca cgg atc cca cag gag ctt 540 Arg Glu Lys Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Leu 65 70 75 gtg aag aag ggc cag ttc ccc atc cca tcc atc acc tgg gaa cat gca 588 Val Lys Lys Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala 80 85 90 ggg cgg tat cgc tgt tac tat ggt agc gac act gca ggc cgc tca gag 636 Gly Arg Tyr Arg Cys Tyr Tyr Gly Ser Asp Thr Ala Gly Arg Ser Glu 95 100 105 agc agt gac ccc ctg gag ctg gtg gtg aca gga gcc tac atc aaa ccc 684 Ser Ser Asp Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro 110 115 120 125 acc ctc tca gcc cag ccc agc ccc gtg gtg aac tca gga ggg aat gta 732 Thr Leu Ser Ala Gln Pro Ser Pro Val Val Asn Ser Gly Gly Asn Val 130 135 140 acc ctc cag tgt gac tca cag gtg gca ttt gat ggc ttc att ctg tgt 780 Thr Leu Gln Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys 145 150 155 aag gaa gga gaa gat gaa cac cca caa tgc ctg aac tcc cag ccc cat 828 Lys Glu Gly Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His 160 165 170 gcc cgt ggg tcg tcc cgc gcc atc ttc tcc gtg ggc ccc gtg agc ccg 876 Ala Arg Gly Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro 175 180 185 agt cgc agg tgg tgg tac agg tgc tat gct tat gac tcg aac tct ccc 924 Ser Arg Arg Trp Trp Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro 190 195 200 205 tat gag tgg tct cta ccc agt gat ctc ctg gag ctc ctg gtc cta ggt 972 Tyr Glu Trp Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly 210 215 220 gtt tct aag aag cca tca ctc tca gtg cag cca ggt cct atc gtg gcc 1020 Val Ser Lys Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala 225 230 235 cct gag gag acc ctg act ctg cag tgt ggc tct gat gct ggc tac aac 1068 Pro Glu Glu Thr Leu Thr Leu Gln Cys Gly Ser Asp Ala Gly Tyr Asn 240 245 250 aga ttt gtt ctg tat aag gac ggg gaa cgt gac ttc ctt cag ctc gct 1116 Arg Phe Val Leu Tyr Lys Asp Gly Glu Arg Asp Phe Leu Gln Leu Ala 255 260 265 ggc gca cag ccc cag gct ggg ctc tcc cag gcc aac ttc acc ctg ggc 1164 Gly Ala Gln Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly 270 275 280 285 cct gtg agc cgc tcc tac ggg ggc cag tac aga tgc tac ggt gca cac 1212 Pro Val Ser Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His 290 295 300 aac ctc tcc tcc gag tgg tcg gcc ccc agc gac ccc ctg gac atc ctg 1260 Asn Leu Ser Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu 305 310 315 atc gca gga cag ttc tat gac aga gtc tcc ctc tcg gtg cag ccg ggc 1308 Ile Ala Gly Gln Phe Tyr Asp Arg Val Ser Leu Ser Val Gln Pro Gly 320 325 330 ccc acg gtg gcc tca gga gag aac gtg acc ctg ctg tgt cag tca cag 1356 Pro Thr Val Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln 335 340 345 gga tgg atg caa act ttc ctt ctg acc aag gag ggg gca gct gat gac 1404 Gly Trp Met Gln Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Asp 350 355 360 365 cca tgg cgt cta aga tca acg tac caa tct caa aaa tac cag gct gaa 1452 Pro Trp Arg Leu Arg Ser Thr Tyr Gln Ser Gln Lys Tyr Gln Ala Glu 370 375 380 ttc ccc atg ggt cct gtg acc tca gcc cat gcg ggg acc tac agg tgc 1500 Phe Pro Met Gly Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys 385 390 395 tac ggc tca cag agc tcc aaa ccc tac ctg ctg act cac ccc agt gac 1548 Tyr Gly Ser Gln Ser Ser Lys Pro Tyr Leu Leu Thr His Pro Ser Asp 400 405 410 ccc ctg gag ctc gtg gtc tca gga ccg tct ggg ggc ccc agc tcc ccg 1596 Pro Leu Glu Leu Val Val Ser Gly Pro Ser Gly Gly Pro Ser Ser Pro 415 420 425 aca aca ggc ccc acc tcc aca tct ggc cct gag gac cag ccc ctc acc 1644 Thr Thr Gly Pro Thr Ser Thr Ser Gly Pro Glu Asp Gln Pro Leu Thr 430 435 440 445 ccc acc ggg tcg gat ccc cag agt ggt ctg gga agg cac ctg ggg gtt 1692 Pro Thr Gly Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val 450 455 460 gtg atc ggc atc ttg gtg gcc gtc atc cta ctg ctc ctc ctc ctc ctc 1740 Val Ile Gly Ile Leu Val Ala Val Ile Leu Leu Leu Leu Leu Leu Leu 465 470 475 ctc ctc ttc ctc atc ctc cga cat cga cgt cag ggc aaa cac tgg aca 1788 Leu Leu Phe Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr 480 485 490 tcg acc cag aga aag gct gat ttc caa cat cct gca ggg gct gtg ggg 1836 Ser Thr Gln Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly 495 500 505 cca gag ccc aca gac aga ggc ctg cag tgg agg tcc agc cca gct gcc 1884 Pro Glu Pro Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala 510 515 520 525 gat gcc cag gaa gaa aac ctc tat gct gcc gtg aag cac aca cag cct 1932 Asp Ala Gln Glu Glu Asn Leu Tyr Ala Ala Val Lys His Thr Gln Pro 530 535 540 gag gat ggg gtg gag atg gac act cgg agc cca cac gat gaa gac ccc 1980 Glu Asp Gly Val Glu Met Asp Thr Arg Ser Pro His Asp Glu Asp Pro 545 550 555 cag gca gtg acg tat gcc gag gtg aaa cac tcc aga cct agg aga gaa 2028 Gln Ala Val Thr Tyr Ala Glu Val Lys His Ser Arg Pro Arg Arg Glu 560 565 570 atg gcc tct cct cct tcc cca ctg tct ggg gaa ttc ctg gac aca aag 2076 Met Ala Ser Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys 575 580 585 gac aga cag gcg gaa gag gac agg cag atg gac act gag gct gct gca 2124 Asp Arg Gln Ala Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala 590 595 600 605 tct gaa gcc ccc cag gat gtg acc tac gcc cag ctg cac agc ttg acc 2172 Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr 610 615 620 ctt aga cgg aag gca act gag cct cct cca tcc cag gaa ggg ccc tct 2220 Leu Arg Arg Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Pro Ser 625 630 635 cca gct gtg ccc agc atc tac gcc act ctg gcc atc cac tag 2262 Pro Ala Val Pro Ser Ile Tyr Ala Thr Leu Ala Ile His 640 645 650 cccagggggg gacgcagacc ccacactcca tggagtctgg aatgcatggg agctgccccc 2322 ccagtggaca ccattggacc ccacccagcc tggatctacc ccaggagact ctgggaactt 2382 ttaggggtca ctcaattctg cagtataaat aactaatgtc tctacaattt tgaaataaag 2442 caacagactt ctcaataatc aatgaagtag ctgagaaaac taagtcagaa agtgcattaa 2502 actgaatcac aatgtaaata ttacacatca agcgatgaaa ctggaaaact acaagccacg 2562 aatgaatgaa ttaggaaaga aaaaaagtag gaaatgaatg atcttggctt tcctataaga 2622 aatttagggc agggcacggt ggctcacgcc tgtaattcca gcactttggg aggccgaggc 2682 gggcagatca cgagttcagg agatcgagac catcttggcc aacatggtga aaccctgtct 2742 ctcctaaaaa tacaaaaatt agctggatgt ggtggcagtg cctgtaatcc cagctatttg 2802 ggaggctgag gcaggagaat cgcttgaacc agggagtcag aggtttcagt gagccaagat 2862 cgcaccactg ctctccagcc tggcgacaag caggtcgtct cgttccagtc gacggcccat 2922 2 650 PRT human 2 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Gly Gln Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Gly Ser Asp Thr Ala Gly Arg Ser Glu Ser Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Gln Pro Ser Pro Val Val Asn Ser Gly Gly Asn Val Thr Leu Gln 130 135 140 Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly 165 170 175 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Trp Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Glu Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Glu Glu 225 230 235 240 Thr Leu Thr Leu Gln Cys Gly Ser Asp Ala Gly Tyr Asn Arg Phe Val 245 250 255 Leu Tyr Lys Asp Gly Glu Arg Asp Phe Leu Gln Leu Ala Gly Ala Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 320 Gln Phe Tyr Asp Arg Val Ser Leu Ser Val Gln Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Trp Met 340 345 350 Gln Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Asp Pro Trp Arg 355 360 365 Leu Arg Ser Thr Tyr Gln Ser Gln Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Gly Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Gln Ser Ser Lys Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu 405 410 415 Leu Val Val Ser Gly Pro Ser Gly Gly Pro Ser Ser Pro Thr Thr Gly 420 425 430 Pro Thr Ser Thr Ser Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly 435 440 445 Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile Gly 450 455 460 Ile Leu Val Ala Val Ile Leu Leu Leu Leu Leu Leu Leu Leu Leu Phe 465 470 475 480 Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr Gln 485 490 495 Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu Pro 500 505 510 Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala Gln 515 520 525 Glu Glu Asn Leu Tyr Ala Ala Val Lys His Thr Gln Pro Glu Asp Gly 530 535 540 Val Glu Met Asp Thr Arg Ser Pro His Asp Glu Asp Pro Gln Ala Val 545 550 555 560 Thr Tyr Ala Glu Val Lys His Ser Arg Pro Arg Arg Glu Met Ala Ser 565 570 575 Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln 580 585 590 Ala Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala 595 600 605 Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg 610 615 620 Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Pro Ser Pro Ala Val 625 630 635 640 Pro Ser Ile Tyr Ala Thr Leu Ala Ile His 645 650 3 2777 DNA human CDS (168)..(2126) 3 agctcagcct gggcggcaca gccagatgcg agatgcgtct ctgctgatct gagtctgcct 60 gcagcatgga cctgggtctt ccctgaagca tctccagggc tggagggacg actgccatgc 120 accgagggct catccatcca cagagcaggg cagtgggagg agacgcc atg acc ccc 176 Met Thr Pro 1 atc ctc acg gtc ctg atc tgt ctc ggg ctg agt ctg ggc ccc agg acc 224 Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly Pro Arg Thr 5 10 15 cac gtg cag gca ggg cac ctc ccc aag ccc acc ctc tgg gct gaa cca 272 His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp Ala Glu Pro 20 25 30 35 ggc tct gtg atc acc cag ggg agt cct gtg acc ctc agg tgt cag ggg 320 Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg Cys Gln Gly 40 45 50 ggc cag gag acc cag gag tac cgt cta tat aga gaa aag aaa aca gca 368 Gly Gln Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys Lys Thr Ala 55 60 65 ctc tgg att aca cgg atc cca cag gag ctt gtg aag aag ggc cag ttc 416 Leu Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys Gly Gln Phe 70 75 80 ccc atc cca tcc atc acc tgg gaa cat gca ggg cgg tat cgc tgt tac 464 Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr Arg Cys Tyr 85 90 95 tat ggt agc gac act gca ggc cgc tca gag agc agt gac ccc ctg gag 512 Tyr Gly Ser Asp Thr Ala Gly Arg Ser Glu Ser Ser Asp Pro Leu Glu 100 105 110 115 ctg gtg gtg aca gga gcc tac atc aaa ccc acc ctc tca gcc cag ccc 560 Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser Ala Gln Pro 120 125 130 agc ccc gtg gtg aac tca gga ggg aat gta atc ctc cag tgt gac tca 608 Ser Pro Val Val Asn Ser Gly Gly Asn Val Ile Leu Gln Cys Asp Ser 135 140 145 cag gtg gca ttt gat ggc ttc agt ctg tgt aag gaa gga gaa gat gaa 656 Gln Val Ala Phe Asp Gly Phe Ser Leu Cys Lys Glu Gly Glu Asp Glu 150 155 160 cac cca caa tgc ctg aac tcc cag ccc cat gcc cgt ggg tcg tcc cgc 704 His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly Ser Ser Arg 165 170 175 gcc atc ttc tcc gtg ggc ccc gtg agc ccg agt cgc agg tgg tgg tac 752 Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg Trp Trp Tyr 180 185 190 195 agg tgc tat gct tat gac tcg aac tct ccc tat gag tgg tct cta ccc 800 Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Glu Trp Ser Leu Pro 200 205 210 agt gat ctc ctg gag ctc ctg gtc cta ggt gtt tct aag aag cca tca 848 Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys Lys Pro Ser 215 220 225 ctc tca gtg cag cca ggt cct atc gtg gcc cct gag gag acc ctg act 896 Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Glu Glu Thr Leu Thr 230 235 240 ctg cag tgt ggc tct gat gct ggc tac aac aga ttt gtt ctg tat aag 944 Leu Gln Cys Gly Ser Asp Ala Gly Tyr Asn Arg Phe Val Leu Tyr Lys 245 250 255 gac ggg gaa cgt gac ttc ctt cag ctc gct ggc gca cag ccc cag gct 992 Asp Gly Glu Arg Asp Phe Leu Gln Leu Ala Gly Ala Gln Pro Gln Ala 260 265 270 275 ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg agc cgc tcc tac 1040 Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Arg Ser Tyr 280 285 290 ggg ggc cag tac aga tgc tac ggt gca cac aac ctc tcc tcc gag tgg 1088 Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Ser Glu Trp 295 300 305 tcg gcc ccc agt gac ccc ctg gac atc ctg atc gca gga cag ttc tat 1136 Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Gln Phe Tyr 310 315 320 gac aga gtc tcc ctc tcg gtg cag ccg ggc ccc acg gtg gcc tca gga 1184 Asp Arg Val Ser Leu Ser Val Gln Pro Gly Pro Thr Val Ala Ser Gly 325 330 335 gag aac gtg acc ctg ctg tgt cag tca cag gga tgg atg caa act ttc 1232 Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Trp Met Gln Thr Phe 340 345 350 355 ctt ctg acc aag gag ggg gca gct gat gac cca tgg cgt cta aga tca 1280 Leu Leu Thr Lys Glu Gly Ala Ala Asp Asp Pro Trp Arg Leu Arg Ser 360 365 370 acg tac caa tct caa aaa tac cag gct gaa ttc ccc atg ggt cct gtg 1328 Thr Tyr Gln Ser Gln Lys Tyr Gln Ala Glu Phe Pro Met Gly Pro Val 375 380 385 acc tca gcc cat gcg ggg acc tac agg tgc tac ggc tca cag agc tcc 1376 Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Gln Ser Ser 390 395 400 aaa ccc tac ctg ctg act cac ccc agt gac ccc ctg gag ctc gtg gtc 1424 Lys Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu Leu Val Val 405 410 415 tca gga ccg tct ggg ggc ccc agc tcc ccg aca aca ggc ccc acc tcc 1472 Ser Gly Pro Ser Gly Gly Pro Ser Ser Pro Thr Thr Gly Pro Thr Ser 420 425 430 435 aca tct gca ggc cct gag gac cag ccc ctc acc ccc acc ggg tcg gat 1520 Thr Ser Ala Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly Ser Asp 440 445 450 ccc cag agt ggt ctg gga agg cac ctg ggg gtt gtg atc ggc atc ttg 1568 Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile Gly Ile Leu 455 460 465 gtg gcc gtc atc cta ctg ctc ctc ctc ctc ctc ctc ctc ttc ctc atc 1616 Val Ala Val Ile Leu Leu Leu Leu Leu Leu Leu Leu Leu Phe Leu Ile 470 475 480 ctc cga cat cga cgt cag ggc aaa cac tgg aca tcg acc cag aga aag 1664 Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr Gln Arg Lys 485 490 495 gct gat ttc caa cat cct gca ggg gct gtg ggg cca gag ccc aca gac 1712 Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu Pro Thr Asp 500 505 510 515 aga ggc ctg cag tgg agg tcc agc cca gct gcc gat gcc cag gaa gaa 1760 Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala Gln Glu Glu 520 525 530 aac ctc tat gct gcc gtg aag cac aca cag cct gag gat ggg gtg gag 1808 Asn Leu Tyr Ala Ala Val Lys His Thr Gln Pro Glu Asp Gly Val Glu 535 540 545 atg gac act cgg cag agc cca cac gat gaa gac ccc cag gca gtg acg 1856 Met Asp Thr Arg Gln Ser Pro His Asp Glu Asp Pro Gln Ala Val Thr 550 555 560 tat gcc gag gtg aaa cac tcc aga cct agg aga gaa atg gcc tct cct 1904 Tyr Ala Glu Val Lys His Ser Arg Pro Arg Arg Glu Met Ala Ser Pro 565 570 575 cct tcc cca ctg tct ggg gaa ttc ctg gac aca aag gac aga cag gcg 1952 Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln Ala 580 585 590 595 gaa gag gac agg cag atg gac act gag gct gct gca tct gaa gcc ccc 2000 Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala Pro 600 605 610 cag gat gtg acc tac gcc cag ctg cac agc ttg acc ctc aga cgg gag 2048 Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Glu 615 620 625 gca act gag cct cct cca tcc cag gaa ggg ccc tct cca gct gtg ccc 2096 Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Pro Ser Pro Ala Val Pro 630 635 640 agc atc tac gcc act ctg gcc atc cac tag cccagggggg gacgcagacc 2146 Ser Ile Tyr Ala Thr Leu Ala Ile His 645 650 ccacactcca tggagtctgg aatgcatggg agctgccccc ccagtggaca ccattggacc 2206 ccacccagcc tggatctacc ccaggagact ctgggaactt ttaggggtca ctcaattctg 2266 cagtataaat aactaatgtc tctacaattt tgaaataaag caatagactt ctcaataatc 2326 aatgaagtag ctgagaaaac taagtcagaa agtgcattaa actgaatcac aatgtaaata 2386 ttacacatca agcgatgaaa ctggaaaact acaagccacg aatgaatgaa ttaggaaaga 2446 aaaaaagtag gaaatgaatg atcttggctt tcctataaga aatttagggc agggcacggt 2506 ggctcacgcc tgtaattcca gcactttggg aggccgaggc gggcagatca cgagttcagg 2566 agatcgagac catcttggcc aacatggtga aaccctgtct ctcctaaaaa tacaaaaatt 2626 agctggatgt ggtggcagtg cctgtaatcc cagctatttg ggaggctgag gcaggagaat 2686 cgcttgaacc agggagtcag aggtttcagt gagccaagat cgcaccactg ctctccagcc 2746 tggcgacaga gggagactcc atctcaaatt a 2777 4 652 PRT human 4 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Gly Gln Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Leu Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Gly Ser Asp Thr Ala Gly Arg Ser Glu Ser Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Gln Pro Ser Pro Val Val Asn Ser Gly Gly Asn Val Ile Leu Gln 130 135 140 Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ser Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly 165 170 175 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Trp Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Glu Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Glu Glu 225 230 235 240 Thr Leu Thr Leu Gln Cys Gly Ser Asp Ala Gly Tyr Asn Arg Phe Val 245 250 255 Leu Tyr Lys Asp Gly Glu Arg Asp Phe Leu Gln Leu Ala Gly Ala Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 320 Gln Phe Tyr Asp Arg Val Ser Leu Ser Val Gln Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Trp Met 340 345 350 Gln Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Asp Pro Trp Arg 355 360 365 Leu Arg Ser Thr Tyr Gln Ser Gln Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Gly Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Gln Ser Ser Lys Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu 405 410 415 Leu Val Val Ser Gly Pro Ser Gly Gly Pro Ser Ser Pro Thr Thr Gly 420 425 430 Pro Thr Ser Thr Ser Ala Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr 435 440 445 Gly Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile 450 455 460 Gly Ile Leu Val Ala Val Ile Leu Leu Leu Leu Leu Leu Leu Leu Leu 465 470 475 480 Phe Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr 485 490 495 Gln Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu 500 505 510 Pro Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala 515 520 525 Gln Glu Glu Asn Leu Tyr Ala Ala Val Lys His Thr Gln Pro Glu Asp 530 535 540 Gly Val Glu Met Asp Thr Arg Gln Ser Pro His Asp Glu Asp Pro Gln 545 550 555 560 Ala Val Thr Tyr Ala Glu Val Lys His Ser Arg Pro Arg Arg Glu Met 565 570 575 Ala Ser Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp 580 585 590 Arg Gln Ala Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser 595 600 605 Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu 610 615 620 Arg Arg Glu Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Pro Ser Pro 625 630 635 640 Ala Val Pro Ser Ile Tyr Ala Thr Leu Ala Ile His 645 650 5 30 DNA human 5 tatgtcgacc atgaccccca tcctcacggt 30 6 52 DNA human 6 tatgggctct gctccaggag aagatcttcc ttctataacc cccaggtgcc tt 52 7 1605 DNA human CDS (93)..(1412) 7 gagcctccaa gtgtccacac cctgtgtgtc ctctgtcctg ccagcaccga gggctcatcc 60 atccacagag cagtgcagtg ggaggagacg cc atg acc ccc atc ctc acg gtc 113 Met Thr Pro Ile Leu Thr Val 1 5 ctg atc tgt ctc ggg ctg agc ctg gac ccc agg acc cac gtg cag gca 161 Leu Ile Cys Leu Gly Leu Ser Leu Asp Pro Arg Thr His Val Gln Ala 10 15 20 ggg ccc ctc ccc aag ccc acc ctc tgg gct gag cca ggc tct gtg atc 209 Gly Pro Leu Pro Lys Pro Thr Leu Trp Ala Glu Pro Gly Ser Val Ile 25 30 35 acc caa ggg agt cct gtg acc ctc agg tgt cag ggg agc ctg gag acg 257 Thr Gln Gly Ser Pro Val Thr Leu Arg Cys Gln Gly Ser Leu Glu Thr 40 45 50 55 cag gag tac cat cta tat aga gaa aag aaa aca gca ctc tgg att aca 305 Gln Glu Tyr His Leu Tyr Arg Glu Lys Lys Thr Ala Leu Trp Ile Thr 60 65 70 cgg atc cca cag gag ctt gtg aag aag ggc cag ttc ccc atc cta tcc 353 Arg Ile Pro Gln Glu Leu Val Lys Lys Gly Gln Phe Pro Ile Leu Ser 75 80 85 atc acc tgg gaa cat gca ggg cgg tat tgc tgt atc tat ggc agc cac 401 Ile Thr Trp Glu His Ala Gly Arg Tyr Cys Cys Ile Tyr Gly Ser His 90 95 100 act gca ggc ctc tca gag agc agt gac ccc ctg gag ctg gtg gtg aca 449 Thr Ala Gly Leu Ser Glu Ser Ser Asp Pro Leu Glu Leu Val Val Thr 105 110 115 gga gcc tac agc aaa ccc acc ctc tca gct ctg ccc agc cct gtg gtg 497 Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val 120 125 130 135 acc tca gga agg aat gtg acc atc cag tgt gac tca cag gtg gca ttt 545 Thr Ser Gly Arg Asn Val Thr Ile Gln Cys Asp Ser Gln Val Ala Phe 140 145 150 gat ggc ttc att ctg tgt aag gaa gga gaa gat gaa cac cca caa tgc 593 Asp Gly Phe Ile Leu Cys Lys Glu Gly Glu Asp Glu His Pro Gln Cys 155 160 165 ctg aac tcc cat tcc cat gcc cgt ggg tca tcc cgg gcc atc ttc tcc 641 Leu Asn Ser His Ser His Ala Arg Gly Ser Ser Arg Ala Ile Phe Ser 170 175 180 gtg ggc ccc gtg agc cca agt cgc agg tgg tcg tac agg tgc tat ggt 689 Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser Tyr Arg Cys Tyr Gly 185 190 195 tat gac tcg cgc gct ccc tat gtg tgg tct cta ccc agt gat ctc ctg 737 Tyr Asp Ser Arg Ala Pro Tyr Val Trp Ser Leu Pro Ser Asp Leu Leu 200 205 210 215 ggg ctc ctg gtc cca ggt gtt tct aag aag cca tca ctc tca gtg cag 785 Gly Leu Leu Val Pro Gly Val Ser Lys Lys Pro Ser Leu Ser Val Gln 220 225 230 ccg ggt cct gtc gtg gcc cct ggg gag aag ctg acc ttc cag tgt ggc 833 Pro Gly Pro Val Val Ala Pro Gly Glu Lys Leu Thr Phe Gln Cys Gly 235 240 245 tct gat gcc ggc tac gac aga ttt gtt ctg tac aag gag tgg gga cgt 881 Ser Asp Ala Gly Tyr Asp Arg Phe Val Leu Tyr Lys Glu Trp Gly Arg 250 255 260 gac ttc ctc cag cgc cct ggc cgg cag ccc cag gct ggg ctc tcc cag 929 Asp Phe Leu Gln Arg Pro Gly Arg Gln Pro Gln Ala Gly Leu Ser Gln 265 270 275 gcc aac ttc acc ctg ggc cct gtg agc cgc tcc tac ggg ggc cag tac 977 Ala Asn Phe Thr Leu Gly Pro Val Ser Arg Ser Tyr Gly Gly Gln Tyr 280 285 290 295 aca tgc tcc ggt gca tac aac ctc tcc tcc gag tgg tcg gcc ccc agc 1025 Thr Cys Ser Gly Ala Tyr Asn Leu Ser Ser Glu Trp Ser Ala Pro Ser 300 305 310 gac ccc ctg gac atc ctg atc aca gga cag atc cgt gcc aga ccc ttc 1073 Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln Ile Arg Ala Arg Pro Phe 315 320 325 ctc tcc gtg cgg ccg ggc ccc aca gtg gcc tca gga gag aac gtg acc 1121 Leu Ser Val Arg Pro Gly Pro Thr Val Ala Ser Gly Glu Asn Val Thr 330 335 340 ctg ctg tgt cag tca cag gga ggg atg cac act ttc ctt ttg acc aag 1169 Leu Leu Cys Gln Ser Gln Gly Gly Met His Thr Phe Leu Leu Thr Lys 345 350 355 gag ggg gca gct gat tcc ccg ctg cgt cta aaa tca aag cgc caa tct 1217 Glu Gly Ala Ala Asp Ser Pro Leu Arg Leu Lys Ser Lys Arg Gln Ser 360 365 370 375 cat aag tac cag gct gaa ttc ccc atg agt cct gtg acc tcg gcc cac 1265 His Lys Tyr Gln Ala Glu Phe Pro Met Ser Pro Val Thr Ser Ala His 380 385 390 gcg ggg acc tac agg tgc tac ggc tca ctc agc tcc aac ccc tac ctg 1313 Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Leu Ser Ser Asn Pro Tyr Leu 395 400 405 ctg act cac ccc agt gac ccc ctg gag ctc gtg gtc tca gga gca gct 1361 Leu Thr His Pro Ser Asp Pro Leu Glu Leu Val Val Ser Gly Ala Ala 410 415 420 gag acc ctc agc cca cca caa aac aag tcc gac tcc aag gct ggt gag 1409 Glu Thr Leu Ser Pro Pro Gln Asn Lys Ser Asp Ser Lys Ala Gly Glu 425 430 435 tga ggagatgctt gccgtgatga cgctgggcac agagggtcag gtcctgtcaa 1462 gaggagctgg gtgtcctggg tggacatttg aagaattata ttcattccaa cttgaagaat 1522 tattcaacac ctttaacaat gtatatgtga agtactttat tctttcatat tttaaaaata 1582 aaagataatt atccatgaga aaa 1605 8 439 PRT human 8 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Asp 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Ser Leu Glu Thr Gln Glu Tyr His Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Leu Trp Ile Thr Arg Ile Pro Gln Glu Leu Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Leu Ser Ile Thr Trp Glu His Ala Gly Arg Tyr 85 90 95 Cys Cys Ile Tyr Gly Ser His Thr Ala Gly Leu Ser Glu Ser Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser 115 120 125 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Arg Asn Val Thr Ile Gln 130 135 140 Cys Asp Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser His Ser His Ala Arg Gly 165 170 175 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Ser Tyr Arg Cys Tyr Gly Tyr Asp Ser Arg Ala Pro Tyr Val Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Gly Leu Leu Val Pro Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Val Val Ala Pro Gly Glu 225 230 235 240 Lys Leu Thr Phe Gln Cys Gly Ser Asp Ala Gly Tyr Asp Arg Phe Val 245 250 255 Leu Tyr Lys Glu Trp Gly Arg Asp Phe Leu Gln Arg Pro Gly Arg Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Thr Cys Ser Gly Ala Tyr Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly 305 310 315 320 Gln Ile Arg Ala Arg Pro Phe Leu Ser Val Arg Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Gly Gly Met 340 345 350 His Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala Asp Ser Pro Leu Arg 355 360 365 Leu Lys Ser Lys Arg Gln Ser His Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Ser Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Leu Ser Ser Asn Pro Tyr Leu Leu Thr His Pro Ser Asp Pro Leu Glu 405 410 415 Leu Val Val Ser Gly Ala Ala Glu Thr Leu Ser Pro Pro Gln Asn Lys 420 425 430 Ser Asp Ser Lys Ala Gly Glu 435 9 2221 DNA human CDS (184)..(1980) 9 gctcactgcc acacgcagct cagcctgggc ggcacagcca gatgcgagat gcgtctctgc 60 tgatctgagt ctgcctgcag catggacctg ggtcttccct gaagcatctc cagggctgga 120 gggacgactg ccatgcaccg agggctcatc catccgcaga gcagggcagt gggaggagac 180 gcc atg acc ccc atc gtc aca gtc ctg atc tgt ctc ggg ctg agt ctg 228 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Gly Leu Ser Leu 1 5 10 15 ggc ccc agg acc cac gtg cag aca ggg acc atc ccc aag ccc acc ctg 276 Gly Pro Arg Thr His Val Gln Thr Gly Thr Ile Pro Lys Pro Thr Leu 20 25 30 tgg gct gag cca gac tct gtg atc acc cag ggg agt ccc gtc acc ctc 324 Trp Ala Glu Pro Asp Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu 35 40 45 agt tgt cag ggg agc ctt gaa gcc cag gag tac cgt cta tat agg gag 372 Ser Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Arg Leu Tyr Arg Glu 50 55 60 aaa aaa tca gca tct tgg att aca cgg ata cga cca gag ctt gtg aag 420 Lys Lys Ser Ala Ser Trp Ile Thr Arg Ile Arg Pro Glu Leu Val Lys 65 70 75 aac ggc cag ttc cac atc cca tcc atc acc tgg gaa cac aca ggg cga 468 Asn Gly Gln Phe His Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg 80 85 90 95 tat ggc tgt cag tat tac agc cgc gct cgg tgg tct gag ctc agt gac 516 Tyr Gly Cys Gln Tyr Tyr Ser Arg Ala Arg Trp Ser Glu Leu Ser Asp 100 105 110 ccc ctg gtg ctg gtg atg aca gga gcc tac cca aaa ccc acc ctc tca 564 Pro Leu Val Leu Val Met Thr Gly Ala Tyr Pro Lys Pro Thr Leu Ser 115 120 125 gcc cag ccc agc cct gtg gtg acc tca gga gga agg gtg acc ctc cag 612 Ala Gln Pro Ser Pro Val Val Thr Ser Gly Gly Arg Val Thr Leu Gln 130 135 140 tgt gag tca cag gtg gca ttt ggc ggc ttc att ctg tgt aag gaa gga 660 Cys Glu Ser Gln Val Ala Phe Gly Gly Phe Ile Leu Cys Lys Glu Gly 145 150 155 gaa gat gaa cac cca caa tgc ctg aac tcc cag ccc cat gcc cgt ggg 708 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly 160 165 170 175 tcg tcc cgc gcc atc ttc tcc gtg ggc ccc gtg agc ccg aat cgc agg 756 Ser Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Asn Arg Arg 180 185 190 tgg tcg cac agg tgc tat ggt tat gac ttg aac tct ccc tat gtg tgg 804 Trp Ser His Arg Cys Tyr Gly Tyr Asp Leu Asn Ser Pro Tyr Val Trp 195 200 205 tct tca ccc agt gat ctc ctg gag ctc ctg gtc cca ggt gtt tct aag 852 Ser Ser Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys 210 215 220 aag cca tca ctc tca gtg cag ccg ggt cct gtc gtg gcc cct ggg gaa 900 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Val Val Ala Pro Gly Glu 225 230 235 agc ctg acc ctc cag tgt gtc tct gat gtc ggc tat gac aga ttt gtt 948 Ser Leu Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val 240 245 250 255 ctg tac aag gag ggg gaa cgt gac ctt cgc cag ctc cct ggc cgg cag 996 Leu Tyr Lys Glu Gly Glu Arg Asp Leu Arg Gln Leu Pro Gly Arg Gln 260 265 270 ccc cag gct ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg agc 1044 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 cgc tcc tac ggg ggc cag tac aga tgc tac ggt gca tac aac ctc tcc 1092 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala Tyr Asn Leu Ser 290 295 300 tcc gag tgg tcg gcc ccc agc gac ccc ctg gac atc ctg atc aca gga 1140 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly 305 310 315 cag atc cat ggc aca ccc ttc atc tca gtg cag cca ggc ccc aca gtg 1188 Gln Ile His Gly Thr Pro Phe Ile Ser Val Gln Pro Gly Pro Thr Val 320 325 330 335 gcc tca gga gag aac gtg acc ctg ctg tgt cag tca tgg cgg cag ttc 1236 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Arg Gln Phe 340 345 350 cac act ttc ctt ctg acc aag gcg gga gca gct gat gcc cca ctc cgt 1284 His Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu Arg 355 360 365 cta aga tca ata cac gaa tat cct aag tac cag gct gaa ttc ccc atg 1332 Leu Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 agt cct gtg acc tca gcc cac gcg ggg acc tac agg tgc tac ggc tca 1380 Ser Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 ctc aac tcc gac ccc tac ctg ctg tct cac ccc agt gag ccc ctg gag 1428 Leu Asn Ser Asp Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu Glu 400 405 410 415 ctc gtg gtc tca gga ccc tcc atg ggt tcc agc ccc cca ccc acc ggt 1476 Leu Val Val Ser Gly Pro Ser Met Gly Ser Ser Pro Pro Pro Thr Gly 420 425 430 ccc atc tcc aca cct gca ggc cct gag gac cag ccc ctc acc ccc act 1524 Pro Ile Ser Thr Pro Ala Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr 435 440 445 ggg tcg gat ccc caa agt ggt ctg gga agg cac ctg ggg gtt gtg atc 1572 Gly Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile 450 455 460 ggc atc ttg gtg gcc gtc gtc cta ctg ctc ctc ctc ctc ctc ctc ctc 1620 Gly Ile Leu Val Ala Val Val Leu Leu Leu Leu Leu Leu Leu Leu Leu 465 470 475 ttc ctc atc ctc cga cat cga cgt cag ggc aaa cac tgg aca tcg acc 1668 Phe Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr 480 485 490 495 cag aga aag gct gat ttc caa cat cct gca ggg gct gtg ggg cca gag 1716 Gln Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu 500 505 510 ccc aca gac aga ggc ctg cag tgg agg tcc agc cca gct gcc gac gcc 1764 Pro Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala 515 520 525 cag gaa gaa aac ctc tat gct gcc gtg aag gac aca cag cct gaa gat 1812 Gln Glu Glu Asn Leu Tyr Ala Ala Val Lys Asp Thr Gln Pro Glu Asp 530 535 540 ggg gtg gag atg gac act cgg gct gct gca tct gaa gcc ccc cag gat 1860 Gly Val Glu Met Asp Thr Arg Ala Ala Ala Ser Glu Ala Pro Gln Asp 545 550 555 gtg acc tac gcc cag ctg cac agc ttg acc ctc aga cgg aag gca act 1908 Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys Ala Thr 560 565 570 575 gag cct cct cca tcc cag gaa agg gaa cct cca gct gag ccc agc atc 1956 Glu Pro Pro Pro Ser Gln Glu Arg Glu Pro Pro Ala Glu Pro Ser Ile 580 585 590 tac gcc acc ctg gcc atc cac tag cccggagggt acgcagactc cacactcagt 2010 Tyr Ala Thr Leu Ala Ile His 595 agaaggagac tcaggactgc tgaaggcacg ggagctgccc ccagtggaca ccaatgaacc 2070 ccagtcagcc tggaccccta acaaagacca tgaggagatg ctgggaactt tgggactcac 2130 ttgattctgc agtcgaaata actaatatcc ctacattttt taattaaagc aacagacttc 2190 tcaataaaag caggtcgtct cgttccaatc t 2221 10 598 PRT human 10 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Thr Gly Thr Ile Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Asp Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Ser 35 40 45 Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Ser Ala Ser Trp Ile Thr Arg Ile Arg Pro Glu Leu Val Lys Asn 65 70 75 80 Gly Gln Phe His Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr 85 90 95 Gly Cys Gln Tyr Tyr Ser Arg Ala Arg Trp Ser Glu Leu Ser Asp Pro 100 105 110 Leu Val Leu Val Met Thr Gly Ala Tyr Pro Lys Pro Thr Leu Ser Ala 115 120 125 Gln Pro Ser Pro Val Val Thr Ser Gly Gly Arg Val Thr Leu Gln Cys 130 135 140 Glu Ser Gln Val Ala Phe Gly Gly Phe Ile Leu Cys Lys Glu Gly Glu 145 150 155 160 Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro His Ala Arg Gly Ser 165 170 175 Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Asn Arg Arg Trp 180 185 190 Ser His Arg Cys Tyr Gly Tyr Asp Leu Asn Ser Pro Tyr Val Trp Ser 195 200 205 Ser Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys Lys 210 215 220 Pro Ser Leu Ser Val Gln Pro Gly Pro Val Val Ala Pro Gly Glu Ser 225 230 235 240 Leu Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val Leu 245 250 255 Tyr Lys Glu Gly Glu Arg Asp Leu Arg Gln Leu Pro Gly Arg Gln Pro 260 265 270 Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Arg 275 280 285 Ser Tyr Gly Gly Gln Tyr Arg Cys Tyr Gly Ala Tyr Asn Leu Ser Ser 290 295 300 Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln 305 310 315 320 Ile His Gly Thr Pro Phe Ile Ser Val Gln Pro Gly Pro Thr Val Ala 325 330 335 Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Arg Gln Phe His 340 345 350 Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu Arg Leu 355 360 365 Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro Met Ser 370 375 380 Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Leu 385 390 395 400 Asn Ser Asp Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu Glu Leu 405 410 415 Val Val Ser Gly Pro Ser Met Gly Ser Ser Pro Pro Pro Thr Gly Pro 420 425 430 Ile Ser Thr Pro Ala Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly 435 440 445 Ser Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Ile Gly 450 455 460 Ile Leu Val Ala Val Val Leu Leu Leu Leu Leu Leu Leu Leu Leu Phe 465 470 475 480 Leu Ile Leu Arg His Arg Arg Gln Gly Lys His Trp Thr Ser Thr Gln 485 490 495 Arg Lys Ala Asp Phe Gln His Pro Ala Gly Ala Val Gly Pro Glu Pro 500 505 510 Thr Asp Arg Gly Leu Gln Trp Arg Ser Ser Pro Ala Ala Asp Ala Gln 515 520 525 Glu Glu Asn Leu Tyr Ala Ala Val Lys Asp Thr Gln Pro Glu Asp Gly 530 535 540 Val Glu Met Asp Thr Arg Ala Ala Ala Ser Glu Ala Pro Gln Asp Val 545 550 555 560 Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys Ala Thr Glu 565 570 575 Pro Pro Pro Ser Gln Glu Arg Glu Pro Pro Ala Glu Pro Ser Ile Tyr 580 585 590 Ala Thr Leu Ala Ile His 595 11 2446 DNA human CDS (171)..(1040) 11 cgcagctcaa cctgagctac acagccagat gcgagatgct tctctgctga tctgagtctg 60 cctgcagcat ggaccttggt cttccctgaa gcatctccag ggctggaggg acgactgcca 120 tgcacctagg gcttatccat ccgcagagca gggcagtggg aggagacgct atg acc 176 Met Thr 1 ccc atc ctc acg gtc ctg atc tgt ctc ggg ctg agt ctg ggc ccc cgg 224 Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly Pro Arg 5 10 15 acc cac gtg cag gca ggg acc ctc ccc aag ccc aca ctc tgg gct gag 272 Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp Ala Glu 20 25 30 cca ggc tct gtg atc acc cag ggg agt ccc gtg acc ctc tgg tgt cag 320 Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Trp Cys Gln 35 40 45 50 ggg atc ctg gag acc cag gag tac cgt ctg tat aga gaa aag aaa aca 368 Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys Lys Thr 55 60 65 gca ccc tgg att aca cgg atc cca cag gag att gtg aag aag ggc cag 416 Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys Lys Gly Gln 70 75 80 ttc ccc atc ccg tcc atc acc tgg gaa cac acc ggg cgg tat cgc tgt 464 Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr Arg Cys 85 90 95 ttc tac ggt agc cac act gca ggc tgg tca gag ccc agt gac ccc ctg 512 Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser Asp Pro Leu 100 105 110 gag ctg gtg gtg aca gga gcc tac atc aaa ccc acc ctc tcg gct cta 560 Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser Ala Leu 115 120 125 130 ccc agc cct gtg gtg acc tca gga ggg aac gtg acc ctc cat tgt gtc 608 Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu His Cys Val 135 140 145 tca cag gtg gca ttt ggc agc ttc att ctg tgt aag gaa gga gaa gat 656 Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu Gly Glu Asp 150 155 160 gaa cac cca caa tgc ctg aac tca cag ccc cgt acc cat ggg tgg tcc 704 Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His Gly Trp Ser 165 170 175 cgg gcc atc ttc tct gtg ggc ccc gtg agc ccg agt cgc agg tgg tcg 752 Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser 180 185 190 tac agg tgc tat gct tat gac tcg aac tct ccc cat gtg tgg tct cta 800 Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val Trp Ser Leu 195 200 205 210 ccc agt gat ctc ctg gag ctc ctg gtc cca gga gca gct gag acc ctc 848 Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Ala Ala Glu Thr Leu 215 220 225 agc cca cca caa aac aag tcc gat tcc aag gct gga gca gct aac acc 896 Ser Pro Pro Gln Asn Lys Ser Asp Ser Lys Ala Gly Ala Ala Asn Thr 230 235 240 ctc agc cca tca caa aac aag act gcc tca cac ccc cag gat tac aca 944 Leu Ser Pro Ser Gln Asn Lys Thr Ala Ser His Pro Gln Asp Tyr Thr 245 250 255 gtg gag aat ctc atc cgc atg ggc ata gct ggc ttg gtc ctg gtg gtc 992 Val Glu Asn Leu Ile Arg Met Gly Ile Ala Gly Leu Val Leu Val Val 260 265 270 ctc ggg att ctg cta ttt gag gct cag cac agc cag aga agc ctc tga 1040 Leu Gly Ile Leu Leu Phe Glu Ala Gln His Ser Gln Arg Ser Leu 275 280 285 gatgcagccg ggaggtgaac agcagagaga agaatgtacc cttcagagtg gtggagcctt 1100 gggaacagat ctgatgatgc caggaggttc cgggagacaa tttagggctg atgctatctg 1160 gactgtctgc caatcatttt tagagggagg aatcagtgtt ggattgcaga gacattttct 1220 ggagtgatcc atgaaggacc attaacatgt gatacctttc ctctctatta atgttgactt 1280 cccttggttg gatcctcttc tttccccacc cccagacaga catgaggcta catcccacat 1340 ggcagcgttg ggtccacacc tctgcacatc tgtgtgctct ggtccatggt gtgtaacaca 1400 gtcttcttta ttactcattg ccatactccc tggtgtgctt tactgagcct ccatctcttc 1460 aattcagagt tccaaacgtg cttcagtaac taaatcaatg ggagagtatc ggatttcaac 1520 caggaaaaga taaatccacc ctgatgccct gacaccctct ctgaacccta cgagcccttc 1580 cctccttctc acatgctacc tgtgcagctt ctccttagat cattgtgtaa ccatcactgc 1640 catcctgttc cacacatggt catcacccta cacccattca gcagccactc cccattccct 1700 cttccctcca gcacctgcta accacaaatg tgctttctgt ctctacggat ttgcctattc 1760 tgtctgaaaa catttcaatc tcctttgacc tgtgagctcc tcacttcgag acttcctgcc 1820 tttccaggca gaaccaaagt acaccacgtc aaaagcaatg ataggcattt gcagtgtgtt 1880 ggtgatccac gaaaggaaaa tcacggaagc aggatagaaa tccagctgca gacaagacct 1940 caggtcgatg aatcttgaca agcagttgag ctgttttttt ctactcacct aggacagtca 2000 ggcagaagta tgcaaaatga ctggggctga ttcttttctg aattgtcgca aacagcaaga 2060 ggacttgagt cctagcatta aagagttcaa catgtctagg tccaagacca ctgttgtgtt 2120 tgaaggatgt aaaaccctgc tgcataggat ggaatatttg gagggaggat cctgaaaaac 2180 atgagggatc aaatagtcct caactttcta ggacaaaggg agcagctatt tgccatctac 2240 cctccagaat aaagaaatct tatcattcac catctaccct ctagaataaa gaaatcttat 2300 cattcgccat ctaccctgta gaataaagaa atcttatcat tcaccgtcta ccctctagag 2360 taaacaaatc ttatcattca ccatctaccc tctagaataa agaaatctta tcattcgcca 2420 tctaccctct agaataaaga aatctt 2446 12 289 PRT human 12 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Trp 35 40 45 Cys Gln Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr 85 90 95 Arg Cys Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu His 130 135 140 Cys Val Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His Gly 165 170 175 Trp Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Ser Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Ala Ala Glu 210 215 220 Thr Leu Ser Pro Pro Gln Asn Lys Ser Asp Ser Lys Ala Gly Ala Ala 225 230 235 240 Asn Thr Leu Ser Pro Ser Gln Asn Lys Thr Ala Ser His Pro Gln Asp 245 250 255 Tyr Thr Val Glu Asn Leu Ile Arg Met Gly Ile Ala Gly Leu Val Leu 260 265 270 Val Val Leu Gly Ile Leu Leu Phe Glu Ala Gln His Ser Gln Arg Ser 275 280 285 Leu 13 1910 DNA human CDS (183)..(1652) 13 ctcactgcca cacgcagctc aacctgagct acacagccag atgcgagatg cttctctgct 60 gatctgagtc tgcctgcagc atggaccttg gtcttccctg aagcatctcc agggctggag 120 ggacgactgc catgcaccga gggctcatcc atccgcagag cagggcagtg ggaggagacg 180 ct atg acc ccc atc gtc aca gtc ctg atc tgt ctc agg ctg agt ctg 227 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Arg Leu Ser Leu 1 5 10 15 ggc ccc cgg acc cac gtg cag gca ggg acc ctc ccc aag ccc aca ctc 275 Gly Pro Arg Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu 20 25 30 tgg gct gag cca ggc tct gtg atc acc cag ggg agt ccc gtg acc ctc 323 Trp Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu 35 40 45 tgg tgt cag ggg atc ctg gag acc cag gag tac cgt ctg tat aga gaa 371 Trp Cys Gln Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu 50 55 60 aag aaa aca gca ccc tgg att aca cgg atc cca cag gag att gtg aag 419 Lys Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys 65 70 75 aag ggc cag ttc ccc atc cca tcc atc acc tgg gaa cac aca ggg cgg 467 Lys Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg 80 85 90 95 tat cgc tgt ttc tac ggt agc cac act gca ggc tgg tca gag ccc agt 515 Tyr Arg Cys Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser 100 105 110 gac ccc ctg gag ctg gtg gtg aca gga gcc tac atc aaa ccc acc ctc 563 Asp Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu 115 120 125 tca gct cta ccc agc cct gtg gtg acc tca gga ggg aac gtg acc ctc 611 Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu 130 135 140 cat tgt gtc tca cag gtg gca ttt ggc agc ttc att ctg tgt aag gaa 659 His Cys Val Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu 145 150 155 gga gaa gat gaa cac cca caa tgc ctg aac tca cag ccc cgt acc cat 707 Gly Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His 160 165 170 175 ggg tgg tcc cgg gcc atc ttc tct gtg ggc ccc gtg agc ccg agt cgc 755 Gly Trp Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg 180 185 190 agg tgg tcg tac agg tgc tat gct tat gac tcg aac tct ccc cat gtg 803 Arg Trp Ser Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val 195 200 205 tgg tct cta ccc agt gat ctc ctg gag ctc ctg gtc cta ggt gtt tct 851 Trp Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser 210 215 220 aag aag cca tca ctc tca gtg cag cca ggt cct ata gtg gcc cct ggg 899 Lys Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Gly 225 230 235 gag agc ctg acc ctc cag tgt gtt tct gat gtc agc tac gac aga ttt 947 Glu Ser Leu Thr Leu Gln Cys Val Ser Asp Val Ser Tyr Asp Arg Phe 240 245 250 255 gtt ctg tat aag gag gga gaa cgt gac ttc ctc cag ctc cct ggc cca 995 Val Leu Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Leu Pro Gly Pro 260 265 270 cag ccc cag gct ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg 1043 Gln Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val 275 280 285 agc cgc tcc tac ggg ggc cag tac aga tgc tcc ggt gca tac aac ctc 1091 Ser Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Ser Gly Ala Tyr Asn Leu 290 295 300 tcc tcc gag tgg tcg gcc ccc agc gac ccc ctg gac atc ctg atc gca 1139 Ser Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala 305 310 315 gga cag ttc cgt ggc aga ccc ttc atc tcg gtg cat ccg ggc ccc acg 1187 Gly Gln Phe Arg Gly Arg Pro Phe Ile Ser Val His Pro Gly Pro Thr 320 325 330 335 gtg gcc tca gga gag aac gtg acc ctg ctg tgt cag tca tgg ggg ccg 1235 Val Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Gly Pro 340 345 350 ttc cac act ttc ctt ctg acc aag gcg gga gca gct gat gcc ccc ctc 1283 Phe His Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu 355 360 365 cgt ctc aga tca ata cac gaa tat cct aag tac cag gct gaa ttc cct 1331 Arg Leu Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro 370 375 380 atg agt cct gtg acc tca gcc cac tcg ggg acc tac agg tgc tac ggc 1379 Met Ser Pro Val Thr Ser Ala His Ser Gly Thr Tyr Arg Cys Tyr Gly 385 390 395 tca ctc agc tcc aac ccc tac ctg ctg tct cac ccc agt gac tcc ctg 1427 Ser Leu Ser Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Asp Ser Leu 400 405 410 415 gag ctc atg gtc tca gga gca gct gag acc ctc agc cca cca caa aac 1475 Glu Leu Met Val Ser Gly Ala Ala Glu Thr Leu Ser Pro Pro Gln Asn 420 425 430 aag tcc gat tcc aag gct gga gca gct aac acc ctc agc cca tca caa 1523 Lys Ser Asp Ser Lys Ala Gly Ala Ala Asn Thr Leu Ser Pro Ser Gln 435 440 445 aac aag act gcc tca cac ccc cag gat tac aca gtg gag aat ctc atc 1571 Asn Lys Thr Ala Ser His Pro Gln Asp Tyr Thr Val Glu Asn Leu Ile 450 455 460 cgc atg ggc ata gct ggc ttg gtc ctg gtg gtc ctc ggg att ctg cta 1619 Arg Met Gly Ile Ala Gly Leu Val Leu Val Val Leu Gly Ile Leu Leu 465 470 475 ttt gag gct cag cac agc cag aga agc ctc tga gatgcagccg ggaggtgaac 1672 Phe Glu Ala Gln His Ser Gln Arg Ser Leu 480 485 agcagagaga agaatgtacc cttcagagtg gtggagcctt gggaacagat ctgatgatgc 1732 caggaggttc cgggagacaa tttagggctg atgttatctg gactgtctgc caatcatttt 1792 tagagggagg aatcagtgtt ggattgcaga gacattttct ggagtgatcc atgaaggacc 1852 attaacatgt gatacctttc ctctctatta atgttgactt cccttggttg gatcctct 1910 14 489 PRT human 14 Met Thr Pro Ile Val Thr Val Leu Ile Cys Leu Arg Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Thr Gln Gly Ser Pro Val Thr Leu Trp 35 40 45 Cys Gln Gly Ile Leu Glu Thr Gln Glu Tyr Arg Leu Tyr Arg Glu Lys 50 55 60 Lys Thr Ala Pro Trp Ile Thr Arg Ile Pro Gln Glu Ile Val Lys Lys 65 70 75 80 Gly Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Thr Gly Arg Tyr 85 90 95 Arg Cys Phe Tyr Gly Ser His Thr Ala Gly Trp Ser Glu Pro Ser Asp 100 105 110 Pro Leu Glu Leu Val Val Thr Gly Ala Tyr Ile Lys Pro Thr Leu Ser 115 120 125 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Gly Asn Val Thr Leu His 130 135 140 Cys Val Ser Gln Val Ala Phe Gly Ser Phe Ile Leu Cys Lys Glu Gly 145 150 155 160 Glu Asp Glu His Pro Gln Cys Leu Asn Ser Gln Pro Arg Thr His Gly 165 170 175 Trp Ser Arg Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg 180 185 190 Trp Ser Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro His Val Trp 195 200 205 Ser Leu Pro Ser Asp Leu Leu Glu Leu Leu Val Leu Gly Val Ser Lys 210 215 220 Lys Pro Ser Leu Ser Val Gln Pro Gly Pro Ile Val Ala Pro Gly Glu 225 230 235 240 Ser Leu Thr Leu Gln Cys Val Ser Asp Val Ser Tyr Asp Arg Phe Val 245 250 255 Leu Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Leu Pro Gly Pro Gln 260 265 270 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 Arg Ser Tyr Gly Gly Gln Tyr Arg Cys Ser Gly Ala Tyr Asn Leu Ser 290 295 300 Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 320 Gln Phe Arg Gly Arg Pro Phe Ile Ser Val His Pro Gly Pro Thr Val 325 330 335 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Gly Pro Phe 340 345 350 His Thr Phe Leu Leu Thr Lys Ala Gly Ala Ala Asp Ala Pro Leu Arg 355 360 365 Leu Arg Ser Ile His Glu Tyr Pro Lys Tyr Gln Ala Glu Phe Pro Met 370 375 380 Ser Pro Val Thr Ser Ala His Ser Gly Thr Tyr Arg Cys Tyr Gly Ser 385 390 395 400 Leu Ser Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Asp Ser Leu Glu 405 410 415 Leu Met Val Ser Gly Ala Ala Glu Thr Leu Ser Pro Pro Gln Asn Lys 420 425 430 Ser Asp Ser Lys Ala Gly Ala Ala Asn Thr Leu Ser Pro Ser Gln Asn 435 440 445 Lys Thr Ala Ser His Pro Gln Asp Tyr Thr Val Glu Asn Leu Ile Arg 450 455 460 Met Gly Ile Ala Gly Leu Val Leu Val Val Leu Gly Ile Leu Leu Phe 465 470 475 480 Glu Ala Gln His Ser Gln Arg Ser Leu 485 15 1725 DNA human CDS (40)..(1491) 15 ctcatccatc cgcagagcag ggcagtggga ggagacgcc atg acc ccc atc ctc 54 Met Thr Pro Ile Leu 1 5 acg gtc ctg atc tgt ctc ggg ctg agt ctg ggc ccc agg acc cac gtg 102 Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly Pro Arg Thr His Val 10 15 20 cag gca ggg cac ctc ccc aag ccc acc ctc tgg gct gag cca ggc tct 150 Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp Ala Glu Pro Gly Ser 25 30 35 gtg atc atc cag gga agt cct gtg acc ctc agg tgt cag ggg agc ctt 198 Val Ile Ile Gln Gly Ser Pro Val Thr Leu Arg Cys Gln Gly Ser Leu 40 45 50 cag gct gag gag tac cat cta tat agg gaa aac aaa tca gca tcc tgg 246 Gln Ala Glu Glu Tyr His Leu Tyr Arg Glu Asn Lys Ser Ala Ser Trp 55 60 65 gtt aga cgg ata caa gag cct ggg aag aat ggc cag ttc ccc atc cca 294 Val Arg Arg Ile Gln Glu Pro Gly Lys Asn Gly Gln Phe Pro Ile Pro 70 75 80 85 tcc atc acc tgg gaa cac gca ggg cgg tat cac tgt cag tac tac agc 342 Ser Ile Thr Trp Glu His Ala Gly Arg Tyr His Cys Gln Tyr Tyr Ser 90 95 100 cac aat cac tca tca gag tac agt gac ccc ctg gag ctg gtg gtg aca 390 His Asn His Ser Ser Glu Tyr Ser Asp Pro Leu Glu Leu Val Val Thr 105 110 115 gga gcc tac agc aaa ccc acc ctc tca gct ctg ccc agc cct gtg gtg 438 Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val 120 125 130 acc tta gga ggg aac gtg acc ctc cag tgt gtc tca cag gtg gca ttt 486 Thr Leu Gly Gly Asn Val Thr Leu Gln Cys Val Ser Gln Val Ala Phe 135 140 145 gac ggc ttc att ctg tgt aag gaa gga gaa gat gaa cac cca caa cgc 534 Asp Gly Phe Ile Leu Cys Lys Glu Gly Glu Asp Glu His Pro Gln Arg 150 155 160 165 ctg aac tcc cat tcc cat gcc cgt ggg tgg tcc tgg gcc atc ttc tcc 582 Leu Asn Ser His Ser His Ala Arg Gly Trp Ser Trp Ala Ile Phe Ser 170 175 180 gtg ggc ccc gtg agc ccg agt cgc agg tgg tcg tac agg tgc tat gct 630 Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser Tyr Arg Cys Tyr Ala 185 190 195 tat gac tcg aac tct ccc tat gtg tgg tct cta ccc agt gat ctc ctg 678 Tyr Asp Ser Asn Ser Pro Tyr Val Trp Ser Leu Pro Ser Asp Leu Leu 200 205 210 gag ctc ctg gtc cca ggt gtt tct aag aag cca tca ctc tca gtg cag 726 Glu Leu Leu Val Pro Gly Val Ser Lys Lys Pro Ser Leu Ser Val Gln 215 220 225 cca ggt cct atg gtg gcc ccc ggg gag agc ctg acc ctc cag tgt gtc 774 Pro Gly Pro Met Val Ala Pro Gly Glu Ser Leu Thr Leu Gln Cys Val 230 235 240 245 tct gat gtc ggc tac gac aga ttt gtt ctg tat aag gag gga gaa cgt 822 Ser Asp Val Gly Tyr Asp Arg Phe Val Leu Tyr Lys Glu Gly Glu Arg 250 255 260 gac ttc ctc cag cgc cct ggt tgg cag ccc cag gct ggg ctc tcc cag 870 Asp Phe Leu Gln Arg Pro Gly Trp Gln Pro Gln Ala Gly Leu Ser Gln 265 270 275 gcc aac ttc acc ctg ggc cct gtg agc ccc tcc cac ggg ggc cag tac 918 Ala Asn Phe Thr Leu Gly Pro Val Ser Pro Ser His Gly Gly Gln Tyr 280 285 290 aga tgc tac agt gca cac aac ctc tcc tcc gag tgg tcg gcc ccc agt 966 Arg Cys Tyr Ser Ala His Asn Leu Ser Ser Glu Trp Ser Ala Pro Ser 295 300 305 gac ccc ctg gac atc ctg atc aca gga cag ttc tat gac aga ccc tct 1014 Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln Phe Tyr Asp Arg Pro Ser 310 315 320 325 ctc tcg gtg cag ccg gtc ccc aca gta gcc cca gga aag aac gtg acc 1062 Leu Ser Val Gln Pro Val Pro Thr Val Ala Pro Gly Lys Asn Val Thr 330 335 340 ctg ctg tgt cag tca cgg ggg cag ttc cac act ttc ctt ctg acc aag 1110 Leu Leu Cys Gln Ser Arg Gly Gln Phe His Thr Phe Leu Leu Thr Lys 345 350 355 gag ggg gca ggc cat ccc cca ctg cat ctg aga tca gag cac caa gct 1158 Glu Gly Ala Gly His Pro Pro Leu His Leu Arg Ser Glu His Gln Ala 360 365 370 cag cag aac cag gct gaa ttc cgc atg ggt cct gtg acc tca gcc cac 1206 Gln Gln Asn Gln Ala Glu Phe Arg Met Gly Pro Val Thr Ser Ala His 375 380 385 gtg ggg acc tac aga tgc tac agc tca ctc agc tcc aac ccc tac ctg 1254 Val Gly Thr Tyr Arg Cys Tyr Ser Ser Leu Ser Ser Asn Pro Tyr Leu 390 395 400 405 ctg tct ctc ccc agt gac ccc ctg gag ctc gtg gtc tca gaa gca gct 1302 Leu Ser Leu Pro Ser Asp Pro Leu Glu Leu Val Val Ser Glu Ala Ala 410 415 420 gag acc ctc agc cca tca caa aac aag aca gac tcc acg act aca tcc 1350 Glu Thr Leu Ser Pro Ser Gln Asn Lys Thr Asp Ser Thr Thr Thr Ser 425 430 435 cta ggc caa cac ccc cag gat tac aca gtg gag aat ctc atc cgc atg 1398 Leu Gly Gln His Pro Gln Asp Tyr Thr Val Glu Asn Leu Ile Arg Met 440 445 450 ggt gtg gct ggc ttg gtc ctg gtg gtc ctc ggg att ctg cta ttt gag 1446 Gly Val Ala Gly Leu Val Leu Val Val Leu Gly Ile Leu Leu Phe Glu 455 460 465 gct cag cac agc cag aga agc cta caa gat gca gcc ggg agg tga 1491 Ala Gln His Ser Gln Arg Ser Leu Gln Asp Ala Ala Gly Arg 470 475 480 acagcagaga ggacaatgca tccttcagcg tggtggagcc tcagggacag atctgatgat 1551 cccaggaggc tctggaggac aatctaggac ctacattatc tggactgtat gctggtcatt 1611 tctagagaca gcaatcaata tttgagtgta aggaaactgt ctggggtgat tcctagaaga 1671 tcattaaact gtggtacatt tttttgtcta aaaagcaggt cgtctcgttc caag 1725 16 483 PRT human 16 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ile Gln Gly Ser Pro Val Thr Leu Arg 35 40 45 Cys Gln Gly Ser Leu Gln Ala Glu Glu Tyr His Leu Tyr Arg Glu Asn 50 55 60 Lys Ser Ala Ser Trp Val Arg Arg Ile Gln Glu Pro Gly Lys Asn Gly 65 70 75 80 Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr His 85 90 95 Cys Gln Tyr Tyr Ser His Asn His Ser Ser Glu Tyr Ser Asp Pro Leu 100 105 110 Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu 115 120 125 Pro Ser Pro Val Val Thr Leu Gly Gly Asn Val Thr Leu Gln Cys Val 130 135 140 Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly Glu Asp 145 150 155 160 Glu His Pro Gln Arg Leu Asn Ser His Ser His Ala Arg Gly Trp Ser 165 170 175 Trp Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser 180 185 190 Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Val Trp Ser Leu 195 200 205 Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys Lys Pro 210 215 220 Ser Leu Ser Val Gln Pro Gly Pro Met Val Ala Pro Gly Glu Ser Leu 225 230 235 240 Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val Leu Tyr 245 250 255 Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Trp Gln Pro Gln 260 265 270 Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro Ser 275 280 285 His Gly Gly Gln Tyr Arg Cys Tyr Ser Ala His Asn Leu Ser Ser Glu 290 295 300 Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln Phe 305 310 315 320 Tyr Asp Arg Pro Ser Leu Ser Val Gln Pro Val Pro Thr Val Ala Pro 325 330 335 Gly Lys Asn Val Thr Leu Leu Cys Gln Ser Arg Gly Gln Phe His Thr 340 345 350 Phe Leu Leu Thr Lys Glu Gly Ala Gly His Pro Pro Leu His Leu Arg 355 360 365 Ser Glu His Gln Ala Gln Gln Asn Gln Ala Glu Phe Arg Met Gly Pro 370 375 380 Val Thr Ser Ala His Val Gly Thr Tyr Arg Cys Tyr Ser Ser Leu Ser 385 390 395 400 Ser Asn Pro Tyr Leu Leu Ser Leu Pro Ser Asp Pro Leu Glu Leu Val 405 410 415 Val Ser Glu Ala Ala Glu Thr Leu Ser Pro Ser Gln Asn Lys Thr Asp 420 425 430 Ser Thr Thr Thr Ser Leu Gly Gln His Pro Gln Asp Tyr Thr Val Glu 435 440 445 Asn Leu Ile Arg Met Gly Val Ala Gly Leu Val Leu Val Val Leu Gly 450 455 460 Ile Leu Leu Phe Glu Ala Gln His Ser Gln Arg Ser Leu Gln Asp Ala 465 470 475 480 Ala Gly Arg 17 1625 DNA human CDS (30)..(1376) 17 cacagctggg gcccctggga ggagacgcc atg atc ccc acc ttc acg gct ctg 53 Met Ile Pro Thr Phe Thr Ala Leu 1 5 ctc tgc ctc ggg ctg agt ctg ggc ccc agg acc cac atg cag gca ggg 101 Leu Cys Leu Gly Leu Ser Leu Gly Pro Arg Thr His Met Gln Ala Gly 10 15 20 ccc ctc ccc aaa ccc acc ctc tgg gct gag cca ggc tct gtg atc agc 149 Pro Leu Pro Lys Pro Thr Leu Trp Ala Glu Pro Gly Ser Val Ile Ser 25 30 35 40 tgg ggg aac tct gtg acc atc tgg tgt cag ggg acc ctg gag gct cgg 197 Trp Gly Asn Ser Val Thr Ile Trp Cys Gln Gly Thr Leu Glu Ala Arg 45 50 55 gag tac cgt ctg gat aaa gag gaa agc cca gca ccc tgg gac aga cag 245 Glu Tyr Arg Leu Asp Lys Glu Glu Ser Pro Ala Pro Trp Asp Arg Gln 60 65 70 aac cca ctg gag ccc aag aac aag gcc aga ttc tcc atc cca tcc atg 293 Asn Pro Leu Glu Pro Lys Asn Lys Ala Arg Phe Ser Ile Pro Ser Met 75 80 85 aca gag gac tat gca ggg aga tac cgc tgt tac tat cgc agc cct gta 341 Thr Glu Asp Tyr Ala Gly Arg Tyr Arg Cys Tyr Tyr Arg Ser Pro Val 90 95 100 ggc tgg tca cag ccc agt gac ccc ctg gag ctg gtg atg aca gga gcc 389 Gly Trp Ser Gln Pro Ser Asp Pro Leu Glu Leu Val Met Thr Gly Ala 105 110 115 120 tac agt aaa ccc acc ctt tca gcc ctg ccg agt cct ctt gtg acc tca 437 Tyr Ser Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Leu Val Thr Ser 125 130 135 gga aag agc gtg acc ctg ctg tgt cag tca cgg agc cca atg gac act 485 Gly Lys Ser Val Thr Leu Leu Cys Gln Ser Arg Ser Pro Met Asp Thr 140 145 150 ttt ctt ctg atc aag gag cgg gca gcc cat ccc cta ctg cat ctg aga 533 Phe Leu Leu Ile Lys Glu Arg Ala Ala His Pro Leu Leu His Leu Arg 155 160 165 tca gag cac gga gct cag cag cac cag gct gaa ttc ccc atg agt cct 581 Ser Glu His Gly Ala Gln Gln His Gln Ala Glu Phe Pro Met Ser Pro 170 175 180 gtg acc tca gtg cac ggg ggg acc tac agg tgc ttc agc tca cac ggc 629 Val Thr Ser Val His Gly Gly Thr Tyr Arg Cys Phe Ser Ser His Gly 185 190 195 200 ttc tcc cac tac ctg ctg tca cac ccc agt gac ccc ctg gag ctc ata 677 Phe Ser His Tyr Leu Leu Ser His Pro Ser Asp Pro Leu Glu Leu Ile 205 210 215 gtc tca gga tcc ttg gag ggt ccc agg ccc tca ccc aca agg tcc gtc 725 Val Ser Gly Ser Leu Glu Gly Pro Arg Pro Ser Pro Thr Arg Ser Val 220 225 230 tca aca gct gca ggc cct gag gac cag ccc ctc atg cct aca ggg tca 773 Ser Thr Ala Ala Gly Pro Glu Asp Gln Pro Leu Met Pro Thr Gly Ser 235 240 245 gtc ccc cac agt ggt ctg aga agg cac tgg gag gta ctg atc ggg gtc 821 Val Pro His Ser Gly Leu Arg Arg His Trp Glu Val Leu Ile Gly Val 250 255 260 ttg gtg gtc tcc atc ctg ctt ctc tcc ctc ctc ctc ttc ctc ctc ctc 869 Leu Val Val Ser Ile Leu Leu Leu Ser Leu Leu Leu Phe Leu Leu Leu 265 270 275 280 caa cac tgg cgt cag gga aaa cac agg aca ttg gcc cag aga cag gct 917 Gln His Trp Arg Gln Gly Lys His Arg Thr Leu Ala Gln Arg Gln Ala 285 290 295 gat ttc caa cgt cct cca ggg gct gcc gag cca gag ccc aag gac ggg 965 Asp Phe Gln Arg Pro Pro Gly Ala Ala Glu Pro Glu Pro Lys Asp Gly 300 305 310 ggc cta cag agg agg tcc agc cca gct gct gac gtc cag gga gaa aac 1013 Gly Leu Gln Arg Arg Ser Ser Pro Ala Ala Asp Val Gln Gly Glu Asn 315 320 325 ttc tgt gct gcc gtg aag aac aca cag cct gag gac ggg gtg gaa atg 1061 Phe Cys Ala Ala Val Lys Asn Thr Gln Pro Glu Asp Gly Val Glu Met 330 335 340 gac act cgg cag agc cca cac gat gaa gac ccc cag gca gtg acg tat 1109 Asp Thr Arg Gln Ser Pro His Asp Glu Asp Pro Gln Ala Val Thr Tyr 345 350 355 360 gcc aag gtg aaa cac tcc aga cct agg aga gaa atg gcc tct cct ccc 1157 Ala Lys Val Lys His Ser Arg Pro Arg Arg Glu Met Ala Ser Pro Pro 365 370 375 tcc cca ctg tct ggg gaa ttc ctg gac aca aag gac aga cag gca gaa 1205 Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln Ala Glu 380 385 390 gag gac aga cag atg gac act gag gct gct gca tct gaa gcc ccc cag 1253 Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala Pro Gln 395 400 405 gat gtg acc tac gcc cgg ctg cac agc ttt acc ctc aga cag aag gca 1301 Asp Val Thr Tyr Ala Arg Leu His Ser Phe Thr Leu Arg Gln Lys Ala 410 415 420 act gag cct cct cca tcc cag gaa ggg gcc tct cca gct gag ccc agt 1349 Thr Glu Pro Pro Pro Ser Gln Glu Gly Ala Ser Pro Ala Glu Pro Ser 425 430 435 440 gtc tat gcc act ctg gcc atc cac taa tccagggggg acccagaccc 1396 Val Tyr Ala Thr Leu Ala Ile His 445 cacaagccat ggagactcag gaccccagaa ggcatggaag ctgcctccag tagacatcac 1456 tgaaccccag ccagcccaga cccctgacac agaccactag aagattccgg gaacgttggg 1516 agtcacctga ttctgcaaag ataaataata tccctgcatt atcaaaataa agtagcagac 1576 ctctcaattc acaatgagtt aactgataaa acaaaacaga agtcaaaaa 1625 18 448 PRT human 18 Met Ile Pro Thr Phe Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr His Met Gln Ala Gly Pro Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Asn Ser Val Thr Ile Trp 35 40 45 Cys Gln Gly Thr Leu Glu Ala Arg Glu Tyr Arg Leu Asp Lys Glu Glu 50 55 60 Ser Pro Ala Pro Trp Asp Arg Gln Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Glu Asp Tyr Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Arg Ser Pro Val Gly Trp Ser Gln Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Leu Val Thr Ser Gly Lys Ser Val Thr Leu Leu Cys 130 135 140 Gln Ser Arg Ser Pro Met Asp Thr Phe Leu Leu Ile Lys Glu Arg Ala 145 150 155 160 Ala His Pro Leu Leu His Leu Arg Ser Glu His Gly Ala Gln Gln His 165 170 175 Gln Ala Glu Phe Pro Met Ser Pro Val Thr Ser Val His Gly Gly Thr 180 185 190 Tyr Arg Cys Phe Ser Ser His Gly Phe Ser His Tyr Leu Leu Ser His 195 200 205 Pro Ser Asp Pro Leu Glu Leu Ile Val Ser Gly Ser Leu Glu Gly Pro 210 215 220 Arg Pro Ser Pro Thr Arg Ser Val Ser Thr Ala Ala Gly Pro Glu Asp 225 230 235 240 Gln Pro Leu Met Pro Thr Gly Ser Val Pro His Ser Gly Leu Arg Arg 245 250 255 His Trp Glu Val Leu Ile Gly Val Leu Val Val Ser Ile Leu Leu Leu 260 265 270 Ser Leu Leu Leu Phe Leu Leu Leu Gln His Trp Arg Gln Gly Lys His 275 280 285 Arg Thr Leu Ala Gln Arg Gln Ala Asp Phe Gln Arg Pro Pro Gly Ala 290 295 300 Ala Glu Pro Glu Pro Lys Asp Gly Gly Leu Gln Arg Arg Ser Ser Pro 305 310 315 320 Ala Ala Asp Val Gln Gly Glu Asn Phe Cys Ala Ala Val Lys Asn Thr 325 330 335 Gln Pro Glu Asp Gly Val Glu Met Asp Thr Arg Gln Ser Pro His Asp 340 345 350 Glu Asp Pro Gln Ala Val Thr Tyr Ala Lys Val Lys His Ser Arg Pro 355 360 365 Arg Arg Glu Met Ala Ser Pro Pro Ser Pro Leu Ser Gly Glu Phe Leu 370 375 380 Asp Thr Lys Asp Arg Gln Ala Glu Glu Asp Arg Gln Met Asp Thr Glu 385 390 395 400 Ala Ala Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Arg Leu His 405 410 415 Ser Phe Thr Leu Arg Gln Lys Ala Thr Glu Pro Pro Pro Ser Gln Glu 420 425 430 Gly Ala Ser Pro Ala Glu Pro Ser Val Tyr Ala Thr Leu Ala Ile His 435 440 445 19 2194 DNA human CDS (67)..(1962) 19 tctctgtcct gccagcactg agggctcatc cctctgcaga gcgcggggtc accggaagga 60 gacgcc atg acg ccc gcc ctc aca gcc ctg ctc tgc ctt ggg ctg agt 108 Met Thr Pro Ala Leu Thr Ala Leu Leu Cys Leu Gly Leu Ser 1 5 10 ctg ggc ccc agg acc cgc gtg cag gca ggg ccc ttc ccc aaa ccc acc 156 Leu Gly Pro Arg Thr Arg Val Gln Ala Gly Pro Phe Pro Lys Pro Thr 15 20 25 30 ctc tgg gct gag cca ggc tct gtg atc agc tgg ggg agc ccc gtg acc 204 Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Ser Pro Val Thr 35 40 45 atc tgg tgt cag ggg agc ctg gag gcc cag gag tac caa ctg gat aaa 252 Ile Trp Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Gln Leu Asp Lys 50 55 60 gag gga agc cca gag ccc ttg gac aga aat aac cca ctg gaa ccc aag 300 Glu Gly Ser Pro Glu Pro Leu Asp Arg Asn Asn Pro Leu Glu Pro Lys 65 70 75 aac aag gcc aga ttc tcc atc cca tcc atg aca cag cac cat gca ggg 348 Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Gln His His Ala Gly 80 85 90 aga tac cgc tgc cac tat tac agc tct gca ggc tgg tca gag ccc agc 396 Arg Tyr Arg Cys His Tyr Tyr Ser Ser Ala Gly Trp Ser Glu Pro Ser 95 100 105 110 gac ccc ctg gag ctg gtg atg aca gga gcc tat agc aaa ccc acc ctc 444 Asp Pro Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys Pro Thr Leu 115 120 125 tca gcc ctg ccc agc cct gtg gtg gcc tca ggg ggg aat atg acc ctc 492 Ser Ala Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Met Thr Leu 130 135 140 cga tgt ggc tca cag aag aga tat cac cat ttt gtt ctg atg aag gaa 540 Arg Cys Gly Ser Gln Lys Arg Tyr His His Phe Val Leu Met Lys Glu 145 150 155 gga gaa cac cag ctc ccc cgg acc ctg gac tca cag cag ctc cac agt 588 Gly Glu His Gln Leu Pro Arg Thr Leu Asp Ser Gln Gln Leu His Ser 160 165 170 ggg ggg ttc cag gcc ctg ttc cct gtg ggc ccc gtg aac ccc agc cac 636 Gly Gly Phe Gln Ala Leu Phe Pro Val Gly Pro Val Asn Pro Ser His 175 180 185 190 agg tgg agg ttc aca tgc tat tac tat tat atg aac acc ccc cgg gtg 684 Arg Trp Arg Phe Thr Cys Tyr Tyr Tyr Tyr Met Asn Thr Pro Arg Val 195 200 205 tgg tcc cac ccc agt gac ccc ctg gag att ctg ccc tca ggc gtg tct 732 Trp Ser His Pro Ser Asp Pro Leu Glu Ile Leu Pro Ser Gly Val Ser 210 215 220 agg aag ccc tcc ctc ctg acc ctg cag ggc cct gtc ctg gcc cct ggg 780 Arg Lys Pro Ser Leu Leu Thr Leu Gln Gly Pro Val Leu Ala Pro Gly 225 230 235 cag agt ctg acc ctc cag tgt ggc tct gat gtc ggc tac gac aga ttt 828 Gln Ser Leu Thr Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe 240 245 250 gtt ctg tat aag gag ggg gaa cgt gac ttc ctc cag cgc cct ggc cag 876 Val Leu Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Gln 255 260 265 270 cag ccc cag gct ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg 924 Gln Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val 275 280 285 agc ccc tcc aat ggg ggc cag tac agg tgc tac ggt gca cac aac ctc 972 Ser Pro Ser Asn Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu 290 295 300 tcc tcc gag tgg tcg gcc ccc agc gac ccc ctg aac atc ctg atg gca 1020 Ser Ser Glu Trp Ser Ala Pro Ser Asp Pro Leu Asn Ile Leu Met Ala 305 310 315 gga cag atc tat gac acc gtc tcc ctg tca gca cag ccg ggc ccc aca 1068 Gly Gln Ile Tyr Asp Thr Val Ser Leu Ser Ala Gln Pro Gly Pro Thr 320 325 330 gtg gcc tca gga gag aac gtg acc ctg ctg tgt cag tca tgg tgg cag 1116 Val Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Trp Gln 335 340 345 350 ttt gac act ttc ctt ctg acc aaa gaa ggg gca gcc cat ccc cca ctg 1164 Phe Asp Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu 355 360 365 cgt ctg aga tca atg tac gga gct cat aag tac cag gct gaa ttc ccc 1212 Arg Leu Arg Ser Met Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro 370 375 380 atg agt cct gtg acc tca gcc cac gcg ggg acc tac agg tgc tac ggc 1260 Met Ser Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly 385 390 395 tca cgc agc tcc aac ccc tac ctg ctg tct cac ccc agt gag ccc ctg 1308 Ser Arg Ser Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu 400 405 410 gag ctc gtg gtc tca gga cac tct gga ggc tcc agc ctc cca ccc aca 1356 Glu Leu Val Val Ser Gly His Ser Gly Gly Ser Ser Leu Pro Pro Thr 415 420 425 430 ggg ccg ccc tcc aca cct ggt ctg gga aga tac ctg gag gtt ttg att 1404 Gly Pro Pro Ser Thr Pro Gly Leu Gly Arg Tyr Leu Glu Val Leu Ile 435 440 445 ggg gtc tcg gtg gcc ttc gtc ctg ctg ctc ttc ctc ctc ctc ttc ctc 1452 Gly Val Ser Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu 450 455 460 ctc ctc cga cgt cag cgt cac agc aaa cac agg aca tct gac cag aga 1500 Leu Leu Arg Arg Gln Arg His Ser Lys His Arg Thr Ser Asp Gln Arg 465 470 475 aag act gat ttc cag cgt cct gca ggg gct gcg gag aca gag ccc aag 1548 Lys Thr Asp Phe Gln Arg Pro Ala Gly Ala Ala Glu Thr Glu Pro Lys 480 485 490 gac agg ggc ctg ctg agg agg tcc agc cca gct gct gac gtc cag gaa 1596 Asp Arg Gly Leu Leu Arg Arg Ser Ser Pro Ala Ala Asp Val Gln Glu 495 500 505 510 gaa aac ctc tat gct gcc gtg aag gac aca cag tct gag gac ggg gtg 1644 Glu Asn Leu Tyr Ala Ala Val Lys Asp Thr Gln Ser Glu Asp Gly Val 515 520 525 gag ctg gac agt cag agc cca cac gat gaa gac ccc cac gca gtg acg 1692 Glu Leu Asp Ser Gln Ser Pro His Asp Glu Asp Pro His Ala Val Thr 530 535 540 tat gcc ccg gtg aaa cac tcc agt cct agg aga gaa atg gcc tct cct 1740 Tyr Ala Pro Val Lys His Ser Ser Pro Arg Arg Glu Met Ala Ser Pro 545 550 555 cct tcc cca ctg tct ggg gaa ttc ctg gac aca aag gac aga cag gca 1788 Pro Ser Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln Ala 560 565 570 gaa gag gac aga cag atg gac act gag gct gct gca tct gaa gcc tcc 1836 Glu Glu Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala Ser 575 580 585 590 cag gat gtg acc tac gcc cag ctg cac agc ttg acc ctt aga cgg aag 1884 Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys 595 600 605 gca act gag cct cct cca tcc cag gaa ggg gaa cct cca gct gag ccc 1932 Ala Thr Glu Pro Pro Pro Ser Gln Glu Gly Glu Pro Pro Ala Glu Pro 610 615 620 agc atc tac gcc act ctg gcc atc cac tag cccggggggt acgcagaccc 1982 Ser Ile Tyr Ala Thr Leu Ala Ile His 625 630 cacactcagc agaaggagac tcaggactgc tgaaggacgg gagctgcccc cagtggacac 2042 cagtgaaccc cagtcagcct ggacccctaa cacagaccat gaggagacgc tgggaacttg 2102 tgggactcac ctgactcaaa gatgactaat atcgtcccat tttggaaata aagcaacaga 2162 cttctcaagc aggtcgtctc gttccaagat ct 2194 20 631 PRT human 20 Met Thr Pro Ala Leu Thr Ala Leu Leu Cys Leu Gly Leu Ser Leu Gly 1 5 10 15 Pro Arg Thr Arg Val Gln Ala Gly Pro Phe Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Gly Ser Val Ile Ser Trp Gly Ser Pro Val Thr Ile Trp 35 40 45 Cys Gln Gly Ser Leu Glu Ala Gln Glu Tyr Gln Leu Asp Lys Glu Gly 50 55 60 Ser Pro Glu Pro Leu Asp Arg Asn Asn Pro Leu Glu Pro Lys Asn Lys 65 70 75 80 Ala Arg Phe Ser Ile Pro Ser Met Thr Gln His His Ala Gly Arg Tyr 85 90 95 Arg Cys His Tyr Tyr Ser Ser Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Met Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala 115 120 125 Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Met Thr Leu Arg Cys 130 135 140 Gly Ser Gln Lys Arg Tyr His His Phe Val Leu Met Lys Glu Gly Glu 145 150 155 160 His Gln Leu Pro Arg Thr Leu Asp Ser Gln Gln Leu His Ser Gly Gly 165 170 175 Phe Gln Ala Leu Phe Pro Val Gly Pro Val Asn Pro Ser His Arg Trp 180 185 190 Arg Phe Thr Cys Tyr Tyr Tyr Tyr Met Asn Thr Pro Arg Val Trp Ser 195 200 205 His Pro Ser Asp Pro Leu Glu Ile Leu Pro Ser Gly Val Ser Arg Lys 210 215 220 Pro Ser Leu Leu Thr Leu Gln Gly Pro Val Leu Ala Pro Gly Gln Ser 225 230 235 240 Leu Thr Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe Val Leu 245 250 255 Tyr Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Gln Gln Pro 260 265 270 Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro 275 280 285 Ser Asn Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Ser 290 295 300 Glu Trp Ser Ala Pro Ser Asp Pro Leu Asn Ile Leu Met Ala Gly Gln 305 310 315 320 Ile Tyr Asp Thr Val Ser Leu Ser Ala Gln Pro Gly Pro Thr Val Ala 325 330 335 Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp Trp Gln Phe Asp 340 345 350 Thr Phe Leu Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Arg Leu 355 360 365 Arg Ser Met Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser 370 375 380 Pro Val Thr Ser Ala His Ala Gly Thr Tyr Arg Cys Tyr Gly Ser Arg 385 390 395 400 Ser Ser Asn Pro Tyr Leu Leu Ser His Pro Ser Glu Pro Leu Glu Leu 405 410 415 Val Val Ser Gly His Ser Gly Gly Ser Ser Leu Pro Pro Thr Gly Pro 420 425 430 Pro Ser Thr Pro Gly Leu Gly Arg Tyr Leu Glu Val Leu Ile Gly Val 435 440 445 Ser Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu Leu Leu 450 455 460 Arg Arg Gln Arg His Ser Lys His Arg Thr Ser Asp Gln Arg Lys Thr 465 470 475 480 Asp Phe Gln Arg Pro Ala Gly Ala Ala Glu Thr Glu Pro Lys Asp Arg 485 490 495 Gly Leu Leu Arg Arg Ser Ser Pro Ala Ala Asp Val Gln Glu Glu Asn 500 505 510 Leu Tyr Ala Ala Val Lys Asp Thr Gln Ser Glu Asp Gly Val Glu Leu 515 520 525 Asp Ser Gln Ser Pro His Asp Glu Asp Pro His Ala Val Thr Tyr Ala 530 535 540 Pro Val Lys His Ser Ser Pro Arg Arg Glu Met Ala Ser Pro Pro Ser 545 550 555 560 Pro Leu Ser Gly Glu Phe Leu Asp Thr Lys Asp Arg Gln Ala Glu Glu 565 570 575 Asp Arg Gln Met Asp Thr Glu Ala Ala Ala Ser Glu Ala Ser Gln Asp 580 585 590 Val Thr Tyr Ala Gln Leu His Ser Leu Thr Leu Arg Arg Lys Ala Thr 595 600 605 Glu Pro Pro Pro Ser Gln Glu Gly Glu Pro Pro Ala Glu Pro Ser Ile 610 615 620 Tyr Ala Thr Leu Ala Ile His 625 630 21 2061 DNA human CDS (67)..(1839) 21 tttgtgtcct gccaggcacc gtggtctcat ccgcctgcac agctgagtcc agtgggagct 60 gacgcc atg acc ctc acc ctc tca gtc ctg att tgc ctc ggg ctg agt 108 Met Thr Leu Thr Leu Ser Val Leu Ile Cys Leu Gly Leu Ser 1 5 10 gtg ggc ccc agg acc tgc gtg cag gca ggc acc ctc ccc aaa ccc acc 156 Val Gly Pro Arg Thr Cys Val Gln Ala Gly Thr Leu Pro Lys Pro Thr 15 20 25 30 ctc tgg gct gag cca gcc tct gtg ata gct cgg ggg aag ccc gtg acc 204 Leu Trp Ala Glu Pro Ala Ser Val Ile Ala Arg Gly Lys Pro Val Thr 35 40 45 ctc tgg tgt cag ggg ccc ctg gag act gag gag tac cgt ctg gat aag 252 Leu Trp Cys Gln Gly Pro Leu Glu Thr Glu Glu Tyr Arg Leu Asp Lys 50 55 60 gag gga ctc cca tgg gcc cgg aag aga cag aac cca ctg gag cct gga 300 Glu Gly Leu Pro Trp Ala Arg Lys Arg Gln Asn Pro Leu Glu Pro Gly 65 70 75 gcc aag gcc aag ttc cac att cca tcc acg gtg tat gac agt gca ggg 348 Ala Lys Ala Lys Phe His Ile Pro Ser Thr Val Tyr Asp Ser Ala Gly 80 85 90 cga tac cgc tgc tac tat gag acc cct gca ggc tgg tca gag ccc agt 396 Arg Tyr Arg Cys Tyr Tyr Glu Thr Pro Ala Gly Trp Ser Glu Pro Ser 95 100 105 110 gac ccc ctg gag ctg gtg gcg aca gga ttc tat gca gaa ccc act ctt 444 Asp Pro Leu Glu Leu Val Ala Thr Gly Phe Tyr Ala Glu Pro Thr Leu 115 120 125 tta gcc ctg ccg agt cct gtg gtg gcc tca gga gga aat gtg acc ctc 492 Leu Ala Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Val Thr Leu 130 135 140 cag tgt gat aca ctg gac gga ctt ctc acg ttt gtt ctt gtt gag gaa 540 Gln Cys Asp Thr Leu Asp Gly Leu Leu Thr Phe Val Leu Val Glu Glu 145 150 155 gaa cag aag ctc ccc agg acc ctg tac tca cag aag ctc ccc aaa ggg 588 Glu Gln Lys Leu Pro Arg Thr Leu Tyr Ser Gln Lys Leu Pro Lys Gly 160 165 170 cca tcc cag gcc ctg ttc cct gtg ggt ccc gtg acc ccc agc tgc agg 636 Pro Ser Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser Cys Arg 175 180 185 190 tgg agg ttc aga tgc tat tac tat tac agg aaa aac cct cag gtg tgg 684 Trp Arg Phe Arg Cys Tyr Tyr Tyr Tyr Arg Lys Asn Pro Gln Val Trp 195 200 205 tcg aac ccc agt gac ctc ctg gag att ctg gtc cca ggc gtg tct agg 732 Ser Asn Pro Ser Asp Leu Leu Glu Ile Leu Val Pro Gly Val Ser Arg 210 215 220 aag ccc tcc ctc ctg atc ccg cag ggc tct gtc gtg gcc cgc gga ggc 780 Lys Pro Ser Leu Leu Ile Pro Gln Gly Ser Val Val Ala Arg Gly Gly 225 230 235 agc ctg acc ctg cag tgt cgc tct gat gtc ggc tat gac ata ttc gtt 828 Ser Leu Thr Leu Gln Cys Arg Ser Asp Val Gly Tyr Asp Ile Phe Val 240 245 250 ctg tac aag gag ggg gaa cat gac ctc gtc cag ggc tct ggc cag cag 876 Leu Tyr Lys Glu Gly Glu His Asp Leu Val Gln Gly Ser Gly Gln Gln 255 260 265 270 ccc cag gct ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg agc 924 Pro Gln Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser 275 280 285 cgc tcc cac ggg ggc cag tac aga tgc tac ggt gca cac aac ctc tcc 972 Arg Ser His Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser 290 295 300 cct agg tgg tcg gcc ccc agc gac ccc ctg gac atc ctg atc gca gga 1020 Pro Arg Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly 305 310 315 ctg atc cct gac ata ccc gcc ctc tcg gtg cag ccg ggc ccc aag gtg 1068 Leu Ile Pro Asp Ile Pro Ala Leu Ser Val Gln Pro Gly Pro Lys Val 320 325 330 gcc tca gga gag aac gtg acc ctg ctg tgt cag tca tgg cat cag ata 1116 Ala Ser Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp His Gln Ile 335 340 345 350 gac act ttc ttt ttg acc aag gag ggg gca gcc cat ccc ccg ctg tgt 1164 Asp Thr Phe Phe Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Cys 355 360 365 cta aag tca aag tac cag tct tat aga cac cag gct gaa ttc tcc atg 1212 Leu Lys Ser Lys Tyr Gln Ser Tyr Arg His Gln Ala Glu Phe Ser Met 370 375 380 agt cct gtg acc tca gcc cag ggt gga acc tac cga tgc tac agc gca 1260 Ser Pro Val Thr Ser Ala Gln Gly Gly Thr Tyr Arg Cys Tyr Ser Ala 385 390 395 atc agg tcc tac ccc tac ctg ctg tcc agc cct agt tac ccc cag gag 1308 Ile Arg Ser Tyr Pro Tyr Leu Leu Ser Ser Pro Ser Tyr Pro Gln Glu 400 405 410 ctc gtg gtc tca gga ccc tct ggg gat ccc agc ctc tca cct aca ggc 1356 Leu Val Val Ser Gly Pro Ser Gly Asp Pro Ser Leu Ser Pro Thr Gly 415 420 425 430 tcc acc ccc aca cct ggc cct gag gac cag ccc ctc acc ccc acg ggg 1404 Ser Thr Pro Thr Pro Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly 435 440 445 ttg gat ccc cag agt ggt ctg gga agg cac ctg ggg gtt gtg act ggg 1452 Leu Asp Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Thr Gly 450 455 460 gtc tca gtg gcc ttc gtc ctg ctg ctg ttc ctc ctc ctc ttc ctc ctc 1500 Val Ser Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu Leu 465 470 475 ctc cga cat cgg cat cag agc aaa cac agg aca tcg gcc cat ttc tac 1548 Leu Arg His Arg His Gln Ser Lys His Arg Thr Ser Ala His Phe Tyr 480 485 490 cgt cct gca ggg gct gcg ggg cca gag ccc aag gac cag ggc ctg cag 1596 Arg Pro Ala Gly Ala Ala Gly Pro Glu Pro Lys Asp Gln Gly Leu Gln 495 500 505 510 aag agg gcc agc cca gtt gct gac atc cag gag gaa att ctc aat gct 1644 Lys Arg Ala Ser Pro Val Ala Asp Ile Gln Glu Glu Ile Leu Asn Ala 515 520 525 gcc gtg aag gac aca cag ccc aag gac ggg gtg gag atg gat gct cgg 1692 Ala Val Lys Asp Thr Gln Pro Lys Asp Gly Val Glu Met Asp Ala Arg 530 535 540 gct gct gca tct gaa gcc ccc cag gat gtg acc tac gcc cag ctg cac 1740 Ala Ala Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His 545 550 555 agc ttg acc ctc aga cgg gag gca act gag cct cct cca tcc cag gaa 1788 Ser Leu Thr Leu Arg Arg Glu Ala Thr Glu Pro Pro Pro Ser Gln Glu 560 565 570 agg gaa cct cca gct gaa ccc agc atc tac gcc ccc ctg gcc atc cac 1836 Arg Glu Pro Pro Ala Glu Pro Ser Ile Tyr Ala Pro Leu Ala Ile His 575 580 585 590 tag cccacggggg acccagatct catactcaac agaaggagac tcagagactc 1889 cagaaggcac aggagctgcc cccagtggac accaatgaac cccagccagc ctggacccct 1949 aacaaagacc accaggacat cctgggaact ctgggactca ctagattctg cagtcaaaga 2009 tgactaatat ccttgcattt ttgaaatgaa gccacagact tctcaataaa tc 2061 22 590 PRT human 22 Met Thr Leu Thr Leu Ser Val Leu Ile Cys Leu Gly Leu Ser Val Gly 1 5 10 15 Pro Arg Thr Cys Val Gln Ala Gly Thr Leu Pro Lys Pro Thr Leu Trp 20 25 30 Ala Glu Pro Ala Ser Val Ile Ala Arg Gly Lys Pro Val Thr Leu Trp 35 40 45 Cys Gln Gly Pro Leu Glu Thr Glu Glu Tyr Arg Leu Asp Lys Glu Gly 50 55 60 Leu Pro Trp Ala Arg Lys Arg Gln Asn Pro Leu Glu Pro Gly Ala Lys 65 70 75 80 Ala Lys Phe His Ile Pro Ser Thr Val Tyr Asp Ser Ala Gly Arg Tyr 85 90 95 Arg Cys Tyr Tyr Glu Thr Pro Ala Gly Trp Ser Glu Pro Ser Asp Pro 100 105 110 Leu Glu Leu Val Ala Thr Gly Phe Tyr Ala Glu Pro Thr Leu Leu Ala 115 120 125 Leu Pro Ser Pro Val Val Ala Ser Gly Gly Asn Val Thr Leu Gln Cys 130 135 140 Asp Thr Leu Asp Gly Leu Leu Thr Phe Val Leu Val Glu Glu Glu Gln 145 150 155 160 Lys Leu Pro Arg Thr Leu Tyr Ser Gln Lys Leu Pro Lys Gly Pro Ser 165 170 175 Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser Cys Arg Trp Arg 180 185 190 Phe Arg Cys Tyr Tyr Tyr Tyr Arg Lys Asn Pro Gln Val Trp Ser Asn 195 200 205 Pro Ser Asp Leu Leu Glu Ile Leu Val Pro Gly Val Ser Arg Lys Pro 210 215 220 Ser Leu Leu Ile Pro Gln Gly Ser Val Val Ala Arg Gly Gly Ser Leu 225 230 235 240 Thr Leu Gln Cys Arg Ser Asp Val Gly Tyr Asp Ile Phe Val Leu Tyr 245 250 255 Lys Glu Gly Glu His Asp Leu Val Gln Gly Ser Gly Gln Gln Pro Gln 260 265 270 Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Arg Ser 275 280 285 His Gly Gly Gln Tyr Arg Cys Tyr Gly Ala His Asn Leu Ser Pro Arg 290 295 300 Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Leu Ile 305 310 315 320 Pro Asp Ile Pro Ala Leu Ser Val Gln Pro Gly Pro Lys Val Ala Ser 325 330 335 Gly Glu Asn Val Thr Leu Leu Cys Gln Ser Trp His Gln Ile Asp Thr 340 345 350 Phe Phe Leu Thr Lys Glu Gly Ala Ala His Pro Pro Leu Cys Leu Lys 355 360 365 Ser Lys Tyr Gln Ser Tyr Arg His Gln Ala Glu Phe Ser Met Ser Pro 370 375 380 Val Thr Ser Ala Gln Gly Gly Thr Tyr Arg Cys Tyr Ser Ala Ile Arg 385 390 395 400 Ser Tyr Pro Tyr Leu Leu Ser Ser Pro Ser Tyr Pro Gln Glu Leu Val 405 410 415 Val Ser Gly Pro Ser Gly Asp Pro Ser Leu Ser Pro Thr Gly Ser Thr 420 425 430 Pro Thr Pro Gly Pro Glu Asp Gln Pro Leu Thr Pro Thr Gly Leu Asp 435 440 445 Pro Gln Ser Gly Leu Gly Arg His Leu Gly Val Val Thr Gly Val Ser 450 455 460 Val Ala Phe Val Leu Leu Leu Phe Leu Leu Leu Phe Leu Leu Leu Arg 465 470 475 480 His Arg His Gln Ser Lys His Arg Thr Ser Ala His Phe Tyr Arg Pro 485 490 495 Ala Gly Ala Ala Gly Pro Glu Pro Lys Asp Gln Gly Leu Gln Lys Arg 500 505 510 Ala Ser Pro Val Ala Asp Ile Gln Glu Glu Ile Leu Asn Ala Ala Val 515 520 525 Lys Asp Thr Gln Pro Lys Asp Gly Val Glu Met Asp Ala Arg Ala Ala 530 535 540 Ala Ser Glu Ala Pro Gln Asp Val Thr Tyr Ala Gln Leu His Ser Leu 545 550 555 560 Thr Leu Arg Arg Glu Ala Thr Glu Pro Pro Pro Ser Gln Glu Arg Glu 565 570 575 Pro Pro Ala Glu Pro Ser Ile Tyr Ala Pro Leu Ala Ile His 580 585 590 23 28 DNA human 23 tatgcggccg ccatgatgac aatgtggt 28 24 25 DNA human 24 tatgcggccg ccccttgcga tagcg 25 25 31 DNA human 25 atagtcgaca acgccatcat gagatgtggt g 31 26 29 DNA human 26 taaagatctg ggctcgttag ctgtcgggt 29 27 33 DNA human 27 tatagatcta cccccaggtg ccttcccaga cca 33 28 42 PRT human VARIANT (2) Xaa is Gly or Arg 28 Leu Xaa Leu Ser Xaa Xaa Pro Arg Thr Xaa Xaa Gln Xaa Gly Xaa Xaa 1 5 10 15 Pro Xaa Pro Thr Leu Trp Ala Glu Pro Xaa Ser Phe Ile Xaa Xaa Ser 20 25 30 Asp Pro Lys Leu Xaa Leu Val Xaa Thr Gly 35 40 29 1016 DNA human CDS (69)..(968) 29 ctgagtctgc ctgtggcatg gacctgcatc ttccctgaag catctccagg gctgaaaaat 60 cactgacc atg gca cca tgg tct cat cca tct gca cag ctg cag cca gtg 110 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val 1 5 10 gga gga gac gcc gtg agc cct gcc ctc atg gtt ctg ctc tgc ctc ggg 158 Gly Gly Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly 15 20 25 30 ctg agt ctg ggc ccc agg acc cac gtg cag gca ggg aac ctc tcc aaa 206 Leu Ser Leu Gly Pro Arg Thr His Val Gln Ala Gly Asn Leu Ser Lys 35 40 45 gcc acc ctc tgg gct gag cca ggc tct gtg atc agc cgg ggg aac tct 254 Ala Thr Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser 50 55 60 gtg acc atc cgg tgt cag ggg acc ctg gag gcc cag gaa tac cgt ctg 302 Val Thr Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu 65 70 75 gtt aaa gag gga agc cca gaa ccc tgg gac aca cag aac cca ctg gag 350 Val Lys Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu 80 85 90 ccc aag aac aag gcc aga ttc tcc atc cca tcc atg aca gag cac cat 398 Pro Lys Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His 95 100 105 110 gca ggg aga tac cgc tgt tac tac tac agc cct gca ggc tgg tca gag 446 Ala Gly Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu 115 120 125 ccc agc gac ccc ctg gag ctg gtg gtg aca gga ttc tac aac aaa ccc 494 Pro Ser Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro 130 135 140 acc ctc tca gcc ctg ccc agt cct gtg gtg acc tca gga gag aac gtg 542 Thr Leu Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val 145 150 155 acc ctc cag tgt ggc tca cgg ctg aga ttc gac agg ttc att ctg act 590 Thr Leu Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr 160 165 170 gag gaa gga gac cac aag ctc tcc tgg acc ttg gac tca cag ctg acc 638 Glu Glu Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr 175 180 185 190 ccc agt ggg cag ttc cag gcc ctg ttc cct gtg ggc cct gtg acc ccc 686 Pro Ser Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro 195 200 205 agc cac agg tgg atg ctc aga tgc tat ggc tct cgc agg cat atc ctg 734 Ser His Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu 210 215 220 cag gta tgg tca gaa ccc agt gac ctc ctg gag att ccg gtc tca gga 782 Gln Val Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly 225 230 235 gca gct gat aac ctc agt ccg tca caa aac aag tct gac tct ggg act 830 Ala Ala Asp Asn Leu Ser Pro Ser Gln Asn Lys Ser Asp Ser Gly Thr 240 245 250 gcc tca cac ctt cag gat tac gca gta gag aat ctc atc cgc atg ggc 878 Ala Ser His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile Arg Met Gly 255 260 265 270 atg gcc ggc ttg atc ctg gtg gtc ctt ggg att ctg ata ttt cag gat 926 Met Ala Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ile Phe Gln Asp 275 280 285 tgg cac agc cag aga agc ccc caa gct gca gct gga agg tga 968 Trp His Ser Gln Arg Ser Pro Gln Ala Ala Ala Gly Arg 290 295 300 acagaagaga gaacaatgca ccattgaatg ctggagcctt ggaagcga 1016 30 299 PRT human 30 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly 1 5 10 15 Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Leu Ser 20 25 30 Leu Gly Pro Arg Thr His Val Gln Ala Gly Asn Leu Ser Lys Ala Thr 35 40 45 Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser Val Thr 50 55 60 Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu Val Lys 65 70 75 80 Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu Pro Lys 85 90 95 Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly 100 105 110 Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu Pro Ser 115 120 125 Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro Thr Leu 130 135 140 Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val Thr Leu 145 150 155 160 Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr Glu Glu 165 170 175 Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr Pro Ser 180 185 190 Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His 195 200 205 Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu Gln Val 210 215 220 Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly Ala Ala 225 230 235 240 Asp Asn Leu Ser Pro Ser Gln Asn Lys Ser Asp Ser Gly Thr Ala Ser 245 250 255 His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile Arg Met Gly Met Ala 260 265 270 Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ile Phe Gln Asp Trp His 275 280 285 Ser Gln Arg Ser Pro Gln Ala Ala Ala Gly Arg 290 295 31 1007 DNA human CDS (95)..(958) 31 caggtgtcag atgtgtctct gctgatctga gtctgcctgt ggcatggacc tgcatcttcc 60 ctgaagcatc tccagggctg aaaaatcact gacc atg gca cca tgg tct cat cca 115 Met Ala Pro Trp Ser His Pro 1 5 tct gca cag ctg cag cca gtg gga gga gac gcc gtg agc cct gcc ctc 163 Ser Ala Gln Leu Gln Pro Val Gly Gly Asp Ala Val Ser Pro Ala Leu 10 15 20 atg gtt ctg ctc tgc ctc ggg aac ctc tcc aaa gcc acc ctc tgg gct 211 Met Val Leu Leu Cys Leu Gly Asn Leu Ser Lys Ala Thr Leu Trp Ala 25 30 35 gag cca ggc tct gtg atc agc cgg ggg aac tct gtg acc atc cgg tgt 259 Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser Val Thr Ile Arg Cys 40 45 50 55 cag ggg acc ctg gag gcc cag gaa tac cgt ctg gtt aaa gag gga agc 307 Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu Val Lys Glu Gly Ser 60 65 70 cca gaa ccc tgg gac aca cag aac cca ctg gag ccc aag aac aag gcc 355 Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu Pro Lys Asn Lys Ala 75 80 85 aga ttc tcc atc cca tcc atg aca gag cac cat gca ggg aga tac cgc 403 Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly Arg Tyr Arg 90 95 100 tgt tac tac tac agc cct gca ggc tgg tca gag ccc agc gac ccc ctg 451 Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu Pro Ser Asp Pro Leu 105 110 115 gag ctg gtg gtg aca gga ttc tac aac aaa ccc acc ctc tca gcc ctg 499 Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro Thr Leu Ser Ala Leu 120 125 130 135 ccc agt cct gtg gtg acc tca gga gag aac gtg acc ctc cag tgt ggc 547 Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val Thr Leu Gln Cys Gly 140 145 150 tca cgg ctg aga ttc gac agg ttc att ctg act gag gaa gga gac cac 595 Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr Glu Glu Gly Asp His 155 160 165 aag ctc tcc tgg acc ttg gac tca cag ctg acc ccc agt ggg cag ttc 643 Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr Pro Ser Gly Gln Phe 170 175 180 cag gcc ctg ttc cct gtg ggc cct gtg acc ccc agc cac agg tgg atg 691 Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His Arg Trp Met 185 190 195 ctc aga tgc tat ggc tct cgc agg cat atc ctg cag gta tgg tca gaa 739 Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu Gln Val Trp Ser Glu 200 205 210 215 ccc agt gac ctc ctg gag att ccg gtc tca gga gca gct gat aac ctc 787 Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly Ala Ala Asp Asn Leu 220 225 230 agt ccg tca caa aac aag tct gac tct ggg act gcc tca cac ctt cag 835 Ser Pro Ser Gln Asn Lys Ser Asp Ser Gly Thr Ala Ser His Leu Gln 235 240 245 gat tac gca gta gag aat ctc atc cgc atg ggc atg gcc ggc ttg atc 883 Asp Tyr Ala Val Glu Asn Leu Ile Arg Met Gly Met Ala Gly Leu Ile 250 255 260 ctg gtg gtc ctt ggg att ctg ata ttt cag gat tgg cac agc cag aga 931 Leu Val Val Leu Gly Ile Leu Ile Phe Gln Asp Trp His Ser Gln Arg 265 270 275 agc ccc caa gct gca gct gga agg tga acagaagaga gaacaatgca 978 Ser Pro Gln Ala Ala Ala Gly Arg 280 285 ccattgaatg ctggagcctt ggaagcgaa 1007 32 287 PRT human 32 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly 1 5 10 15 Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Asn Leu 20 25 30 Ser Lys Ala Thr Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly 35 40 45 Asn Ser Val Thr Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr 50 55 60 Arg Leu Val Lys Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro 65 70 75 80 Leu Glu Pro Lys Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu 85 90 95 His His Ala Gly Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp 100 105 110 Ser Glu Pro Ser Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn 115 120 125 Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu 130 135 140 Asn Val Thr Leu Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile 145 150 155 160 Leu Thr Glu Glu Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln 165 170 175 Leu Thr Pro Ser Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val 180 185 190 Thr Pro Ser His Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His 195 200 205 Ile Leu Gln Val Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val 210 215 220 Ser Gly Ala Ala Asp Asn Leu Ser Pro Ser Gln Asn Lys Ser Asp Ser 225 230 235 240 Gly Thr Ala Ser His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile Arg 245 250 255 Met Gly Met Ala Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ile Phe 260 265 270 Gln Asp Trp His Ser Gln Arg Ser Pro Gln Ala Ala Ala Gly Arg 275 280 285 33 956 DNA human CDS (115)..(912) 33 ctcagcctgg gctacacagc caggtgtcag atgtgtctct gctgatctga gtctgcctgt 60 ggcatggacc tgcatcttcc ctgaagcatc tccagggctg aaaaatcact gacc atg 117 Met 1 gca cca tgg tct cat cca tct gca cag ctg cag cca gtg gga gga gac 165 Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly Asp 5 10 15 gcc gtg agc cct gcc ctc atg gtt ctg ctc tgc ctc ggg ctg agt ctg 213 Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Leu Ser Leu 20 25 30 ggc ccc agg acc cac gtg cag gca ggg aac ctc tcc aaa gcc acc ctc 261 Gly Pro Arg Thr His Val Gln Ala Gly Asn Leu Ser Lys Ala Thr Leu 35 40 45 tgg gct gag cca ggc tct gtg atc agc cgg ggg aac tct gtg acc atc 309 Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser Val Thr Ile 50 55 60 65 cgg tgt cag ggg acc ctg gag gcc cag gaa tac cgt ctg gtt aaa gag 357 Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu Val Lys Glu 70 75 80 gga agc cca gaa ccc tgg gac aca cag aac cca ctg gag ccc aag aac 405 Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu Pro Lys Asn 85 90 95 aag gcc aga ttc tcc atc cca tcc atg aca gag cac cat gca ggg aga 453 Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly Arg 100 105 110 tac cgc tgt tac tac tac agc cct gca ggc tgg tca gag ccc agc gac 501 Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu Pro Ser Asp 115 120 125 ccc ctg gag ctg gtg gtg aca gga ttc tac aac aaa ccc acc ctc tca 549 Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro Thr Leu Ser 130 135 140 145 gcc ctg ccc agt cct gtg gtg acc tca gga gag aac gtg acc ctc cag 597 Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val Thr Leu Gln 150 155 160 tgt ggc tca cgg ctg aga ttc gac agg ttc att ctg act gag gaa gga 645 Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr Glu Glu Gly 165 170 175 gac cac aag ctc tcc tgg acc ttg gac tca cag ctg acc ccc agt ggg 693 Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr Pro Ser Gly 180 185 190 cag ttc cag gcc ctg ttc cct gtg ggc cct gtg acc ccc agc cac agg 741 Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His Arg 195 200 205 tgg atg ctc aga tgc tat ggc tct cgc agg cat atc ctg cag gta tgg 789 Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu Gln Val Trp 210 215 220 225 tca gaa ccc agt gac ctc ctg gag att ccg gtc tca ggt gag gaa gcc 837 Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly Glu Glu Ala 230 235 240 aca gtc ttc tct agt aca att cag gga agc cag aca ggt tgt gga gag 885 Thr Val Phe Ser Ser Thr Ile Gln Gly Ser Gln Thr Gly Cys Gly Glu 245 250 255 ctt tac agg cag ggc agc ccc tgc taa gaaagacaaa aaggggaagg 932 Leu Tyr Arg Gln Gly Ser Pro Cys 260 265 agaacacaga aatcctaggg acac 956 34 265 PRT human 34 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly 1 5 10 15 Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Leu Ser 20 25 30 Leu Gly Pro Arg Thr His Val Gln Ala Gly Asn Leu Ser Lys Ala Thr 35 40 45 Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly Asn Ser Val Thr 50 55 60 Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr Arg Leu Val Lys 65 70 75 80 Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro Leu Glu Pro Lys 85 90 95 Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu His His Ala Gly 100 105 110 Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp Ser Glu Pro Ser 115 120 125 Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn Lys Pro Thr Leu 130 135 140 Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu Asn Val Thr Leu 145 150 155 160 Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile Leu Thr Glu Glu 165 170 175 Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln Leu Thr Pro Ser 180 185 190 Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val Thr Pro Ser His 195 200 205 Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His Ile Leu Gln Val 210 215 220 Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val Ser Gly Glu Glu 225 230 235 240 Ala Thr Val Phe Ser Ser Thr Ile Gln Gly Ser Gln Thr Gly Cys Gly 245 250 255 Glu Leu Tyr Arg Gln Gly Ser Pro Cys 260 265 35 997 DNA human CDS (73)..(834) 35 tgatctgagt ctgcctgtgg catggacctg catcttccct gaagcatctc cagggctgaa 60 aaatcactga cc atg gca cca tgg tct cat cca tct gca cag ctg cag cca 111 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro 1 5 10 gtg gga gga gac gcc gtg agc cct gcc ctc atg gtt ctg ctc tgc ctc 159 Val Gly Gly Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu 15 20 25 ggg aac ctc tcc aaa gcc acc ctc tgg gct gag cca ggc tct gtg atc 207 Gly Asn Leu Ser Lys Ala Thr Leu Trp Ala Glu Pro Gly Ser Val Ile 30 35 40 45 agc cgg ggg aac tct gtg acc atc cgg tgt cag ggg acc ctg gag gcc 255 Ser Arg Gly Asn Ser Val Thr Ile Arg Cys Gln Gly Thr Leu Glu Ala 50 55 60 cag gaa tac cgt ctg gtt aaa gag gga agc cca gaa ccc tgg gac aca 303 Gln Glu Tyr Arg Leu Val Lys Glu Gly Ser Pro Glu Pro Trp Asp Thr 65 70 75 cag aac cca ctg gag ccc aag aac aag gcc aga ttc tcc atc cca tcc 351 Gln Asn Pro Leu Glu Pro Lys Asn Lys Ala Arg Phe Ser Ile Pro Ser 80 85 90 atg aca gag cac cat gca ggg aga tac cgc tgt tac tac tac agc cct 399 Met Thr Glu His His Ala Gly Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro 95 100 105 gca ggc tgg tca gag ccc agc gac ccc ctg gag ctg gtg gtg aca gga 447 Ala Gly Trp Ser Glu Pro Ser Asp Pro Leu Glu Leu Val Val Thr Gly 110 115 120 125 ttc tac aac aaa ccc acc ctc tca gcc ctg ccc agt cct gtg gtg acc 495 Phe Tyr Asn Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val Thr 130 135 140 tca gga gag aac gtg acc ctc cag tgt ggc tca cgg ctg aga ttc gac 543 Ser Gly Glu Asn Val Thr Leu Gln Cys Gly Ser Arg Leu Arg Phe Asp 145 150 155 agg ttc att ctg act gag gaa gga gac cac aag ctc tcc tgg acc ttg 591 Arg Phe Ile Leu Thr Glu Glu Gly Asp His Lys Leu Ser Trp Thr Leu 160 165 170 gac tca cag ctg acc ccc agt ggg cag ttc cag gcc ctg ttc cct gtg 639 Asp Ser Gln Leu Thr Pro Ser Gly Gln Phe Gln Ala Leu Phe Pro Val 175 180 185 ggc cct gtg acc ccc agc cac agg tgg atg ctc aga tgc tat ggc tct 687 Gly Pro Val Thr Pro Ser His Arg Trp Met Leu Arg Cys Tyr Gly Ser 190 195 200 205 cgc agg cat atc ctg cag gta tgg tca gaa ccc agt gac ctc ctg gag 735 Arg Arg His Ile Leu Gln Val Trp Ser Glu Pro Ser Asp Leu Leu Glu 210 215 220 att ccg gtc tca ggt gag gaa gcc aca gtc ttc tct agt aca att cag 783 Ile Pro Val Ser Gly Glu Glu Ala Thr Val Phe Ser Ser Thr Ile Gln 225 230 235 gga agc cag aca ggt tgt gga gag ctt tac agg cag ggc agc ccc tgc 831 Gly Ser Gln Thr Gly Cys Gly Glu Leu Tyr Arg Gln Gly Ser Pro Cys 240 245 250 taa gaaagacaaa aaggggaagg agaacacaga aatcctaggg acacaaattc 884 agggtgagga aaacaaagca agggctgggc acagtggctc acacgtgtaa tctcagcact 944 ttgggaggcc gaggcaggtg gatcacctga tgtcaggagt tcaagaccag cct 997 36 253 PRT human 36 Met Ala Pro Trp Ser His Pro Ser Ala Gln Leu Gln Pro Val Gly Gly 1 5 10 15 Asp Ala Val Ser Pro Ala Leu Met Val Leu Leu Cys Leu Gly Asn Leu 20 25 30 Ser Lys Ala Thr Leu Trp Ala Glu Pro Gly Ser Val Ile Ser Arg Gly 35 40 45 Asn Ser Val Thr Ile Arg Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr 50 55 60 Arg Leu Val Lys Glu Gly Ser Pro Glu Pro Trp Asp Thr Gln Asn Pro 65 70 75 80 Leu Glu Pro Lys Asn Lys Ala Arg Phe Ser Ile Pro Ser Met Thr Glu 85 90 95 His His Ala Gly Arg Tyr Arg Cys Tyr Tyr Tyr Ser Pro Ala Gly Trp 100 105 110 Ser Glu Pro Ser Asp Pro Leu Glu Leu Val Val Thr Gly Phe Tyr Asn 115 120 125 Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val Thr Ser Gly Glu 130 135 140 Asn Val Thr Leu Gln Cys Gly Ser Arg Leu Arg Phe Asp Arg Phe Ile 145 150 155 160 Leu Thr Glu Glu Gly Asp His Lys Leu Ser Trp Thr Leu Asp Ser Gln 165 170 175 Leu Thr Pro Ser Gly Gln Phe Gln Ala Leu Phe Pro Val Gly Pro Val 180 185 190 Thr Pro Ser His Arg Trp Met Leu Arg Cys Tyr Gly Ser Arg Arg His 195 200 205 Ile Leu Gln Val Trp Ser Glu Pro Ser Asp Leu Leu Glu Ile Pro Val 210 215 220 Ser Gly Glu Glu Ala Thr Val Phe Ser Ser Thr Ile Gln Gly Ser Gln 225 230 235 240 Thr Gly Cys Gly Glu Leu Tyr Arg Gln Gly Ser Pro Cys 245 250 37 1451 DNA human CDS (1)..(1347) 37 ccc aag ccc acc ctc tgg gct aag cca ggc tct gtg atc agc tgg aga 48 Pro Lys Pro Thr Leu Trp Ala Lys Pro Gly Ser Val Ile Ser Trp Arg 1 5 10 15 agc ccc atg acc atg tgg tgt cag ggg acc ctg gaa gcc cag gag tac 96 Ser Pro Met Thr Met Trp Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr 20 25 30 cat ctg tat aaa gag gga agc aca gag ccc tgg gac aga acg aat cca 144 His Leu Tyr Lys Glu Gly Ser Thr Glu Pro Trp Asp Arg Thr Asn Pro 35 40 45 ctg gag acc agg aac aag gcc aga tac tcc atc cca tcc atg aca cag 192 Leu Glu Thr Arg Asn Lys Ala Arg Tyr Ser Ile Pro Ser Met Thr Gln 50 55 60 cac cat gca gtg aga tat cag tgt tac tat ctc agc cct gca ggc tgg 240 His His Ala Val Arg Tyr Gln Cys Tyr Tyr Leu Ser Pro Ala Gly Trp 65 70 75 80 tca gag ccc agt gac ccc ctg gag ctg gtg atg aca gga ttc tac agc 288 Ser Glu Pro Ser Asp Pro Leu Glu Leu Val Met Thr Gly Phe Tyr Ser 85 90 95 aaa ccc acc ctc tca gcc ctg ccc agc cct gtg gtg gcc tca ggg ggg 336 Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val Ala Ser Gly Gly 100 105 110 aaa gtg acc ctc cga tgt ggc tca cag aag gga tat cac cat ttt gtt 384 Lys Val Thr Leu Arg Cys Gly Ser Gln Lys Gly Tyr His His Phe Val 115 120 125 ctg atg aag gaa gga gaa cac cag ctc ccc cgg acc ctg gac tca cag 432 Leu Met Lys Glu Gly Glu His Gln Leu Pro Arg Thr Leu Asp Ser Gln 130 135 140 cag ctc cac agt ggg ggg ttc cag gcc ctg ttc cct gtg ggc ccc gtg 480 Gln Leu His Ser Gly Gly Phe Gln Ala Leu Phe Pro Val Gly Pro Val 145 150 155 160 acc ccc agc cac agg tgg agg ttc aca tgc tat tac tat tat atg aac 528 Thr Pro Ser His Arg Trp Arg Phe Thr Cys Tyr Tyr Tyr Tyr Met Asn 165 170 175 acc ccc cag gtg tgg tcc cac ccc agt gac ccc ctg gag att ctg ccc 576 Thr Pro Gln Val Trp Ser His Pro Ser Asp Pro Leu Glu Ile Leu Pro 180 185 190 tca gga cag agc tct ccc cct gtc ctg gcc cct gga gag acc ctg acc 624 Ser Gly Gln Ser Ser Pro Pro Val Leu Ala Pro Gly Glu Thr Leu Thr 195 200 205 ctc cag tgt ggc tct gat gtc ggc tac gac aga ttc act ctg tac aag 672 Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe Thr Leu Tyr Lys 210 215 220 gag ggg gaa tgt gac ttc ctc cag cgc cct ggc cag cag ccc cag gct 720 Glu Gly Glu Cys Asp Phe Leu Gln Arg Pro Gly Gln Gln Pro Gln Ala 225 230 235 240 ggg ctc tcc cag gcc aac ttc acc ctg ggc cct gtg agg ggc tcc cac 768 Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Arg Gly Ser His 245 250 255 ggg ggc cag tac aga tgc tcc ggt gca cac aac ctc tcc tcc gag tgg 816 Gly Gly Gln Tyr Arg Cys Ser Gly Ala His Asn Leu Ser Ser Glu Trp 260 265 270 tcg gcc ccc agt gac ccc ctg gac atc ctg atc gca gga cag atc cct 864 Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Gln Ile Pro 275 280 285 ggc aga ccc tcc ctc tcg gtg cag ttg tgg ccc aca gtg gcc tca gga 912 Gly Arg Pro Ser Leu Ser Val Gln Leu Trp Pro Thr Val Ala Ser Gly 290 295 300 gag aac gtg acc ctg ctg tgt caa tca caa gag tgg atg cac act ttc 960 Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Glu Trp Met His Thr Phe 305 310 315 320 ctt ctg acc aag gag ggg gca gcc cat ccc ctg ctg tgt ctg aga tca 1008 Leu Leu Thr Lys Glu Gly Ala Ala His Pro Leu Leu Cys Leu Arg Ser 325 330 335 aag tac gga gct cat aag tac cag gct gaa ttc ccc atg agt cct gtg 1056 Lys Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser Pro Val 340 345 350 acc tca gcc cac acg ggg acc tac agg tgc tac ggc tca ctc agc tcc 1104 Thr Ser Ala His Thr Gly Thr Tyr Arg Cys Tyr Gly Ser Leu Ser Ser 355 360 365 gac ccc tac ctg ctg tct cac ccc agt ggc ccc gtg gag ctc gtg gtc 1152 Asp Pro Tyr Leu Leu Ser His Pro Ser Gly Pro Val Glu Leu Val Val 370 375 380 tca gcc tca cac ctt cag gat tac gca gtg gag aat ctc atc cac atg 1200 Ser Ala Ser His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile His Met 385 390 395 400 ggc gtg gct ggc ttg atc ctg gtg gtc ctc ggg att ctg tca ttt gag 1248 Gly Val Ala Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ser Phe Glu 405 410 415 gct tgg cac agc cag aga agc ttc cca aga tgc agc cgg gag gtg aac 1296 Ala Trp His Ser Gln Arg Ser Phe Pro Arg Cys Ser Arg Glu Val Asn 420 425 430 agc aga gag gat aat gta ctt tat aga gtc gtg aag cct cag gaa cag 1344 Ser Arg Glu Asp Asn Val Leu Tyr Arg Val Val Lys Pro Gln Glu Gln 435 440 445 atc tgatgatccc aggaggtgct ggaagaaaat ctagggccga tgctatctgg 1397 Ile actgtctgct ggtcatttcc agaggaagga atcaatgtcc gagtgcaggg acat 1451 38 449 PRT human 38 Pro Lys Pro Thr Leu Trp Ala Lys Pro Gly Ser Val Ile Ser Trp Arg 1 5 10 15 Ser Pro Met Thr Met Trp Cys Gln Gly Thr Leu Glu Ala Gln Glu Tyr 20 25 30 His Leu Tyr Lys Glu Gly Ser Thr Glu Pro Trp Asp Arg Thr Asn Pro 35 40 45 Leu Glu Thr Arg Asn Lys Ala Arg Tyr Ser Ile Pro Ser Met Thr Gln 50 55 60 His His Ala Val Arg Tyr Gln Cys Tyr Tyr Leu Ser Pro Ala Gly Trp 65 70 75 80 Ser Glu Pro Ser Asp Pro Leu Glu Leu Val Met Thr Gly Phe Tyr Ser 85 90 95 Lys Pro Thr Leu Ser Ala Leu Pro Ser Pro Val Val Ala Ser Gly Gly 100 105 110 Lys Val Thr Leu Arg Cys Gly Ser Gln Lys Gly Tyr His His Phe Val 115 120 125 Leu Met Lys Glu Gly Glu His Gln Leu Pro Arg Thr Leu Asp Ser Gln 130 135 140 Gln Leu His Ser Gly Gly Phe Gln Ala Leu Phe Pro Val Gly Pro Val 145 150 155 160 Thr Pro Ser His Arg Trp Arg Phe Thr Cys Tyr Tyr Tyr Tyr Met Asn 165 170 175 Thr Pro Gln Val Trp Ser His Pro Ser Asp Pro Leu Glu Ile Leu Pro 180 185 190 Ser Gly Gln Ser Ser Pro Pro Val Leu Ala Pro Gly Glu Thr Leu Thr 195 200 205 Leu Gln Cys Gly Ser Asp Val Gly Tyr Asp Arg Phe Thr Leu Tyr Lys 210 215 220 Glu Gly Glu Cys Asp Phe Leu Gln Arg Pro Gly Gln Gln Pro Gln Ala 225 230 235 240 Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Arg Gly Ser His 245 250 255 Gly Gly Gln Tyr Arg Cys Ser Gly Ala His Asn Leu Ser Ser Glu Trp 260 265 270 Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Ala Gly Gln Ile Pro 275 280 285 Gly Arg Pro Ser Leu Ser Val Gln Leu Trp Pro Thr Val Ala Ser Gly 290 295 300 Glu Asn Val Thr Leu Leu Cys Gln Ser Gln Glu Trp Met His Thr Phe 305 310 315 320 Leu Leu Thr Lys Glu Gly Ala Ala His Pro Leu Leu Cys Leu Arg Ser 325 330 335 Lys Tyr Gly Ala His Lys Tyr Gln Ala Glu Phe Pro Met Ser Pro Val 340 345 350 Thr Ser Ala His Thr Gly Thr Tyr Arg Cys Tyr Gly Ser Leu Ser Ser 355 360 365 Asp Pro Tyr Leu Leu Ser His Pro Ser Gly Pro Val Glu Leu Val Val 370 375 380 Ser Ala Ser His Leu Gln Asp Tyr Ala Val Glu Asn Leu Ile His Met 385 390 395 400 Gly Val Ala Gly Leu Ile Leu Val Val Leu Gly Ile Leu Ser Phe Glu 405 410 415 Ala Trp His Ser Gln Arg Ser Phe Pro Arg Cys Ser Arg Glu Val Asn 420 425 430 Ser Arg Glu Asp Asn Val Leu Tyr Arg Val Val Lys Pro Gln Glu Gln 435 440 445 Ile 39 8 PRT human 39 Asp Tyr Lys Asp Asp Asp Asp Lys 1 5 

What is claimed is:
 1. An isolated nucleic acid molecule encoding an LIR polypeptide, wherein said LIR polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:22, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36 and SEQ ID NO:38.
 2. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule has a nucleotide sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:21, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35 and SEQ ID NO:37.
 3. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 171-1040 of SEQ ID NO:11.
 4. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 183-1652 of SEQ ID NO:13.
 5. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 67-1839 of SEQ ID NO:21.
 6. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 69-968 of SEQ I) NO:29.
 7. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 95-958 of SEQ ID NO:31.
 8. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 115-912 of SEQ ID NO:33.
 9. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 73-834 of SEQ ID NO:35.
 10. An isolated nucleic acid molecule according to claim 1, wherein the nucleic acid molecule comprises nucleotides 1-1350 of SEQ ID NO:37.
 11. An isolated nucleic acid molecule encoding a soluble LIR polypeptide, wherein said LIR polypeptide comprises an amino acid sequence selected from the group consisting of: the extracellular domain of a LIR family member, wherein the extracellular domain is selected from the group consisting of: amino acids x₅ to 261 of SEQ ID NO:12, wherein x₅ is amino acid 1 or 17; amino acids x₆ to 461 of SEQ ID NO:14, wherein x₆is amino acid 1 or 17; amino acids x₁₀ to 456 of SEQ ID NO:22₁₀, wherein x is amino acid 1 or 17; amino acids x₁₁ to 262 of SEQ ID NO:30, wherein x₁₁ is amino acid 1 or 35; amino acids x₁₂ to 250 of SEQ ID NO:32, wherein x₁₂ is amino acid 1 or 36; amino acids x₁₃ to 265 of SEQ ID NO:34, wherein x₁₃ is amino acid 1 or 35;. amino acids x₁₄ to 253 of SEQ ID NO:36, wherein x₁₄ is amino acid 1 or 36; and amino acids 1-393 of SEQ ID NO:38.
 12. An isolated nucleic acid molecule encoding a soluble LIR polypeptide comprising at least one Ig-like domain, wherein said LIR polypeptide comprises at least 85 amino acids selected from the group consisting of: amino acids x₅ to 261 of SEQ ID NO:12, wherein x₅ is amino acid 1 or 17; amino acids x₆to 461 of SEQ ID NO:14, wherein x₆ is amino acid 1 or 17; amino acids x₁₀ to 456 of SEQ ID NO:22₁₀, wherein x is amino acid 1 or 17; amino acids x₁₁ to 262 of SEQ ID NO:30, wherein x₁₁ is amino acid 1 or 35; amino acids x₁₂to 250 of SEQ ID NO:32, wherein x₁₂ is amino acid 1 or 36; amino acids x₁₃ to 265 of SEQ ID NO:34, wherein x₁₃ is amino acid 1 or 35; amino acids x₁₄ to 253 of SEQ ID NO:36, wherein x₁₄ is amino acid 1 or 36; and amino acids 1 to 393 of SEQ ID NO:38.
 13. An isolated polypeptide encoded by a nucleic acid molecule of claim
 1. 14. An antibody capable of binding specifically to a polypeptide of claim
 13. 15. A nucleic acid molecule that encodes a fusion protein comprising the Fc region of Ig and an amino acid sequence selected from the group consisting of: amino acids x₅ to 261 of SEQ ID NO:12, wherein x5 is amino acid 1 or 17; amino acids x₆ to 461 of SEQ ID NO:14, wherein x₆ is amino acid 1 or 17; amino acids x₁₀ to 456 of SEQ ID NO:22, , wherein x₁₀ is amino acid 1 or 17; amino acids x₁₁ to 262 of SEQ ID NO:30, wherein x₁₁ is amino acid 1 or 35; amino acids x₁₂ to 250 of SEQ ID NO:32, wherein x₁₂ is amino acid 1 or 36; amino acids x₁₃ to 265 of SEQ ID NO:34, wherein x₁₃ is amino acid 1 or 35; amino acids x₁₄ to 253 of SEQ ID NO:36, wherein x₁₄ is amino acid 1 or 36; amino acids 1 to 393 of SEQ ID NO:38.
 16. A recombinant expression vector comprising a nucleic acid molecule according to claim
 1. 17. A process for preparing an LIR polypeptide, the process comprising culturing a host cell transformed with an expression vector of claim 16 under conditions that promote expression of said polypeptide, and recovering said polypeptide.
 18. A composition comprising a pyhsiologically acceptable carrier and a polypeptide of claim
 13. 19. A host cell transformed or transfected with an expression vector according to claim
 16. 